

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 10-K**

(Mark one)

- ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
- TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from April 1, 2015 to December 31, 2015.

Commission file number 000-20970

---

**COGENTIX MEDICAL, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of incorporation or organization)

**13-3430173**  
(I.R.S. Employer Identification No.)

**5420 Feltl Road**  
**Minnetonka, Minnesota**  
(Address of principal executive offices)

**55343**  
(Zip Code)

**(952) 426-6140**  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

**Common Stock, \$0.01 par value**  
(Title of class)

**The NASDAQ Capital Market**  
(Name of Exchange on which registered)

Securities registered pursuant to Section 12(g) of the Act:  
**None**

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES  NO

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES  NO

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES  NO

---

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). YES  NO

The aggregate market value of the voting stock and nonvoting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked prices of such common equity, as of September 30, 2015 was \$26,692,079.

As of March 15, 2016, the registrant had 25,975,617 shares of common stock outstanding.

#### **DOCUMENTS INCORPORATED BY REFERENCE**

*Portions of our Proxy Statement for our 2016 Annual Meeting of Stockholders (the "Proxy Statement"), are incorporated by reference in Part III.*

---

**TABLE OF CONTENTS**

<u>PART I</u>	1
ITEM 1. <u>BUSINESS</u>	1
ITEM 1A. <u>RISK FACTORS</u>	18
ITEM 1B. <u>UNRESOLVED STAFF COMMENTS</u>	28
ITEM 2. <u>PROPERTIES</u>	29
ITEM 3. <u>LEGAL PROCEEDINGS</u>	29
ITEM 4. <u>MINE SAFETY DISCLOSURE</u>	30
<u>PART II</u>	30
ITEM 5. <u>MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</u>	30
ITEM 6. <u>SELECTED FINANCIAL DATA</u>	31
ITEM 7. <u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</u>	31
ITEM 7A. <u>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</u>	42
ITEM 8. <u>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</u>	42
ITEM 9. <u>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</u>	42
ITEM 9A. <u>CONTROLS AND PROCEDURES</u>	42
ITEM 9B. <u>OTHER INFORMATION</u>	43
<u>PART III</u>	43
ITEM 10. <u>DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</u>	43
ITEM 11. <u>EXECUTIVE COMPENSATION</u>	43
ITEM 12. <u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</u>	43
ITEM 13. <u>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</u>	43
ITEM 14. <u>PRINCIPAL ACCOUNTANT FEES AND SERVICES</u>	44
<u>PART IV</u>	44
ITEM 15. <u>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</u>	44
<u>EXHIBIT INDEX TO TRANSITION REPORT ON FORM 10-K</u>	i

[Table of Contents](#)

*This annual report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and is subject to the safe harbor created by those sections. For more information, see “Part I. Item 1. Business — Cautionary Note Regarding Forward-Looking Statements.”*

*As used in this report, the terms “Cogentix,” “Cogentix Medical,” the “Company,” “we,” “us,” “our” and similar references refer to Cogentix Medical, Inc. (formerly known as Vision-Sciences, Inc.) and our consolidated subsidiaries, and the term “common stock” refers to our common stock, par value \$0.01 per share. References to “VSCI,” “Vision-Sciences” or “Vision” generally refer to Vision-Sciences, Inc. and its consolidated subsidiaries prior to the consummation of the merger of Uroplasty, Inc. with and into Vision’s wholly-owned merger subsidiary (“Merger Sub”) on March 31, 2015 (the “merger”), and sometimes also are used as references to our current, ongoing operations related to the historical VSCI that continue following the merger. References to “UPI” or “Uroplasty” generally refer to Uroplasty, Inc., and its consolidated subsidiaries prior to the consummation of the merger, and sometimes are also used as reference to our current ongoing operations related to the historical UPI that continue following the merger and sometimes also are used as reference to our current, ongoing operations related to the historical Uroplasty that continue following the merger.*

*All share and per share amounts have been adjusted to reflect the one-for-five reverse split of Vision’s outstanding common stock effective on March 31, 2015 immediately prior to the effective time of the merger. All numbers and prices related to common shares and options of Uroplasty that predated the merger have been adjusted to reflect the exchange ratio of 3.6331 shares of our common stock for each share of Uroplasty common stock, as well as the above mentioned one-for-five reverse stock split, a combined impact of 0.72662 shares of our common stock for each Uroplasty share of common stock.*

*This report contains the following trademarks, trade names and service marks of ours: PrimeSight™, Vision-Sciences®, EndoSheath®, Slide-On®, EndoWipe®, The Vision System®, and Urgent® for our neuromodulation product, Macroplastique® for our urological tissue bulking product, VOX® for our otolaryngology tissue bulking products, PTQ® for our colorectal tissue bulking product and Uroplasty® for Uroplasty LLC, one of our subsidiaries. This report also contains trademarks, trade names and service marks that are owned by other persons or entities.*

*On December 10, 2015, we changed our fiscal year from a fiscal year ending on March 31 of each year to a fiscal year ending on December 31 of each year effective as of December 31, 2015. This action created a transition period of April 1, 2015 through December 31, 2015 (the “Transition Period”). Unless otherwise indicated herein, comparisons of fiscal year results in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” portion of this Transition Report, and elsewhere herein, compare results for the nine-month transition period from April 1, 2015 through December 31, 2015 to the nine-month unaudited period from April 1, 2014 through December 31, 2014 and the 12-month period of the fiscal year ended March 31, 2015, 2014, and 2013, respectively, and accordingly are not comparing results for a comparable period of time.*

---

**PART I**

**ITEM 1. BUSINESS**

On December 21, 2014, Vision-Sciences entered into a merger agreement with Uroplasty, a publicly traded corporation. The merger agreement provided for the merger of Uroplasty with and into a newly created, wholly-owned merger subsidiary of Vision-Sciences (“Merger Sub”). Following the approval of the merger by Vision-Sciences’ and Uroplasty’s stockholders on March 30, 2015 and pursuant to the terms of the merger agreement, on March 31, 2015, Uroplasty merged with and into Merger Sub, with the Merger Sub continuing as the surviving entity and a wholly-owned subsidiary of Vision-Sciences under the name, “Uroplasty, LLC.” Vision-Sciences changed its name to “Cogentix Medical, Inc.” immediately following the merger and our common stock now trades on the NASDAQ Capital Market under the new symbol “CGNT.”

The merger was accounted for as a reverse acquisition due to a number of factors including the relative voting interests in the combined company of the former Vision-Sciences and Uroplasty stockholders following the merger. As a result, Uroplasty and its consolidated subsidiaries represent the accounting acquirer in the merger, and Vision-Sciences and its consolidated subsidiary represent the legal acquirer in the merger. Accordingly, while Vision-Sciences was the legal acquirer in the merger, Uroplasty is treated as the acquiring company in the merger for accounting purposes, and the merger has been accounted for as a reverse acquisition under the acquisition method of accounting for business combinations.

As a result of the merger, our financial statements prior to March 31, 2015 are the historical financial statements of Uroplasty, and our financial statements on and after March 31, 2015 reflect the results of the operations of Uroplasty and Vision-Sciences on a consolidated basis. We refer you to Note 2 to the “Notes to Consolidated Financial Statements” in Part II, Item 8 of this report for additional description of this merger, the accounting treatment of the merger, and the pro forma financial information for Cogentix Medical on a combined basis.

## Overview of the Company

Cogentix Medical is a global medical device company headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom. We design, develop, manufacture and market a robust line of high performance fiberoptic and video endoscopy products under the PrimeSight™ brand that are used across multiple surgical specialties in diagnostic and treatment procedures. We also offer the Urgent® PC Neuromodulation System, a device that delivers percutaneous tibial nerve stimulation (“PTNS”), for the office-based treatment of overactive bladder (“OAB”). OAB is a chronic condition that affects approximately 40 million adults in the U.S. The symptoms include urinary urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence that is primarily due to intrinsic sphincter deficiency.

The PrimeSight flexible endoscopes are used in conjunction with the proprietary sterile, single-use microbial barrier known as the EndoSheath® Protective Barrier. Because the EndoSheath barrier is placed over the patient contact area of the scope, it eliminates the need for high-level disinfection between cases. This allows a scope to be ready in substantially less time than with conventional reprocessing. Key advantages to the PrimeSight endoscopes when used with the EndoSheath protective barrier are reduction in costs and time associated with traditional reprocess, increased practice productivity and patient throughput. The PrimeSight endoscopy line also include rigid endoscopes and highly portable peripherals such as the video system and stroboscopy unit.

We target two primary market spaces for our PrimeSight Endoscopy line:

- Urology – we manufacture, market and sell our cystoscopy systems and EndoSheath protective barriers to urologists.
- Airway Management – we manufacture, market, and sell our: (i) bronchoscopy systems (an endoscope that allows detailed viewing of the lungs) and EndoSheath protective barrier to intensivists, pulmonologists, thoracic surgeons, and other airway-related physicians, (ii) TNE (transnasal esophagoscopy) systems and EndoSheath protective barrier to general surgeons, primarily bariatric and gastroesophageal reflux disease (“GERD”) surgeons, and (iii) ENT (ear, nose and throat) endoscopy systems to ENT physicians and speech pathologists.

Our Urgent® PC Neuromodulation System (“Urgent PC System”) is a U.S. Food and Drug Administration (the “FDA”) cleared, minimally invasive nerve stimulation device designed for office-based treatment of OAB and the associated symptoms of urge incontinence, urinary urgency and urinary frequency. Using a small-gauge needle electrode inserted above the ankle, our Urgent PC System delivers electrical impulses to the tibial nerve that affects the sacral nerve plexus, a control center for pelvic floor and bladder function. Components of our Urgent PC System include a 34 gauge needle electrode, a lead set and an external, handheld, battery-powered stimulator. For each 30-minute office-based therapy session, the physician or other qualified health care provider inserts the needle electrode above the ankle and connects the electrode to the stimulator. Typically, a patient undergoes a course of 12 consecutive weekly treatments, and, subsequently, a personal treatment plan of single treatments at a lesser frequency to sustain the therapeutic effect. We believe physicians prefer our Urgent PC System because it offers effective therapies for patients that can be administered in an office setting and provides the physicians with a profitable revenue stream. We believe patients prefer the Urgent PC System to pharmaceutical treatment options or surgeries because it is a minimally invasive treatment alternative that does not have the side effects associated with pharmaceutical treatment options or the adverse events associated with surgeries.

Macroplastique® (“Macroplastique”) is an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily resulting from intrinsic sphincter deficiency. It is designed to restore the patient’s urinary continence immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a proprietary composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. We believe our compound is better than other commercially available bulking agents because, with its unique composition, shape and size, it does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site.

## **Overview of Strategy for Calendar Year 2016 and Beyond**

Our strategy for 2016 and beyond is to continue to leverage our assets to generate organic growth and to expand our product portfolio. We currently have a distribution platform that includes 48 direct sales representatives in the U.S., with 41 sales representatives serving the Urology market and 7 sales representatives serving the Airway Management and Other markets. Internationally, we have 8 direct sales representatives in certain geographies and a network of distributor relationships. We believe this sales force has the capacity to add more products to their existing portfolio, and a key element of our strategy is to continue to leverage this distribution platform to generate revenue growth. We plan to expand our product portfolio through merger, acquisition, licensing or distribution opportunities. We believe that there are underperforming yet innovative assets available that we can add to our portfolio and grow at double digit rates. Examples of such assets include orphaned technologies within larger organizations, new technologies ready for commercialization with which our existing distribution platform can penetrate the market quickly, and existing products that are not meeting their potential due to undersized sales forces within their current company.

## **Products and Markets**

We produce and market the following products:

- PrimeSight Endoscopes (i.e., cystoscopes, laryngoscopes, transnasal esophagoscopes and bronchoscopes for medical use; and borescopes for industrial use) and digital processing units (DPU);
- EndoSheath Protective Barrier;
- Urgent PC System;
- Macroplastique; and
- Other Products and Applications.

### ***PrimeSight Endoscopes and PrimeSight Digital Processing Units for Medical Use***

In 2016, we initiated a program that brings the entire endoscopy portfolio under the company’s new PrimeSight brand. The PrimeSight Endoscopy family of products will encompass our state-of-the-art endoscopes, processors, accessories, as well as the endoscope-associated EndoSheath and EndoWipe products.

We have developed two visualization platforms for flexible endoscopy: fiber optic (4000 Series) and video (5000 Series and 7000 Series). Our 4000 Series fiberscopes contain advanced fiber optic imaging systems with high quality functional aspects, such as small diameter endoscopes and portability options, through the use of a battery-powered light source. Our lightweight, advanced, digital video-based endoscopes facilitate diagnostic and therapeutic procedures. Our small diameter video endoscopes contain a high resolution, tiny charge-coupled device (“CCD”) camera at the tip of the scope, offering a sharp, vibrant, full screen image. The 7000 Series and 5000 Series video endoscopes also feature pioneering functional aspects, including the elimination of an external light source, the inclusion of an integrated light emitting diode (“LED”), industry leading small diameter sizes and robust durability.

Our 7000 Series and 5000 Series of PrimeSight video endoscopes are utilized with our multi-functional 7000 Series digital processing unit (“DPU”), or video processor. Unlike conventional video endoscopy “towers,” we have integrated key peripherals into a single all-in-one unit, providing a more cost-effective design that allows for maximum portability in various health care settings. The 7000 Series DPU provides high quality imaging along with workflow efficiency features and plug-and-play simplicity in operation. Users can easily capture video and images during various endoscopic procedures to patient files for future viewing. Our LCD provides full screen presentation with no truncation (framing) of image, commonly seen in other endoscope manufacturer’s products. Along with our EndoSheath Protective Barrier, our DPU contributes significantly to portability by allowing bedside procedures where space is limited. Our DPU is also easily transported from facility to facility allowing physicians to perform video endoscopy even in the remotest locations. Our 7000 Series DPU includes a simplified user interface, programmable user preference controls, expanded on-screen notifications, and easy-to-maintain patient lists, all of which allow end-users to improve productivity and workflow by customizing the operation of the system to the day-to-day needs of the practice. Additionally, the system incorporates a “one-touch” integrated keyboard to ensure quick activation of functions, including full control of video playback options, such as frame-by-frame review or historical image comparison, both of which are ideal for patient progress review.

In the U.S., we sell our endoscopes and sheaths through our direct sales force. Internationally, our endoscopes and sheaths are sold by distributors.

**Urology Market.** Within the Urology market, we developed unique products for urology with our PrimeSight fiber and video cystoscopes, both utilizing the EndoSheath Protective Barrier. Our cystoscopes consist of two components: (i) a reusable flexible endoscope incorporating our proprietary design, and (ii) a proprietary, sterile, single-use EndoSheath Protective Barrier.

Our PrimeSight line includes our advanced digital, video-based flexible cystoscopes, a CCD-based video imaging endoscopy system, which features an integrated built-in LED light source and operates with our all-in-one PrimeSight video processor or DPU. We also market and distribute a fiber optic cystoscope.

We also developed a video-based flexible ureteroscope. This endoscope gives surgeons unsurpassed high-definition visualization of the ureters and kidneys with up to 240 degrees of articulation allowing access to the areas of the kidney that are otherwise difficult to access. Our ureteroscope features an integrated LED, which eliminates the need for a separate light source.

**Airway Management Market.** We developed unique products for the ENT, pulmonology / critical care and Bariatric/GI specialties. We manufacture and market fiber and video laryngoscopes, which we refer to as ENT scopes. Our fiber and video ENT scopes can be used with or without the EndoSheath Protective Barrier, as they do not feature any working channels and are diagnostic only. We market and sell products for pulmonology using our fiber and video bronchoscopes. Our bronchoscopes utilize our EndoSheath Protective Barrier and are inserted through the mouth or nose and into the lower airway, providing visualization of the lungs and the ability to perform a variety of diagnostic and therapeutic procedures. We have also developed a digital, video-based flexible TNE endoscope, which utilizes our EndoSheath Protective Barrier. Our TNE system provides visualization of the esophageal anatomy via a sedation-free transnasal approach. Each of our video airway management scopes is a CCD-based video imaging endoscopy system, which includes an integrated built-in LED light source and operates with our all-in-one DPU.

#### ***Endoscopes (Borescopes) and Digital Processing Units for Industrial Use***

Through our wholly-owned subsidiary, Machida Incorporated (“Machida”), we design, manufacture and sell borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers or a small camera for the visual inspection of narrow cavities. Our borescopes are used to inspect aircraft engines, cast parts and ground turbines, among other items. Machida’s quality line of borescopes includes a number of advanced standard features normally found only in custom designed instruments. We were the first to offer a flexible borescope with a grinding attachment, allowing users to “blend” or smooth small cracks in turbine blades of jet engines without disassembling the engine, saving our customers a significant amount of expense and time.

### ***EndoSheath Protective Barrier***

We have developed the EndoSheath Protective Barrier for use with our proprietary PrimeSight endoscopes. The protective barrier is made with materials using our proprietary process that makes the barrier material lubricious (smooth), allowing the health care practitioner to easily install the disposable onto the endoscope. In addition, our protective barrier technology has an optically clear window that fits securely over the endoscope tip, providing a clear image. Once installed, the protective barrier offers complete isolation between the endoscope and the patient. After the procedure is completed, the barrier easily slides off and is removed from the endoscope and discarded.

Our EndoSheath Protective Barrier offers various-size working channels, unlike conventional flexible endoscopes, which have the working channel inside the endoscope itself, allowing our users to customize the scope to the procedure (e.g., diagnostic cystoscopy, which requires a small working channel, or therapeutic cystoscopy, which requires a larger working channel). This enables us to provide procedure-specific EndoSheath Protective Barrier without requiring physicians to purchase a new endoscope for a different procedure.

Within the Urology market, we offer urologists two EndoSheath Protective Barrier models for each of our fiber and video cystoscopes: a diagnostic model with a 1.5mm working channel size that provides enhanced patient comfort, and a therapeutic model with a 2.1mm working channel size that provides the same capabilities as conventional cystoscopes. Our protective barrier installs easily onto the cystoscope; it includes a covering for the endoscope and a working channel, which may be used for irrigation, suction and therapeutic tool delivery as well as an additional covering for the control body (handle), where the physician operates the cystoscope. The protective barrier is the only component that comes into contact with the patient and is discarded after each procedure.

Within the TNE market, we market and distribute two EndoSheath Protective Barrier models for our video TNE endoscope: a diagnostic model with a 1.5mm working channel size, and a therapeutic model with a 2.1mm working channel size. This unique feature of our EndoSheath Protective Barrier design provides gastroenterologists, ENT physicians, bariatric surgeons and others with two choices: a diagnostic model with a smaller overall diameter (due to a smaller working channel) for patient comfort, and a therapeutic model with a larger working channel, providing the same capabilities as conventional endoscopes.

Within the Pulmonology market, we market and distribute four EndoSheath Protective Barrier models for video and fiber bronchoscopy: a 1.5mm working channel, a 2.1mm working channel, a 2.8mm working channel (currently available outside of the U.S. only), and one without a working channel. We are currently seeking clearance to market the 2.8mm channel model in the U.S. The multiple sizes are necessary due to various procedures that are performed by pulmonologists and airway management physicians. Depending on the type of procedure being performed, a pulmonologist or airway management physician may use a very small diameter model, with or without a working channel, or a larger diameter model with a working channel.

In November 2015, the ECRI Institute (a nonprofit organization dedicated to bringing the discipline of applied scientific research to discovering which medical procedures, devices, drugs, and processes are best to improve patient care) listed inadequate reprocessing of flexible endoscopes and the potential for cross-contamination and patient infection as the number one most dangerous hazard on its list of the top-ten health technology hazards for 2016. The use of our PrimeSight Endoscopy systems with the EndoSheath Protective Barrier allows health care providers to perform a simplified and efficacious reprocessing routine after their use of endoscopes, avoiding the elaborate – and sometimes inadequate - high level disinfection/sterilization routines required by the FDA for conventional endoscopes. The FDA requires that all conventional flexible endoscopes be reprocessed according to FDA-cleared manufacturers' instruction for use, whether they are used in hospitals, clinics or office settings. With our protective barrier, we are able to prevent the endoscope from coming into contact with the patient and organic material during the procedure, reducing the steps needed to reprocess flexible endoscopes from approximately 27 to three, thereby saving time, lowering costs and reducing the complexity of the process.

This design of our “always ready, always sterile” equipment, provides a multitude of benefits to health care practitioners, such as redefining health care economics by lowering per procedure costs through less capital equipment investment, less service and maintenance costs of capital equipment, less required use of toxic chemicals, increased patient scheduling flexibility and procedure volume, improved practice efficiency, and the capacity to reallocate unproductive labor resources from reprocessing activities to more productive tasks of patient care and throughput.

### ***Urgent PC Systems***

Our Urgent PC System is a minimally invasive nerve stimulation device designed for office-based treatment of OAB and the associated symptoms of urge incontinence, urinary urgency and urinary frequency. Using a small-gauge needle electrode inserted above the ankle, our Urgent PC System delivers electrical impulses to the tibial nerve that affect the sacral nerve plexus, a control center for pelvic floor and bladder function.

For individuals with overactive bladder symptoms, the nervous system control for bladder filling and urinary voiding is incompetent. For OAB patients, signals to indicate a full bladder are sent early and frequently, triggers to allow the bladder to relax for filling are ineffective, and nervous controls of the urethral sphincter to keep the bladder closed until an appropriate time are inadequate. An individual with OAB may exhibit one or all of the symptoms that characterize overactive bladder: urinary urgency (i.e., the strong, compelling need to urinate), urinary frequency (i.e., repetitive need to void) and urge incontinence (i.e., involuntary loss of urine associated with an abrupt, strong desire to urinate).

When patients seek treatment for OAB, physicians normally start with conservative therapies such as biofeedback and behavioral modification (e.g., bladder training, scheduled voiding techniques and pelvic floor training). When, as is often the case, these therapies are not entirely successful, the next treatment of choice is drug therapy. If, as is the case with a majority of the patients, the drug therapy is ineffective or cannot be tolerated by the patient, the physicians suggest other treatments. For those patients, we believe our minimally invasive Urgent PC System treatments offer an alternative to the more invasive treatments such as surgery, implantation of a sacral nerve stimulation device, or injection of OnabotulinumtoxinA, a prescription drug marketed under the name of Botox, into the bladder.

Our Urgent PC System is an FDA-cleared, minimally-invasive, neuromodulation system that delivers PTNS for office-based treatment of OAB and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence. For each 30-minute office-based therapy session, the physician or other qualified health care provider inserts the needle electrode above the ankle and connects the electrode to the stimulator. Typically, a patient undergoes a course of 12 consecutive weekly treatments, and, subsequently, a personal treatment plan of single treatments at a lesser frequency to sustain the therapeutic effect.

### ***Macroplastique***

Macroplastique is an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency (“ISD”). Urinary incontinence is defined as the involuntary loss of urine and is the result of either bladder or urethral dysfunction.

In 2007, the U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases reported that, depending on the definition of urinary incontinence used, 5% to 50% of the U.S. adult population suffers from some form of urinary incontinence. Per the American Urological Association, there are three types of urinary incontinence:

- *Stress Urinary Incontinence* — Stress urinary incontinence (“SUI”) refers to the involuntary loss of urine due to an increase in intra-abdominal pressure from ordinary physical activities, such as coughing, sneezing, laughing, straining or lifting. SUI, the most common form of urinary incontinence among women, is estimated to affect almost 30 million women over the age of 18 in the U.S. (Hampel et al., 1997 and 2000 U.S. census data). SUI is caused by urethral hypermobility and/or ISD. Urethral hypermobility – abnormal movement of the bladder neck and urethra – can occur when the anatomic supports for the bladder neck and urethra have weakened. This anatomical change can result from pregnancy, childbirth or age-related tissue deterioration. SUI can also be caused by ISD, or the inability of the urinary sphincteric mechanism to function properly. ISD can be due to congenital or age-related sphincter weakness or can result from damage to the sphincteric mechanism following pelvic trauma, surgery, neurologic diseases or radiation therapy.
- *Urge Incontinence* — Urge incontinence refers to the involuntary loss of urine associated with an abrupt, strong desire to urinate. Urge incontinence often occurs when neurologic problems cause the bladder to *contract and empty with little or no warning, and is part of the overactive bladder syndrome.*

- *Overflow Incontinence* — *Overflow incontinence is associated with an over-distention of the bladder. This can be the result of an under-active bladder or an obstruction in the bladder or urethra.*

Macroplastique is an injectable, urethral bulking agent that is designed to restore the patient's urinary continence immediately following treatment. Macroplastique is a soft-textured, permanent implant injected, under endoscopic visualization, around the urethra distal to the bladder neck. It is a proprietary composition of heat vulcanized, solid, soft, irregularly shaped polydimethylsiloxane (solid silicone elastomer) implants suspended in a biocompatible excretable carrier gel. We believe our compound is better than other commercially available bulking agents because, with its unique composition, shape and size, it does not degrade, is not absorbed into surrounding tissues and does not migrate from the implant site.

We have sold Macroplastique for urological indications in over 40 countries outside the United States since 1991. We began marketing Macroplastique in the United States in 2007.

#### ***Other Products and Applications***

We also provide and market the following additional products and applications:

**Macroplastique® for Vesicoureteral Reflux.** Outside the U.S., we market our Macroplastique products for treatment of vesicoureteral reflux - the abnormal backflow of urine from the bladder into the ureters or kidneys that is most prevalent in infants and children whose ureters did not fully develop. In this application, a bolus of the elastomer implant is injected around the orifice or valve where the ureter enters the bladder.

**PTQ® Implants.** We also market our silicone elastomer implants under the name PTQ® Implants outside of the U.S. as a minimally invasive product to address fecal incontinence (sometimes referred to as bowel incontinence). Our PTQ Implants offer minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence. PTQ is implanted circumferentially into the submucosa of the anal canal, creating a "bulking" and supportive effect around the anal sphincter. PTQ is CE marked and currently sold outside the United States in various international markets.

**Urgent PC for Fecal Incontinence.** Our Urgent PC System is CE marked and sold outside of the United States for the treatment of fecal incontinence.

**VOX® Implants.** In addition to urological applications, we market our silicone elastomer bulking material outside the United States to help improve speech and swallowing function in patients with unilateral vocal cord paralysis. The implants are sold for vocal cord rehabilitation applications under the trade name VOX® Implants.

**Distributed Products.** In The Netherlands and United Kingdom only, we distribute certain wound care products in accordance with a distributor agreement. Under the terms of the distributor agreement, we are not obligated to purchase any minimum level of wound care products.

#### **Sales, Distribution and Marketing**

##### ***Medical Products***

The end users of our endoscopy systems for medical use and related products primarily consist of urologists, pulmonologists, thoracic surgeons, gastroenterologists, bariatric surgeons, and ENT doctors in medical clinics, physicians' private offices, ambulatory surgical centers, and hospitals. Other physicians may also use our medical devices performing procedures in alternate settings. The end users of our Urgent PC System and Macroplastique products are primarily urologists, urogynecologists and gynecologists with significant office-based and outpatient surgery-based patient volume.

We market and distribute these medical products worldwide. In the U.S., we sell our products through a direct sales force. Outside the U.S., we sell our products through a combination of a direct sales force and a network of distributor organizations. Most of our distributors outside the U.S. also market and distribute products of other companies.

In the United States, we have a sales organization that consists of 48 direct field sales representatives, six Regional Sales Directors, three clinical specialists and a marketing organization to market our products directly to our customers. Of our 48 direct sales representatives, 41 specialize in the urology market and seven specialize in the airway management and other markets.

Outside of the United States, we sell our Urgent PC System and Macroplastique products primarily through a direct sales organization in the United Kingdom, The Netherlands, Switzerland, Ireland, Belgium, Finland, Sweden and Denmark, and in all other markets primarily through distributors. Each of our distributors has a territory-specific distribution agreement, including requirements they may not sell products that compete directly with ours. Our PrimeSight endoscopy systems and products are sold internationally through regional or national distributors.

We use clinical studies and worldwide scientific community awareness programs to demonstrate the safety and efficacy of our products. Publications of clinical data in peer-reviewed journals and presentations at professional society meetings by clinical researchers increase the scientific community's awareness of our products, including patient indications, treatment technique and expected outcomes. We provide a range of activities designed to support physicians in their clinical research.

Our sales team will focus its time and efforts on the sale of our PrimeSight Endoscopy portfolio and our Urgent PC System, both in the United States and internationally. We will emphasize the "always ready, always sterile" attribute of our PrimeSight systems utilizing the EndoSheath Protective Barrier, as well as its ability to enable physicians to safely and cost-effectively treat more patients in less time, thereby providing physicians with flexibility to better manage increased patient demand. We will continue to focus on generating greater patient and physician awareness of our Urgent PC system and on training physicians in the proper use and clinical benefits of our Urgent PC System for overactive bladder. We do not expect to see significant growth in our Macroplastique business because we believe it is a small, mature market that is competitively penetrated.

### ***Borescopes for Industrial Use***

Our borescopes are sold directly by our subsidiary, Machida, and through a global network of independent sales representatives.

We regularly evaluate the effectiveness of all of our sales channels and may change them if we believe a different method would increase our revenues.

### **Third-Party Reimbursement**

In the United States as well as in foreign countries, sales of our medical products depend in significant part on the availability of reimbursement from third-party payers. In the United States, third-party payers consist of government programs such as Medicare, private health insurance plans, managed care organizations and other similar programs. For any product, three factors are critical to reimbursement:

1. coding, which ensures uniform descriptions of procedures, diagnoses and medical products;
2. coverage, which is the payer's policy describing the clinical circumstances under which the payer will pay for a given treatment; and
3. payment processes and amounts.

Whether a particular procedure qualifies for third-party reimbursement depends upon factors such as the safety and effectiveness of the procedure. Reimbursement may be denied if the medical device used was experimental or was used for a non-approved indication. We believe, based upon our knowledge and experience of third-party reimbursement practices and advice from consultants in this area, that third-party reimbursement is available for most procedures that utilize our products.

### ***PrimeSight Endoscopes***

Third-party payers use a variety of mechanisms to determine reimbursement amounts for procedures such as endoscopies. In most cases, payment is based upon amounts determined by the Centers for Medicare & Medicaid Services ("CMS"), a governmental agency under the U.S. Department of Health and Human Services. As part of its responsibilities, CMS assigns relative value units ("RVUs") to over 10,000 physician services. An RVU for a specific procedure is comprised of values for work, practice expense and malpractice insurance, and when multiplied by a conversion factor, represents a dollar value for a specific procedure.

CMS has multiple fee schedules to accommodate payment to the hospital, the ambulatory surgery center, and the physician. Physician services are reimbursed based on where the service is performed. If the physician performs the service in his or her office and the office bears the burden of overhead costs, the physician is reimbursed based on non-facility RVUs to accommodate the overhead costs. If the physician performs the service in a hospital or the ambulatory surgery center, the payment to the physician is lower, reflecting the physician work and malpractice expenses, but without the overhead since the facility bears that financial burden.

We believe that the number of procedures performed in non-facility settings will increase. As these procedures move to non-facility settings, physicians will have to contend with the cost and effort required to reprocess conventional endoscopes. We believe our PrimeSight Endoscopy portfolio will provide an economically beneficial alternative to the use of conventional endoscopes based upon the provider not having to purchase multiple endoscopes or expensive disinfecting equipment and supplies, and not having to spend his or her valuable time cleaning endoscopes. We believe that with over 100 million people in the U.S. over the age of 50, the number of endoscopic procedures that physicians will perform will increase. Our EndoSheath technology, combined with the resource-based system for setting values for physician services, represents a sound economic solution for physicians to perform diagnostic and therapeutic procedures in their offices.

#### ***EndoSheath Protective Barrier***

Most third-party payers do not reimburse health-care providers separately for the cost of our sterile, single-use EndoSheath Protective Barrier products.

#### ***Urgent PC System***

Sales of our Urgent PC System are significantly influenced by the availability of third-party reimbursement for PTNS treatments. Effective January 2011, the American Medical Association granted a Category 1 Current Procedural Terminology (“CPT”) code for PTNS treatments.

As of February 29, 2016, all regional Medicare carriers, with approximately 50 million covered lives, provide coverage for PTNS treatments. In addition, we estimate that private payers insuring approximately 160 million lives provide coverage for PTNS treatments.

Outside of the U.S., our Urgent PC System treatments are reimbursed under an available reimbursement code in the Netherlands. In other countries in Europe, there are no specific reimbursement codes for Urgent PC System treatments, and generally reimbursement is from fund-holder trusts or global hospital budgets.

#### ***Macroplastique***

We believe there are appropriate CPT codes available to describe the use of Macroplastique to treat adult female stress urinary incontinence due to intrinsic sphincter deficiency in the United States. Outside of the United States, government managed health care systems and private insurance control reimbursement for devices and procedures. Reimbursement systems in international markets vary significantly by country. In the European Union, reimbursement decision-making is neither regulated nor integrated at the European Union level. Each country has its own system, often closely protected by its corresponding national government. Reimbursement for Macroplastique has been successful in multiple international markets where hospitals and physicians have budgets approved by fund-holder trusts or global hospital budgets.

### **Manufacturing and Suppliers**

#### ***PrimeSight Endoscopes***

We manufacture our flexible endoscopes for medical and industrial use at our facility in Orangeburg, New York, using purchased components and subassemblies as well as certain proprietary components we or our subcontractors produce. Some purchased components and subassemblies are available from more than one supplier. For most of our purchases, we have no long-term agreements with our vendors or suppliers, and we purchase our components and supplies on a purchase order basis. For certain critical components, we have long-term supply arrangements with third parties, such as Applitec LTD, which is based in Israel.

### ***EndoSheath Protective Barrier***

We currently manufacture our EndoSheath disposable barriers at our facility in Westborough, Massachusetts using raw materials, molded parts, and components purchased from independent vendors, some of which are manufactured to our specifications. We also design and build our own production machines and tools. Our EndoSheath line includes products for all medical markets we currently serve.

Most components we purchase are available from multiple sources, with the exception of certain key components that are supplied to us by key suppliers, with whom we have long-term supply arrangements, but no long-term supply agreements. We purchase our components and supplies on a purchase order basis and seek to maintain adequate inventory levels of such components to prevent supply disruptions. We contract with third parties for the sterilization of all of our EndoSheath disposables.

### ***Urgent PC System***

We subcontract the manufacturing of both the stimulator and lead set components of our Urgent PC System. Each component is manufactured by a single source supplier meeting our quality and other requirements. Although we believe our sources of supply could be replaced if necessary without undue disruption, it is possible that the process of qualifying new suppliers could cause an interruption in our ability to manufacture our products, which could have a negative impact on sales.

### ***Macroplastique***

We have FDA-registered manufacturing facilities in Minnetonka, Minnesota, Westborough, MA and Orangeburg, NY where we manufacture all of our tissue bulking products, Endosheath products and endoscope products, respectively. Our facilities use dedicated heating, cooling, ventilation and high efficiency particulate air filtration systems to provide cleanroom and other controlled working environments. Our trained technicians perform all critical manufacturing processes in qualified environments according to validated written procedures. We use qualified vendors to sterilize our products using validated methods.

## **Competition**

### ***PrimeSight Endoscopy and EndoSheath Protective Barrier (Flexible Endoscopes and Disposables)***

We believe that the primary competitive factors in the medical device market for flexible endoscopes include safety and effectiveness, the optical quality of product offerings, product reliability, price, physician familiarity with the manufacturer and its products, ease of use and third-party reimbursement policies.

Our ability to compete is directly affected by several factors, such as our sales and marketing capabilities, our product development and innovation capabilities, our ability to obtain required regulatory clearances, our ability to protect the proprietary technology which our products are based upon, our manufacturing skills and our ability to attract and retain skilled employees.

We believe our proprietary PrimeSight endoscopes and EndoSheath platform currently provides us with a competitive advantage over our competition. Currently, most of our competitors sell endoscopes that require elaborate and time-consuming reprocessing procedures. Some newer competitors sell disposable endoscopes that sacrifice optical quality and functional performance in favor of single-use safety. Our unique platform provides the safety of a sterile, single use device as well as the performance of a high quality reusable device.

Our current and future medical endoscopes face global competition, primarily from companies such as Olympus, Pentax, and Karl Storz. Some of our competitors and some potential competitors may have greater financial resources, experience, sales and marketing personnel and capabilities, research and development, and manufacturing personnel and capabilities than we do. In addition, any company that is able to significantly redesign conventional flexible endoscopes to simplify or significantly improve their reprocessing, may result in competition for our products.

In our industrial markets, we believe that our over 35-year history of product effectiveness, ease of use, product reliability and competitive pricing are the principal competitive factors contributing to our success. Among our competitors are Olympus, Lenox, and Karl Storz Industrial.

### ***Urgent PC System***

We believe our Urgent PC System offers a minimally invasive, office-based treatment alternative in the continuum of care for OAB patients. Conservative therapies such as dietary restrictions, pelvic floor exercises, bladder retraining, biofeedback, and anticholinergic drugs usually precede our Urgent PC System treatments. Anticholinergic medications that could be seen as competing with PTNS include Detrol® and Toviaz® (both by Pfizer Inc.); Ditropan® (Johnson & Johnson); Enablex® (Novartis AG); Sanctura® (Allergan, Inc.) and Vesicare® (GlaxoSmithKline plc). These medications treat symptoms of OAB, some by preventing unwanted bladder contractions and others by tightening the bladder or urethra muscles or by relaxing bladder muscles. We believe our Urgent PC System normally is prescribed after these drugs are used but discontinued because they were ineffective or had unwanted side effects. In the case of anticholinergic medications, the side effects often include dry eyes, dry mouth, constipation, cognitive changes and blurred vision.

Allergan, Inc. began to commercialize Botulinum toxin A (Botox®) for OAB treatments in calendar 2013, and this treatment is a direct competitor for our Urgent PC System following unsuccessful drug therapy. In this procedure, Botox is injected into the bladder wall, often with approximately twenty individual injection sites, to numb and mask the symptoms of urgency and frequency. We believe that marketing campaigns by Allergan, Inc. will increase awareness of OAB. However, we also believe that the side effects of Botox injections for this application, which can include urinary retention and urinary tract infection, will lead many patients to choose our less invasive solution.

Medtronic's InterStim neuromodulation device, which stimulates the sacral nerve, requires surgical implantation of a lead near the patient's spine in addition to a battery powered stimulator in the buttocks. In contrast, our Urgent PC System allows minimally invasive stimulation of the sacral nerve plexus in an office-based setting without any surgical intervention. Additionally, we anticipate Medtronic to formally launch a competing PTNS technology in 2016. Other companies may also enter the U.S. market with neuromodulation or other products for the treatment of OAB.

### ***Macroplastique***

Injectable urethral bulking agents for stress urinary incontinence competing directly with Macroplastique in the United States include: Durasphere® manufactured by Carbon Medical Technologies, Inc. and distributed by Coloplast Corp; and Coaptite® manufactured by Merz Aesthetics, Inc. and distributed by Boston Scientific Corporation. We believe Macroplastique competes effectively against these products because it will not degrade, resorb or migrate, has no special preparation or storage requirements, and is safe and effective for treating adult female stress urinary incontinence.

Outside of the United States, Deflux® (manufactured by Q-Med AB, a wholly owned subsidiary of Galderma S.A., and distributed by Salix Pharmaceuticals, Ltd.) and Bulkamid® (manufactured by Contura, Inc., Denmark and distributed by SEP Pharma) compete with Macroplastique for vesicoureteral reflux and SUI, respectively.

### **Government Regulation**

The testing, manufacturing, promotion, marketing and distribution of our medical products in the United States, Canada, Europe and other parts of the world are subject to regulation by numerous governmental authorities, including the FDA, the European Union and other analogous agencies. Unlike our medical products, the manufacturing of our Machida industrial scopes is not subject to direct government regulation.

#### ***United States***

Our products are regulated in the United States as medical devices by the FDA under the Food, Drug and Cosmetic Act ("FDC Act"). Noncompliance with applicable requirements can result in, among other things:

- fines, injunctions, and civil penalties;
- recall or seizure of products;
- operating restrictions, or total or partial suspension of production;
- denial of requests for 510(k) clearance or pre-market approval of new products;

[Table of Contents](#)

- withdrawal of existing approvals; and
- criminal prosecution.

Depending on the degree of risk posed by the medical device and the extent of controls needed to ensure safety and effectiveness, there are two pathways for FDA marketing clearance of medical devices. For devices deemed by FDA to pose relatively less risk (Class I or Class II devices), manufacturers, in most instances, must submit a pre-market notification requesting permission for commercial distribution, known as 510(k) clearance. Devices deemed by FDA to pose the greatest risk (Class III devices), such as life-sustaining, life-supporting or implantable devices, or a device deemed not to be substantially equivalent to a previously cleared 510(k) device, require the submission of a pre-market approval (PMA) application. The FDA can also impose restrictions on the sale, distribution or use of devices at the time of their clearance or approval, or subsequent to marketing.

Our PrimeSight flexible endoscopes and accessory products have been classified by the FDA as Class II devices and EndoSheath Protective Barrier products have been classified by the FDA as Class II sterile devices. We have received FDA clearance for all of our endoscopes and accessory products that require clearance with the exception of the bronchoscope 2.8mm EndoSheath model, for which we are currently seeking FDA clearance. We expect that we will be required to file 510(k) Pre-market Notifications for each additional endoscope that we develop in the future.

In October 2005, our initial version of the Urgent PC System received 510(k) clearance for sale within the United States. In July 2006, our second generation Urgent PC System received 510(k) clearance for sale within the United States.

In October 2006, we received FDA pre-market approval for the use of Macroplastique to treat female stress urinary incontinence in the United States. As part of the FDA-approval process, we are conducting a customary post-market study.

After a device is placed on the market, numerous regulatory requirements apply. These include:

- Quality System Regulations, which require manufacturers to follow design, testing, control, documentation and other quality assurance procedures during the manufacturing process;
- labeling regulations, which govern product labels and labeling, prohibit the promotion of products for unapproved or “off-label” uses and impose other restrictions on labeling and promotional activities;
- medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if such malfunction were to recur; and
- notices of correction or removal, and recall regulations.

The FDC Act requires that medical devices be manufactured in accordance with FDA’s current Quality System Regulations, which require, among other things, that we:

- regulate our design and manufacturing processes and control them by the use of written procedures;
- investigate any deficiencies in our manufacturing process or in the products we produce;
- keep detailed records and maintain a corrective and preventative action plan; and
- allow the FDA to inspect our manufacturing facilities on a periodic basis to monitor our compliance with Quality System Regulations.

### ***European Union, Canada and Other Regions***

The European Union has adopted rules that require that medical products receive the right to affix the CE mark, which stands for Conformité Européenne. The CE mark demonstrates adherence to quality standards and compliance with relevant European medical device directives. Products that bear the CE mark can be imported to, sold or distributed within the European Union.

We have received CE certification from Underwriters Laboratories UK for conformity with the European Union Medical Devices Directive allowing us CE mark our endoscopes and accessory product lines currently sold in Europe.

Our initial version of the Urgent PC System received CE marking in November 2005. Our second generation Urgent PC System received CE mark approval and approval from the Canadian Therapeutic Products Directorate of Health in June 2006.

We received the CE mark approval for Macroplastique in 1996 for the treatment of male and female stress urinary incontinence and vesicoureteral reflux; for VOX in 2000 for vocal cord rehabilitation and; for PTQ in 2002 for the treatment of fecal incontinence. Our manufacturing facilities and processes have been inspected and certified by AMTAC Certification Services, a recognized Notified Body, a testing and certification firm based in the United Kingdom.

Under the Canadian Medical Devices Regulations, all medical devices are classified into four classes, Class I being the lowest risk class and Class IV being the highest risk. Class I devices include among others, devices that make only non-invasive contact with the patient. Classes II, III and IV include devices of increasingly higher risk as determined by such factors as degree of invasiveness and the potential consequences to the patient if the device fails or malfunctions. Our current endoscopes and accessory products sold in Canada generally fall into Classes I and II. All Class II, III and IV medical devices must have a valid Medical Device License issued by the Therapeutic Products Directorate of Health Canada before they may be sold in Canada (Class I non-sterile devices require only an establishment license, which we have obtained and maintain on an annual basis). We have obtained applicable Medical Device Licenses in Canada for all of our currently marketed endoscopes and accessory products.

### ***Quality Standards***

In August 2005, the quality system certification at our facility in Natick, Massachusetts was updated to establish conformance with International Organization for Standardization ("ISO") 13485: 2003 and continued conformance with Medical Devices Directive ("MDD") 93/42/EEC and the Canadian Medical Device Regulations ("CMDR"). In September 2015, we completed a facility transfer from Natick, Massachusetts to Westborough, Massachusetts. All regulatory and quality standards have been met, allowing ongoing operations for domestic and international distribution.

In April 2007, our facility in Orangeburg, New York successfully completed an expansion audit and we were awarded ISO 13485: 2003 certification for this location. This certification allowed us to start shipping scopes from our facility in Orangeburg, New York, in addition to shipments from our facility in Natick, Massachusetts. The Natick and Orangeburg facilities are registered with the FDA as medical device manufacturers. As a result, these facilities are subject to the FDA's Quality System Regulations, which regulate the design, manufacturing, testing, quality control, and documentation procedures. We are also required to comply with the FDA's labeling requirements, as well as its information reporting regulations.

Our manufacturing facility in Minnetonka, Minnesota and our manufacturing processes at that facility have been inspected and certified in compliance with ISO 13485, applicable European medical device directives and Canadian Medical Device Requirements.

The export of medical devices is also subject to regulation in certain instances. Our compliance with these various regulatory requirements is monitored through periodic inspections by the FDA and audits by independent authorities to maintain our ISO 13485, Canadian Medical Device Requirements and European medical device directives status. We routinely update our systems to comply with changes to applicable regulations such as the recent changes to the European medical device directives, as amended by 2007/47/EC.

In addition to the three-year ISO certification audits, we undergo annual surveillance audits to confirm that we are properly maintaining our quality system. This quality system has been developed in accordance with the ISO to ensure that companies are aware of the standards of quality to which their products will be held worldwide.

## **Patents, Trademarks and Licenses**

We seek to establish and protect our proprietary technology using a combination of patents, trademarks, copyrights, trade secrets, and nondisclosure and non-competition agreements. We file patent applications for patentable technologies we consider important to the development of our business based on an analysis of the cost of obtaining a patent, the likely scope of protection, and the relative benefits of patent protection compared to trade secret protection, among other considerations.

As of March 1, 2016, we hold 26 U.S. patents, and we have 9 U.S. patent applications pending. In addition, we have 89 foreign patents granted and have five foreign patent applications pending. The issued and granted patents will expire on various dates in the years 2017 through 2029. These patents relate to electro-nerve stimulation; soft-tissue bulking materials, processes and applications; disposable sheaths for endoscopes; endoscopic designs and features; and reusable flexible endoscopes, as well as other various products, endoscopy and non-endoscopy related.

While we believe that our patents adequately protect our technologies, there can be no assurance that any of our issued patents are of sufficient scope or strength to provide meaningful protection and that any of our pending patent applications will result in patents being issued to us. In addition, there can be no assurance that any of our current or future patents will not be challenged, narrowed, invalidated or circumvented by others, or that our patents will provide us with any competitive advantage. Any legal proceedings to maintain, defend or enforce our patent rights could be lengthy and costly, with no guarantee of success. Third parties could also hold patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would be available to us on reasonable terms, or if at all.

We also seek to protect our trade secrets by requiring employees, consultants, and other parties to sign confidentiality agreements and noncompetition agreements, and by limiting access by outside parties to our confidential information. There can be no assurance that these measures will prevent any unauthorized disclosure or use of our confidential information or that others will not be able to independently develop such information.

In the U.S. and throughout the European Union, we have registered “Cogentix Medical” as our Company name, “Urgent” for our neuromodulation product, “Macroplastique” for our urological tissue bulking products, “VOX” for our otolaryngology tissue bulking products, and “PTQ” for our colorectal tissue bulking products. We own the U.S.-registered trademarks Vision Sciences<sup>®</sup>, EndoSheath<sup>®</sup>, Slide-On<sup>®</sup>, EndoWipe<sup>®</sup> and The Vision System<sup>®</sup>.

We have certain royalty agreements under which we pay royalties on sales of Macroplastique and the Macroplastique implantation needle-positioning device.

## **Research and Development**

We have research and development projects and activities to develop, enhance and evaluate potential new products for which we incur costs for regulatory submissions, regulatory compliance and clinical research. Our expenditures for clinical research include studies for new applications or indications for existing products, post-approval regulatory compliance and marketing and reimbursement approval by third-party payers. Our expenditures for research and development totaled approximately \$3.2 million for the Transition Period ended December 31, 2015, \$2.2 million for the nine-month period between April 1, 2014 and December 31, 2014 and \$2.9 million for the fiscal year ended March 31, 2015.

With respect to our industrial segment, our ability to custom-design for specific applications is common practice in our business. On-wing inspections with blending borescopes have become an indispensable tool for aircraft engine manufacturers and service providers. We work closely with Pratt & Whitney, GE and other engine manufacturers, developing and producing the most efficient borescopes for their specific applications. We are developing a new processor with a video recording capability. Also, we are currently testing inexpensive C-MOS camera chips for industrial inspection applications.

## **Product Liability**

The medical device industry is subject to substantial litigation. The nature of our products exposes us to significant product liability risks. We currently carry a worldwide product liability insurance policy that covers up to \$10 million in liability. We believe that such coverage amount is appropriate, given our business, products, past sales levels and our anticipated sales levels. However, we cannot assure that our existing insurance coverage limits are adequate to protect us from liabilities we might incur. Product liability insurance is expensive to obtain and maintain, and may not be available to us in the future on terms that are acceptable to us, if at all. We evaluate the adequacy of our coverage periodically to determine if adjustments should be made. Furthermore, we do not expect to be able to obtain insurance covering our costs and losses as a result of any product recall. A successful claim in excess of our insurance coverage could materially deplete our assets. Moreover, any claim against us could generate negative publicity, which could decrease the demand for our products and our ability to generate revenues.

## **Compliance with Environmental Laws**

Our operations are regulated under various federal, state, and local laws governing the environment, including laws governing the discharge of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the clean-up of contaminated sites. We have infrastructures in place to ensure that our operations are in compliance with all applicable environmental regulations. Our compliance with applicable environmental requirements for the Transition Period and during our fiscal years ended on March 31, 2015 and 2014, respectively, has not had a material effect upon our capital expenditures, earnings or competitive position.

## **Dependence on Major Customers**

During the Transition Period and our fiscal 2015 and 2014, none of our customers individually accounted for 10% or more of our net sales.

## **Backlog**

We did not have significant backlog at the end of the Transition Period or fiscal year-end 2015 or 2014.

## **Employees**

As of December 31, 2015, we had 181 employees, of which 178 were full-time and three were part time. No employee was subject to a collective bargaining agreement. We believe we maintain good relations with our employees.

## **Executive Officers**

The table below sets forth, as of March 15, 2016, certain information concerning our executive officers. No family relationships exist among any of our directors and executive officers.

[Table of Contents](#)

<b>Name</b>	<b>Age</b>	<b>Title</b>
Robert C. Kill	52	Chairman of the Board, President, Chief Executive Officer and Corporate Secretary
Darin Hammers	51	Chief Operating Officer

The following is a biographical summary of the experiences of our executive officers:

**Robert C. Kill** has been a director, Chairman of the Board of Directors, and President and Chief Executive Officer of Cogentix since March 31, 2015. He served as a director from December 2010 until March 31, 2015, as Chairman of the Board of Directors from May 2014 until March 31, 2015, as interim Chief Executive Officer from April 2013 until July 2013, and as President and Chief Executive Officer from July 2013 until March 31, 2015 of Uroplasty, Inc. Since 2012, Mr. Kill has been an Operating Partner with Altamont Capital Partners, a private equity firm. He served as President from 2007 to 2012, as Chairman and CEO from 2009 to 2010 while the company was public, and as CEO and a Board member from 2010 to 2012 after it became a private company, of Virtual Radiologic Corporation, a national radiology organization that uses technology to enhance radiologic practice. Prior to joining Virtual Radiologic, Mr. Kill was President of Physicians Systems for Misys Healthcare Systems, a provider of clinical and practice management software applications to physician practices, group practices, health systems and managed services organizations. Before joining Misys Healthcare Systems in 2002, Mr. Kill was Executive Vice President of Entertainment Publications, Inc., where he was employed from 1996 through 2001, and Vice President of Operations for Baxter Healthcare, where he was employed from 1986 through 1996.

**Darin Hammers** has served as Cogentix's Senior Vice President of Global Sales and Marketing since March 31, 2015 until January 4, 2016, when he was promoted to the position of Chief Operating Officer, and had served in the same role for Uroplasty, Inc. from September 2013 until March 31, 2015. From February 2013 until September 2013, he served as Uroplasty's Vice President of Global Sales. Prior to joining Uroplasty, Mr. Hammers was Vice President of Sales – Bard Medical Division at CR Bard from 2009 to 2013. He held roles of increasing responsibility in sales and sales management with Boston Scientific Corporation from 1996 to 2009.

#### **Incorporation and Current Subsidiaries**

We were incorporated as a Delaware corporation, and are the successor of operations originally begun in 1987. We have two subsidiaries, Machida Incorporated, a Delaware corporation, and Uroplasty, LLC, a Delaware limited liability company.

Machida Incorporated manufactures and sells our borescope products to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries.

Uroplasty LLC manufactures and sells Urgent PC System, Macroplastique, VOX Implants, PTQ Implants, and all of their accessories in the United States. Uroplasty, LLC has two wholly owned foreign subsidiaries and their respective principal functions are as follows:

Uroplasty BV Incorporated in The Netherlands, distributes the Urgent PC System, Macroplastique, VOX Implants, PTQ Implants, all of their accessories, and wound care products. Products are sold primarily through our direct sales force in the United Kingdom, The Netherlands, Switzerland and the Nordic countries, and through distributors in all other markets.

Uroplasty LTD Incorporated in the United Kingdom and acts as the sole distributor of the Urgent PC System, Macroplastique, PTQ Implants, all of their accessories, and wound care products in the United Kingdom and Ireland. Products are sold primarily through a direct sales organization.

#### **Available Information**

Our principal executive offices are located at 5420 Feltl Road, Minnetonka, Minnesota 55343. Our telephone number at this address is (952) 426-6140. Our website is located at [www.cogentixmedical.com](http://www.cogentixmedical.com). The information contained on our website or connected to our website is not incorporated by reference into and should not be considered part of this report.

You can access, free of charge, our filings with the Securities and Exchange Commission, including our annual report on Form 10-K, our quarterly reports on Form 10-Q, current reports on Form 8-K and any other amendments to those reports, at our website or at the Securities and Exchange Commission's website at [www.sec.gov](http://www.sec.gov).

#### **Cautionary Note Regarding Forward-Looking Statements**

This annual report on Form 10-K contains not only historical information, but also forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. In addition, we or others on our behalf may make forward-looking statements from time to time in oral presentations, including telephone conferences and/or web casts open to the public, in news releases or reports, on its Internet web site or otherwise. All statements other than statements of historical facts included in this report that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our plans, objectives, strategies and prospects regarding, among other things, our business, operating results and financial condition. We have identified some of these forward-looking statements with words like "believe," "may," "could," "would," "might," "possible," "potential," "project," "will," "should," "expect," "intend," "plan," "predict," "anticipate," "estimate," "approximate," "contemplate" and "continue," the negative of these words, other words and terms of similar meaning and the use of future dates. These forward-looking statements may be contained in this section, the notes to our financial statements and elsewhere in this report, including under the heading "*Part II. Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations.*" Our forward-looking statements generally relate to:

- Our future revenues, future operating expenses, anticipated cash burn rate and whether and how long our existing cash and cash equivalents will be sufficient to fund our operations, and our continuing losses;
- the market size and market acceptance of our products;
- the status of our product development programs; and
- the effect of new accounting pronouncements and future health care, tax and other legislation.

Forward-looking statements involve risks and uncertainties. These uncertainties include factors that affect all businesses as well as matters specific to us. Some of the factors known to us that could cause our actual results to differ materially from what we have anticipated in our forward-looking statements are described under the heading "*Part I. Item 1A. Risk Factors*" below. We caution readers not to place undue reliance on any forward-looking statement that speaks only as of the date made and to recognize that forward-looking statements are predictions of future results, which may not occur as anticipated. Actual results could differ materially from those anticipated in the forward-looking statements and from historical results, due to the risks and uncertainties described under the heading "*Part I. Item 1A. Risk Factors*" below, as well as others that we may consider immaterial or do not anticipate at this time. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. Our expectations reflected in our forward-looking statements can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties, including those described below under the heading "*Part I. Item 1A. Risk Factors.*" The risks and uncertainties described under the heading "*Item 1A. Risk Factors*" below are not exclusive and further information concerning us and our business, including factors that potentially could materially affect our operating results or financial condition, may emerge from time to time. We assume no obligation to update our forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements. We advise you, however, to consult any further disclosures we make on related subjects in our quarterly reports on Form 10-Q and current reports on Form 8-K that we file with or furnish to the Securities and Exchange Commission.

**ITEM 1A. RISK FACTORS**

*Our operations are subject to a number of risks and uncertainties that may affect our financial results, our accounting, and the accuracy of the statements we make in this Form 10-K. For example, we make statements about our belief in the efficacy of our product, the impact of regulatory and reimbursement approvals on our products and revenues, the attributes of our products versus those of our competitors, the adequacy of our resources, including cash, available to us, and other matters all of which represent our expectations or beliefs about future events. Our actual results may vary from these expectations because of a number of factors that affect our business, the most important of which include the following:*

***Our future results will suffer if we do not effectively manage our expanded operations.***

We anticipate that the size of our business will increase significantly beyond the current size of our predecessor businesses. Our future success depends, in part, upon our ability to manage this expanded business, which will pose substantial challenges for management, including challenges related to the management and monitoring of new operations and associated increased costs and complexity. There are no assurances that we will be successful or that we will realize the expected operating efficiencies, cost savings and other benefit currently anticipated from the merger.

***Our actual financial positions and results of operations may differ materially from the unaudited pro forma financial data.***

The unaudited pro forma financial information contained in Note 2 to the “Notes to Consolidated Financial Statements” in Part II, Item 8 of this report and previously provided by us has been presented for illustrative purposes only and may not be an indication of what our financial position or results of operations will be in the future. The pro forma financial information has been derived from the audited and unaudited historical financial statements of Uroplasty and Vision-Sciences, and certain adjustments and assumptions have been made regarding the combined company after giving effect to the transaction. The assets and liabilities of Uroplasty and Vision-Sciences have been measured at their fair value based on various preliminary estimates using assumptions that management believes are reasonable utilizing information currently available. The process for estimating the fair value of acquired assets and assumed liabilities requires the use of judgment in determining the appropriate assumptions and estimates. These purchase price estimates may be revised as additional information becomes available and as additional analyses are performed. Differences between preliminary estimates in the pro forma financial information and the final acquisition accounting will occur and could have a material impact on the pro forma financial information and our financial position and future results of operations.

The assumptions used in preparing the pro forma financial information may not prove to be accurate, and other factors may affect our financial condition or results of operations. Any potential decline in our financial condition or results of operations may cause significant variations in our share price.

***If goodwill or other intangible assets that we recorded in connection with the merger become impaired, we could be required to take significant charges against earnings.***

In connection with the accounting for the merger, we have recorded a significant amount of goodwill and other intangible assets. Under U.S. GAAP, we must assess, at least annually and potentially more frequently, whether the value of our goodwill and other indefinitely-lived intangible assets has been impaired. Amortizing intangible assets will be assessed for impairment in the event of an impairment indicator. Any impairment of the value of goodwill or other intangible assets will result in a charge against earnings, which could materially adversely affect our results of operations and stockholders’ equity in future periods.

***We may obtain additional financing, which may not be available on favorable terms at the time it is needed and which could reduce our operational and strategic flexibility.***

We may obtain additional financing in 2016. We will seek to acquire that through additional equity and/or debt financing arrangements, which may or may not be available on favorable terms at such time. If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we do not have, or are not able to obtain, sufficient funds, we may have to delay development or commercialization of our products or license to third parties the rights to commercialize products or technologies that we would otherwise seek to commercialize. We also may have to reduce marketing, customer support or other resources devoted to our products or cease operations.

***We may be unable to successfully integrate Uroplasty's and Vision's operations or realize the anticipated cost savings and other potential benefit of the merger in a timely manner, if at all. As a result, the value of our shares may be adversely affected.***

Uroplasty and Vision entered into the merger agreement because each company believed that the merger will be beneficial to our respective stockholders, other stakeholders and businesses. Achieving the anticipated potential benefit of the merger will depend in part upon whether we are able to integrate predecessor companies' operations in an efficient and effective manner. The integration process may not be completed smoothly or successfully. The necessity of coordinating geographically separated organizations, systems and facilities and addressing possible differences in business backgrounds, corporate cultures and management philosophies may increase the difficulties of integration. Uroplasty and Vision operated numerous systems, including those involving management information, purchasing, accounting and finance, sales, billing, payroll, employee benefit and regulatory compliance. Uroplasty and Vision have inconsistencies in standards, controls, procedures or policies that could affect our ability to maintain relationships with customers and employees and/or to achieve the anticipated benefit of the merger. The integration of certain operations requires the dedication of significant management resources, which may temporarily distract management's attention from our day-to-day business. Employee uncertainty and lack of focus during the integration process may also disrupt our business. A failure of our management to integrate successfully the operations of the two companies, or such integration of the operations, if any, within a longer time frame than expected could have a material adverse effect on our business and operating results. We may not be able to achieve the anticipated operating and cost synergies or long-term strategic benefit of the merger. An inability to realize the full extent of, or any of, the anticipated benefit of the merger, as well as any delays encountered in the integration process, could have an adverse effect on our business and operating results, which may negatively affect the value of our shares.

Our success will depend in part upon the ability to retain key employees of each predecessor company. Competition for qualified personnel can be very intense. In addition, key employees may depart because of issues relating to the uncertainty or difficulty of integration or a desire not to remain with us. Accordingly, no assurance can be given that key employees will be retained.

We are substantially completed with the process of combining the two predecessor companies. The remaining integration components may result in additional and unforeseen expenses, and the anticipated benefit of the final integration items may not be realized.

***We have historically incurred losses and may never reach profitability.***

We have incurred net losses in each of the last five fiscal years, including the nine-month transition period ended December 31, 2015. As of December 31, 2015, we had an accumulated deficit of approximately \$59 million primarily because of costs relating to the development, including seeking regulatory approvals, and commercialization of our products. We expect our operating expenses relating to sales and marketing activities along with product development and clinical trials will continue to increase during the foreseeable future. To achieve profitability, we must generate substantially more revenue than we have generated in prior years. Our ability to achieve significant revenue growth will depend, in large part, on our ability to successfully integrate our predecessor companies following the merger, to achieve widespread market acceptance of our products and successfully expand our business in the U.S. We may never achieve these objectives or otherwise become profitable.

***The size and resources of our competitors may render it difficult for us to successfully compete in the marketplace.***

Our products compete against similar medical devices and other treatment methods, including drugs. Many of our competitors, which include some of the largest medical products and pharmaceutical companies in the world, have significantly greater financial, research and development, manufacturing and marketing resources than we have. Our competitors could use and have used these resources to develop and/or acquire products that may be safer, more effective, less invasive, less expensive or more readily accepted than our products. Their products could make our technology and products obsolete or noncompetitive. Our competitors could also devote greater resources to the marketing and sale of their products and adopt more aggressive pricing policies than we can. Additionally, in 2016 we anticipate the formal launch of a competing PTNS technology from a large, well-known medical device manufacturer.

Our ability to compete effectively depends upon our ability to distinguish our brand and our products from our competitors' brands and their products and to obtain adequate reimbursement for procedures performed using our products. Factors affecting our competitive position include:

- ability to sell products tailored to meet the needs of our customers and patients;
- sales, marketing, and distribution capabilities;
- product performance and design;
- quality of customer support;
- product pricing;
- product safety;
- success and timing of new product development and introductions; and
- intellectual property protection.

***Our stock price may fluctuate and be volatile.***

The trading price of our common stock may be subject to significant fluctuations due to the following factors, among others:

- actual or anticipated variations in operating results;
- conditions or trends in the medical device market;
- announcements of new or acquired products or technologies by us or our competitors;
- announcements by us or our competitors of significant customer wins or losses, gains or losses of distributors;
- technological innovations, new products or services;
- the success of our efforts to acquire or license additional products;
- additions or departures of key personnel;
- actual or expected sales of a large number of shares of our common stock;
- availability of sources of capital;
- adverse litigation;
- unfavorable legislative or regulatory decisions;
- developments in U.S. or international reimbursement systems;
- variations in interest rates;
- general market and economic conditions;
- availability of components on acceptable terms;
- availability of distributor arrangements on favorable terms; and
- changes in accounting standards, policies, guidance or interpretations.

In addition, the stock market in general, the NASDAQ Capital Market, and the market for shares of novel technology and medical device companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Further, the market prices of life science companies have been unusually volatile in recent years, and such volatility may continue for the foreseeable future. These broad market and industry factors may materially harm the market price of our common stock, regardless of our operating performance. In addition, this volatility and the low level of market liquidity for our common stock could adversely affect an investor's ability to sell shares of our common stock and the market price for such shares, at any given time.

In the past, companies that have experienced volatility in the market price of their stock have been the targets of securities class action litigation. We may become the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert management attention, which could seriously harm our business.

***We may attempt to acquire new products or technologies, and if we are unable to successfully complete these acquisitions or to integrate acquired businesses, products, technologies or employees, we may fail to realize expected benefits or harm our existing business.***

Our success will depend, in part, on our ability to expand our product offerings and grow our business in response to changing technologies, customer demands and competitive pressures. In some circumstances, we may seek to do so through the acquisition of complementary businesses, products or technologies rather than through internal development. The identification of suitable acquisition candidates and obtaining adequate financing can be difficult, time consuming and costly, and we may not be able to successfully complete identified acquisitions. Furthermore, even if we successfully complete an acquisition, we may not be able to successfully integrate newly acquired organizations, products or technologies into our operations, and the process of integration could be expensive and time consuming, and may strain our resources. Consequently, we may not achieve anticipated benefits of the acquisitions, which could harm our existing business. In addition, future acquisitions could result in potentially dilutive issuances of equity securities or the incurrence of debt, contingent liabilities or expenses, or other charges such as in-process research and development, any of which could harm our business and affect our financial results or cause a reduction in the price of our common stock.

***If we are not able to acquire or license other products, our business and future growth prospects could suffer.***

As part of our growth strategy, we intend to acquire or license additional products and technologies for development and commercialization. The success of this strategy depends upon our ability to identify, select and acquire the right products and technologies.

Products and technologies that we license or acquire may require additional development prior to sale, including clinical testing and approval by the FDA and other regulatory bodies, and we may encounter difficulties or delays in completing the development or receiving the necessary approvals. We may find that the product or technology cannot be manufactured economically or commercialized successfully. We may not be able to acquire or license the right to products on terms that we find acceptable, if at all.

Even if we complete future acquisitions, our business, financial condition and the results of operations could be negatively affected because we may be unable to integrate the acquired business or products successfully and realize anticipated economic, operational and other benefit in a timely manner; and/or the acquisition may disrupt our ongoing business, distract our management team and divert our resources.

***Product liability claims could adversely affect our business and results of operations.***

The manufacture and sale of our products expose us to significant risk of product liability claims, which may have a negative impact on our business. Any defects or risks that we have not yet identified with our products may give rise to product liability claims. Our existing worldwide product liability insurance coverage of up to \$10 million in liability may be inadequate to protect us from liabilities we may incur. We may also not be able to maintain adequate product liability insurance at acceptable rates. If a product liability claim (or series of claims) would be brought against us for uninsured liabilities or in excess of our insurance coverage, and ultimately it is determined that we are liable, our business could suffer. Additionally, we could experience a material design or manufacturing failure in our products, a quality system failure, or other safety issues or heightened regulatory scrutiny that would warrant a recall of some of our products. A recall of any of our products would likely be costly, would be uninsured and could also result in increased product liability claims. Further, while we train our physician customers in the proper use of our products, we cannot be certain that they will implement our instructions accurately. If our products are used incorrectly by our customers, injury may occur and this could give rise to product liability claims against us.

***Product quality problems could lead to reduced revenue, gross margins and net income.***

We produce highly complex video-based endoscope products that incorporate sophisticated technology, including hardware and software. Software typically contains bugs that can unexpectedly interfere with operations. Our quality assurance testing programs may not be adequate to detect all defects, either ones in individual products or ones that could affect numerous shipments, which might interfere with customer satisfaction, reduce sales opportunities, increase warranty repairs, or reduce gross margins. In the past, we have had to replace certain components and provide remediation in response to defects or bugs in our products. There can be no assurance that such a remediation, depending on the products involved, would not have a material impact on our revenue, margins, and net income. An inability to cure a product defect could result in the failure of a product line, a product recall, temporary or permanent withdrawal of a product from a market, damage to our reputation, inventory costs or product reengineering expenses, any of which could have a material adverse impact on our revenue, margins, and net income.

***We expect gross margins to vary over time, and our level of product gross margins may not be sustainable.***

The current levels of our product gross margins may not be sustainable and may continue to be adversely affected by numerous factors, including:

- obsolescence of components or products due to sales trends and new product introductions;
- our inability to reduce supply and production costs;
- increases in material or labor costs;
- changes in shipment volume;
- loss of cost savings due to changes in component pricing, including the impact of foreign exchange rates for components purchased overseas;
- changes in distribution channels; and
- increased warranty costs.

***The use and acceptance of certain of our products depend heavily upon the availability of third-party reimbursement for the procedures in which our products are used.***

In the U.S., healthcare providers that purchase medical devices, including our products, generally rely on third-party payers, including Medicare, Medicaid, private health insurance carriers and managed care organizations, to reimburse all or part of the cost and fees associated with the procedures performed using these devices. The commercial success of our products will depend on the ability of healthcare providers to obtain adequate reimbursement from third-party payers for the procedures in which our products are used. Third-party payers are more frequently challenging the coverage and pricing of medical products and procedures.

Even if a procedure is eligible for reimbursement, the level of reimbursement may not be adequate to justify the use of our products. In addition, third-party payers may deny reimbursement if they determine that the device used in a treatment was not cost-effective or was used for a non-approved indication, particularly if there is not a published Current Procedural Terminology, or CPT, code for reimbursement. For example, in 2009, the American Medical Association advised the medical community that the previously recommended Category 1 CPT code for percutaneous tibial nerve stimulation, or PTNS, treatments should be replaced with an unlisted code. As a result, many third-party insurers delayed or denied reimbursement for PTNS treatments, significantly impacting the sales of our Urgent PC System, until a new code was introduced effective in January 2011.

Reimbursement and healthcare payment systems in international markets vary significantly by country, with some countries offering government-sponsored healthcare or private insurance, or both. In many countries where there is government-sponsored healthcare reimbursement, decisions are made by individual hospitals with the government setting an upper limit of reimbursement. In most foreign countries, there are also insurance systems that may offer payments for alternative procedures. We cannot be certain that we, or in countries in which we work with our distributors, those distributors, will successfully and cost-effectively manage all of these payment systems.

All third-party reimbursement programs, whether government-funded or commercially insured, inside the U.S. or outside, are developing increasingly sophisticated methods of controlling health care costs through prospective reimbursement and capitation programs, group purchasing, redesign of benefit, second opinions, careful review of bills, encouragement of healthier lifestyles and exploration of more cost-effective methods of delivering healthcare. These types of programs can potentially limit the amount that healthcare providers may be willing to pay for medical devices and could have a material adverse effect on our financial position and results of operations.

***We cannot predict how quickly or how broadly the market will accept our products.***

In addition to the availability of third-party reimbursement, market acceptance of our products will depend on our ability to demonstrate the safety, clinical efficacy, perceived benefit, and cost-effectiveness of our products compared to products or treatment options of our competitors. We cannot assure you that we will be successful in educating the marketplace about the benefit of our products.

***We may not have the resources to successfully market our products, which would adversely affect our business and results of operations.***

The marketing of our products requires a significant amount of time and expense in order to identify the physicians who would use our products and to train a sales force that is large enough to interact with the targeted physicians. The ease and predictability of third-party reimbursement significantly impacts the success of our marketing activities. We may not have adequate resources to market our products successfully against larger competitors who have more resources than we do. If we cannot market our products successfully, our business and results of operations would be adversely affected.

***If we are not able to attract, retain and motivate our sales force and expand our distribution channels, our sales and revenues will suffer.***

In the U.S., we have a sales organization consisting primarily of direct sales representatives, and a marketing organization to market our products directly and support our distributor organizations. We expect to expand our sales and marketing organization, as needed, to support our growth. We have and will continue to incur significant additional expenses to support this organization. We cannot be certain that our sales organization will be able to generate sales of our urology and endoscopy products at levels that justify our expense, or even if we can, that we will be able to recruit, train, motivate or retain qualified sales and marketing personnel.

A significant portion of our revenue outside of the United States is through a network of independent distributors. Our ability to increase product sales in foreign markets will largely depend on our ability to develop and maintain relationships with our distributors and on their ability to successfully market and sell our products. We may not be able to retain distributors who are willing to commit the necessary resources to marketing and selling our products to the level of our expectations. Failure to maintain or expand our distribution channels or to recruit, retain and motivate qualified personnel could have a material adverse effect on our product sales and revenues.

In addition, we have a limited ability to direct or influence the activities of our third-party, independent distributors. Our distributors could take one or more of the following actions, any of which could have a material adverse effect on our business, prospects and brand:

- sell products that compete with our products in breach of their non-competition agreements with us;
- fail to adequately promote our products; or
- fail to provide proper service to our end users.

If we are unable to adequately manage our distribution network, or if our distributors fail to meet their obligations under their agreements with us, our corporate image among end users of our products could be damaged, resulting in a failure to meet our sales goals. In addition, foreign governments have increased their anti-bribery efforts in the healthcare sector to reduce improper payments received by hospital administrators and doctors in connection with the purchase of pharmaceutical products and medical devices. We are subject to the regulations of the Foreign Corrupt Practices Act and are required to monitor our activities associated with our foreign sales. To our knowledge, none of our distributors engages in corrupt practices. However, our distributors may violate these laws or otherwise engage in illegal practices with respect to their sales or marketing of our products, which would adversely affect our corporate image and business.

***Our distributors may not obtain regulatory approvals on a timely basis, if at all.***

We often rely on our distributors in countries outside the U.S. in seeking regulatory approval to market our products in particular countries. To the extent we do so, we are dependent on persons outside of our direct control to make regulatory submissions and secure approvals, and we do not, and will not, have direct access to health care agencies in those markets to ensure timely regulatory approvals or prompt resolution of regulatory or compliance matters. If our distributors fail to obtain the required approvals or do not do so in a timely manner, our sales from our international operations and our results of operations may be adversely affected.

***If we cannot attract and retain our key personnel and management team, we may not be able to manage and operate successfully, and we may not be able to meet our strategic objectives.***

Our future success depends, in large part, upon our ability to attract and retain and motivate our management team and key managerial, scientific, sales and technical personnel. Key personnel may depart because of difficulties with change or a desire not to remain with us. We are highly dependent on our senior management team, and any unanticipated loss or interruption of their services could significantly reduce our ability to meet our strategic objectives because, given the intense competition for senior management and other key personnel, it may not be possible for us to find appropriate replacement personnel should the need arise. The loss of a member of our senior management or our professional staff would require the remaining senior executive officers to divert immediate and substantial attention to seeking a replacement. There is no guarantee that we will be successful in retaining our current personnel or in hiring or retaining qualified personnel in the future. Loss of key personnel or the inability to hire or retain qualified personnel in the future could have a material adverse effect on our ability to operate successfully. Further, our inability, if any, to enforce non-compete arrangements related to key personnel who have left the company could have a material adverse effect on our business.

***If third parties claim that our products infringe upon their intellectual property rights, we may incur liabilities and costs and may have to redesign or discontinue selling the affected product.***

The medical device industry is litigious with respect to patents and other intellectual property rights. Companies operating in our industry routinely seek patent protection for their product designs, and many of our principal competitors have large patent portfolios. Companies in the medical device industry have used intellectual property litigation to gain a competitive advantage. Whether a product infringes a patent involves complex legal and factual issues, the determination of which is often uncertain and costly. We face the risk of claims that our products have infringed on third parties' intellectual property rights. Our efforts to identify and avoid infringing on third parties' intellectual property rights may not always be successful. Any claims of patent or other intellectual property infringement, even those without merit, could:

- be expensive and time consuming for us to defend;
- result in us being required to pay significant damages to third parties;
- cause us to cease making or selling products that incorporate the challenged intellectual property;
- require us to redesign, reengineer or rebrand our products, if feasible;
- require us to enter into royalty or licensing agreements in order to obtain the right to use a third party's intellectual property, which agreements may not be available on terms acceptable to us, or at all;
- divert the attention of our management; or
- result in our customers or potential customers deferring or limiting their purchases or use of the affected products until resolution of the litigation.

In addition, new patents obtained by our competitors could threaten our products' continued life in the market even after it has already been introduced.

***If we are unable to adequately protect our intellectual property rights, we may not be able to compete effectively.***

Our success depends in part on our ability to protect the proprietary rights to the technologies used in our products. We rely on patent protection, as well as a combination of trademark laws and confidentiality, noncompetition and other contractual arrangements to protect our proprietary technology. However, these legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep a competitive advantage. Our patents and patent applications, if issued, may not be broad enough to prevent competitors from introducing similar products into the market. Our patents, if challenged or if we attempt to enforce them, may not necessarily be upheld by the courts. In addition, patent protection in foreign countries may be different from patent protection under U.S. laws and may not be favorable to us.

We also rely on unpatented proprietary technology. We cannot assure you that we can meaningfully protect all of our rights in our unpatented proprietary technology or that others will not independently develop substantially equivalent products or processes or otherwise gain access to our unpatented proprietary technology. We attempt to protect our trade secrets and other unpatented proprietary technology through the use of confidentiality and noncompetition agreements with our current key employees and with other parties to whom we have divulged trade secrets. However, these agreements may not be enforceable or may not provide meaningful protection for our proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements or in the event competitors discover or independently develop similar proprietary information.

Efforts on our part to enforce any of our proprietary rights could be time-consuming and expensive, which could adversely affect our business and prospects and divert our management's attention.

***Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.***

In the ordinary course of our business, we use our networks to collect and store sensitive data, including intellectual property, our proprietary business information and that of our customers, suppliers and business partners, personally identifiable information of our customers and employees, and data relating to patients who use our products. The secure processing, maintenance and transmission of this information is critical to our operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, and regulatory penalties, disrupt our operations and the services we provide to our customers, damage our reputation, and cause a loss of confidence in our products and services, which could adversely affect our operating margins, revenues and competitive position.

***The loss or interruption of materials from any of our key suppliers could delay the manufacture of our products, which would limit our ability to generate sales and revenues.***

We currently purchase several key materials used in our products from single source suppliers, including the finished products for our Urgent PC System. If one of these suppliers delayed or curtailed shipments to us, our ability to manufacture and deliver product would be impaired, our sales would decline or be curtailed for that product, and we would be forced to quickly locate an alternative source of supply. We cannot be sure that acceptable alternative arrangements could be made on a timely basis. Further, our reliance on such suppliers and the cost and difficulty we would encounter in qualifying an alternative subjects us to increased risk of price increases by single source suppliers. Additionally, the qualification of materials and processes as a result of a supplier change could be deemed as unacceptable to regulatory authorities and cause delays and increased costs due to additional test requirements. A significant interruption in the supply of materials, for any reason, could delay the manufacture and sale of our products, which would limit our ability to generate revenues.

Certain components for our fiber-based endoscopes and video-based endoscopes are generally only available from one source. Our inability to obtain any of these parts could delay or prevent us from making and selling products, which would have a material adverse effect on our future financial condition and results of operations.

Our borescopes are assembled using components and subassemblies purchased from independent vendors. While most components and subassemblies are currently available from more than one supplier, certain critical components are currently purchased only from limited key suppliers with which we do not have long or short term contracts. Our failure to obtain a sufficient quantity of such components on favorable terms could materially adversely affect the sales in our industrial business.

***Our medical products and manufacturing practices are subject to regulation by the FDA and by other state and foreign regulatory agencies.***

Our medical products are subject to extensive regulation in the U.S. and in the foreign countries where we do business. There can be no assurance that the required regulatory clearances will be obtained, and those obtained may include significant limitations on the uses of the product in question. In addition, changes in existing regulations or the adoption of new regulations could make our regulatory compliance more difficult in the future. The failure to obtain required regulatory clearances or to comply with applicable regulations may result in fines, delays, suspensions of clearances, seizures, recalls of products, operating restrictions or criminal prosecutions, and could have a material adverse effect on our operations.

***If we are not able to maintain sufficient quality controls, regulatory approvals of our products by the European Union, Canada, the FDA or other relevant authorities could be delayed or denied and our sales and revenues will suffer.***

The FDA, European Union, Canada or other related authorities could stop or delay approval of production of products if our manufacturing facilities do not comply with applicable manufacturing requirements. The FDA's Quality System Regulations impose extensive testing, control, documentation and other quality assurance requirements. Canada and the European Union also impose requirements on quality systems of manufacturers, who are inspected and certified on a periodic basis and may be subject to additional unannounced inspections. Further, our suppliers are also subject to these regulatory requirements. Failure by any of our suppliers or us to comply with these requirements could prevent us from obtaining or retaining approval and marketing of our products.

***Currency exchange rate fluctuations could adversely affect our operating results.***

Because some of our business includes international business transactions, costs and prices of our products or components in overseas countries are affected by foreign exchange rate changes. As a result, foreign exchange rate fluctuations may adversely affect our business, operating results and financial condition.

Currently, we do not have any foreign exchange forward contracts and we do not hedge anticipated foreign currency cash flows.

***We derive a significant portion of our sales from outside of the U.S. and are subject to the risks of international operations.***

We derived approximately 25% of our net sales in the Transition Period ended December 31, 2015 from customers and operations in international markets. The sale and shipping of our products and services across international borders, as well as the purchase of components and products from international sources, subject us to a number of risks, including:

- the imposition of additional U.S. and foreign governmental controls or regulations;
- the imposition of costly and lengthy export licensing requirements;
- local political and economic instability;
- fluctuations in the value of the U.S. dollar relative to foreign currencies;

- difficulties in recruiting and maintaining distributors and staff in remote locations, including sales people;
- changes in duties and tariffs, license obligations and other non-tariff barriers to trade;
- the imposition of new trade restrictions;
- the imposition of restrictions on the activities of foreign agents, representatives and distributors;
- foreign taxation compliance and penalties;
- pricing pressure that we may experience internationally;
- laws and business practices favoring local companies;
- longer payment cycles;
- difficulties in enforcing agreements and collecting receivables through certain foreign legal systems; and
- difficulties in enforcing or defending intellectual property rights.

We cannot assure that one or more of these factors will not harm our business.

***Failure to comply with the U.S. Foreign Corrupt Practices Act could subject us to, among other things, penalties and legal expenses that could harm our reputation and have a material adverse effect on our business, financial condition and operating results.***

We are required to comply with the U.S. Foreign Corrupt Practices Act, or FCPA, which generally prohibits covered entities and their intermediaries from engaging in bribery or making other prohibited payments to foreign officials for the purpose of obtaining or retaining business or other benefit. In addition, the FCPA imposes accounting standards and requirements on publicly traded U.S. corporations and their foreign affiliates, which are intended to prevent the diversion of corporate funds to the payment of bribes and other improper payments, and to prevent the establishment of “off books” slush funds from which such improper payments can be made. We also are subject to similar anticorruption legislation implemented in Europe under the Organization for Economic Co-operation and Development’s Convention on Combating Bribery of Foreign Public Officials in International Business Transactions. We either operate or plan to operate in a number of jurisdictions that pose a high risk of potential violations of the FCPA and other anticorruption laws, and we utilize a number of distributors for whose actions we could be held liable under the FCPA and other anticorruption laws. We inform our personnel, distributors and agents of the requirements of the FCPA and other anticorruption laws, including, but not limited to their reporting requirements. We also have developed and will continue to develop and implement systems for formalizing contracting processes, performing due diligence on personnel, distributors and agents and improving our recordkeeping and auditing practices regarding these regulations. However, there is no guarantee that our personnel, distributors or agents have not or will not engage in conduct undetected by our processes and for which we might be held responsible under the FCPA or other anticorruption laws.

If our personnel, distributors or agents are found to have engaged in practices in violation of the FCPA or other anticorruption laws, we could suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures, including further changes or enhancements to our procedures, policies and controls, as well as potential personnel changes and disciplinary actions. During the past few years, the SEC has increased its enforcement of violations of the FCPA against companies, including several medical device companies. Although we do not believe we are currently a target, any investigation of any potential violations of the FCPA or other anticorruption laws by U.S. or foreign authorities could have an adverse impact on our business, financial condition and operating results.

Certain foreign companies, including some of our competitors, are not subject to prohibitions as strict as those under the FCPA or, even if subjected to strict prohibitions, such prohibitions may be laxly enforced in practice. If our competitors engage in corruption, extortion, bribery, pay-offs, theft or other fraudulent practices, they may receive preferential treatment from personnel of some companies, giving our competitors an advantage in securing business, or from government officials, who might give them priority in obtaining new licenses, which would put us at a competitive disadvantage.

***Our corporate documents contain provisions that could discourage, delay or prevent a change in control of the company.***

Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger or acquisition, even if our stockholders consider the terms favorable. Our certificate of incorporation and bylaws provide for a staggered board of directors, requiring our directors to serve for three-year terms, with approximately one third of the directors standing for reelection each year. A staggered board could make it more difficult for a third party to obtain control of our board of directors through a proxy contest, which may be a necessary step in an acquisition of us that is not favored by our board of directors.

***Our officers and directors have the ability to exercise significant control over the company.***

As of March 15, 2016, our officers and directors owned an aggregate of approximately 11.5% of outstanding shares of our common stock. Under a convertible note dated September 19, 2012, as amended (the “2012 Note”), Mr. Lewis C. Pell, a member of our Board of Directors, at his option at any time prior to maturity, but not until after three years following the effective date of the merger or, if earlier, three days prior to the record date for the declaration of any dividend or distribution on our common stock in cash or other property other than common stock, has the right to convert the unpaid principal balance, which was \$20.0 million as of March 15, 2016, into 3,333,333 shares of our common stock. Under a convertible note dated September 25, 2013, as amended (the “2013 Note”), Mr. Pell, at his option at any time prior to maturity, but not until after three years following the effective date of the merger or, if earlier, three days prior to the record date for the declaration of any dividend or distribution on our common stock in cash or other property other than common stock, has the right to convert the unpaid principal balance, which was \$3.5 million as of March 15, 2016, into additional 786,516 shares of our common stock. Under a convertible promissory note dated June 16, 2014 (the “2014 Note”), Mr. Pell, at his option has the right to convert the unpaid principal balance, which was \$4.99 million as of March 15, 2016, into additional 899,099 shares of our common stock. Mr. Pell also has three warrants to purchase an aggregate of 376,123 shares of our common stock at a weighted average exercise price of \$9.31 per share. The conversion of the 2012 Note, the 2013 Note and the 2014 Note and exercise of the warrants would increase the aggregate ownership of our officers and directors (assuming that our other directors and officers exercise their options) to approximately 35.9% of outstanding shares of our common stock as of March 15, 2016. As such, our directors and officers exercise significant control over all matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control of the company or forcing management to change our operating strategies, which may be to the benefit of management but not in the interest of the stockholders.

**ITEM 1B. UNRESOLVED STAFF COMMENTS**

None.

**ITEM 2. PROPERTIES**

We lease an 18,258 square-foot office, warehouse and manufacturing facility in Minnetonka, Minnesota for our corporate headquarters pursuant to a lease agreement with Liberty Property Limited Partnership expiring in June 2019. At the Minnetonka facility, we also manufacture Macroplastique and warehouse and ship Urgent PC and Macroplastique.

We lease a 20,500 square-foot office, warehouse and manufacturing facility in Orangeburg, New York pursuant to a lease agreement with GHP Office Realty, LLC that expires in August 2017. At the Orangeburg facility, we manufacture our advanced line of endoscopy-based medical products, including our flexible fiber and video endoscopes, for a variety of specialties and markets and industrial borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries.

We leased a 9,835 square foot office, warehouse and manufacturing facility in Natick, Massachusetts, where we manufactured EndoSheath products, pursuant to a lease agreement with Yellow Brick, LLC, assignee of Nivek Investments I, LLC, which expired in August 2015.

On April 2, 2015, we leased approximately 24,400 square feet in Westborough, Massachusetts. As of August 2015, upon the expiration of our Natick lease, we now manufacture EndoSheath products at this location, pursuant to a lease agreement with Glenborough Flanders Park, LLC expiring in December 2025.

We own 9,774 square feet of office and warehouse space in Geleen, The Netherlands. At this facility, we maintain our European headquarters and warehouse and ship Urgent PC and Macroplastique.

We believe that these facilities are suitable and adequate for our operations for the foreseeable future.

**ITEM 3. LEGAL PROCEEDINGS**

We are not involved in any material active legal actions, however, from time to time may be subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time.

**ITEM 4. MINE SAFETY DISCLOSURE**

Not applicable.

**PART II**

**ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES**

**Market Information**

Our common stock is listed on the NASDAQ Capital Market under the symbol "CGNT." Prior to the completion of the merger on March 31, 2015, our stock traded under the symbol "VSCI."

The following table sets forth the high and low sales prices for our common stock for each of our full quarterly periods within the Transition Period and two most recent completed fiscal years ended March 31, 2015 and March 31, 2014 as reported on the NASDAQ Capital Markets. The prices for the two fiscal years ended March 31, 2015 and March 31, 2014 have been adjusted to reflect the one to five reverse stock split that occurred on March 31, 2015.

<u>Transition Period ended December 31, 2015</u>	<u>Low</u>	<u>High</u>
April 1, 2015 – June 30, 2015	\$ 1.42	\$ 2.40
July 1, 2015 – September 30, 2015	\$ 1.10	\$ 1.72
October 1, 2015 – December 31, 2015	\$ 1.10	\$ 1.70
<u>Fiscal year ended March 31, 2015</u>	<u>Low</u>	<u>High</u>
First Quarter	\$ 4.80	\$ 6.45
Second Quarter	\$ 4.25	\$ 6.20
Third Quarter	\$ 3.36	\$ 6.10
Fourth Quarter	\$ 1.75	\$ 3.62
<u>Fiscal year ended March 31, 2014</u>	<u>Low</u>	<u>High</u>
First Quarter	\$ 4.45	\$ 5.75
Second Quarter	\$ 4.15	\$ 5.50
Third Quarter	\$ 3.90	\$ 7.50
Fourth Quarter	\$ 4.92	\$ 8.75

As of March 15, 2016, we had approximately 101 holders of record of our common stock. Registered ownership includes nominees who may hold securities on behalf of multiple beneficial owners. We have never declared or paid cash dividends on our common stock. We currently intend to retain all future earnings, if any, for the operation and expansion of our business and, therefore, do not anticipate declaring or paying cash dividends on our common stock in the foreseeable future.

**Securities Authorized for Issuance Under Equity Compensation Plans.**

The following table provides particular information regarding our equity compensation plans as of December 31, 2015.

<b>Plan Category</b>	<b>Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a)</b>	<b>Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights (b)</b>	<b>Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in the column (a)) (c)</b>
<b>Equity Compensation Plans Approved by Security Holders (1)</b>	2,355,654	\$ 4.56	1,276,186
<b>Equity Compensation Plans Not Approved by Security Holders (2)</b>	290,646	\$ 3.45	-
<b>Total</b>	2,573,640	\$ 4.46	1,276,186

- (1) Consists of options outstanding under the Cogentix Medical, Inc. 2015 Omnibus Incentive Plan, the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan, as amended, the Vision-Sciences, Inc. 2000 Plan, the Vision-Sciences, Inc. 2003 Director Option Plan and the Vision-Sciences, Inc. 2007 Stock Incentive Plan
- (2) Represents non-qualified options to purchase shares of our common stock (all of which are vested), granted outside of any plan to one former executive officer in fiscal 2005 and 2006. Such option awards expire in May 2016.

## **ITEM 6. SELECTED FINANCIAL DATA**

### **Summary Statement of Operations Data**

Not required to be disclosed.

## **ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

You should read this discussion of our financial condition and results of operations in conjunction with, and we qualify our discussion in its entirety by, the consolidated financial statements and notes thereto included elsewhere within this report, the material contained under Part 1, Item 1. "Description of Business" and Part I, Item 1A. "Risk Factors" of this report, and the cautionary disclosure about forward-looking statements at the front of Part I of this report.

### **Overview**

Cogentix Medical is a global medical device company. We design, develop, manufacture and market innovative proprietary technologies serving the urology and airway management markets. The Urgent<sup>®</sup> PC Neuromodulation System is an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). The FDA-cleared PrimeSight Endoscopy Systems utilizing the EndoSheath Protective Barrier combine state-of-the-art endoscopic technology with a sterile, disposable microbial barrier, providing practitioners and healthcare facilities with a solution to meet the growing need for safe, efficient and cost-effective flexible endoscopy. We also offer Macroplastique<sup>®</sup> a urethral bulking agent for the treatment of stress urinary incontinence. Outside the U.S., the company markets additional bulking agents: PTQ<sup>®</sup> for the treatment of fecal incontinence and the VOX<sup>®</sup> for vocal cord augmentation.

On December 21, 2014, Vision-Sciences entered into a merger agreement with Uroplasty, a publicly traded corporation. The merger agreement provided for the merger of Uroplasty with and into a newly created, wholly-owned merger subsidiary of Vision-Sciences. Following the approval of the merger by Vision-Sciences' and Uroplasty's stockholders on March 30, 2015 and pursuant to the terms of the merger agreement, on March 31, 2015, Uroplasty merged with and into the Merger Sub, with Merger Sub continuing as the surviving entity and a wholly-owned subsidiary of Vision-Sciences under the name "Uroplasty, LLC." Vision-Sciences changed its name to "Cogentix Medical, Inc."

The merger was accounted for as a reverse acquisition due to a number of factors including the relative voting interests in the combined company of the former Vision-Sciences and Uroplasty stockholders following the merger. As a result, Uroplasty and its consolidated subsidiaries represent the accounting acquirer in the merger, and Vision and its consolidated subsidiary represent the legal acquirer in the merger. Accordingly, while Vision was the legal acquirer in the merger, Uroplasty is treated as the acquiring company in the merger for accounting purposes.

As a result of the merger, our financial statements prior to March 31, 2015 are the historical financial statements of Uroplasty, and our financial statements on and after March 31, 2015 reflect the results of the operations of Uroplasty and Vision-Sciences on a combined basis. We refer you to Note 2 to the “Notes to Consolidated Financial Statements” in Part II, Item 8 of this report for additional description of this merger, the accounting treatment of the merger, and the pro forma financial information for Cogentix on a combined basis.

### **Critical Accounting Policies**

We prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles (“GAAP”), which require us to make estimates and assumptions in certain circumstances that affect amounts reported. In preparing these consolidated financial statements, we have made our best estimates and judgments of certain amounts, giving due consideration to materiality. We believe that of our significant accounting policies, the following can be characterized as “critical accounting policies” and are particularly important to the portrayal of our results of operations and financial position. These critical policies may require the application of a higher level of judgment by us, and as a result are subject to an inherent degree of uncertainty.

#### *Revenue Recognition*

We recognize revenue in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) 605 (Topic 605, *Revenue Recognition*). ASC 605 requires that four basic criteria must be met before revenue can be recognized:

1. persuasive evidence that an arrangement exists;
2. delivery has occurred or services were rendered;
3. the fee is fixed and determinable; and
4. collectability is reasonably assured

We recognize revenue when title passes to the customer, generally upon shipment of our products F.O.B. shipping point. Revenue for service repairs of equipment is recognized after service has been completed, and service contract revenue is recognized ratably over the term of the contract.

We include shipping and handling charges billed to customers in net sales, and include related costs incurred by us in cost of goods sold. Typically our agreements contain no customer acceptance provisions or clauses. We sell our products to end users and to distributors. Payment terms range from prepayment to 120 days. The distributor payment terms are not contingent on the distributor selling the product to end users. Customers do not have the right to return products except for warranty claims. We offer customary product warranties.

#### *Accounts Receivable*

We grant credit to our customers in the normal course of business and, generally, do not require collateral or any other security to support amounts due. If necessary, we have an outside party assist us with performing credit and reference checks and establishing credit limits for the customer. Accounts outstanding longer than the contractual payment terms, are considered past due. We carry our accounts receivable at the original invoice amount less an estimated allowance for doubtful receivables based on a periodic review of all outstanding amounts. We determine the allowance for doubtful accounts based on the customer’s financial health, and both historical and expected credit loss experience. We write off our accounts receivable when we deem them uncollectible. We record recoveries of accounts receivable previously written off when received. We are not always able to timely anticipate changes in the financial condition of our customers and if circumstances related to these customers deteriorate, our estimates of the recoverability of accounts receivable could be materially affected and we may be required to record additional allowances. Alternatively, if more allowances are provided than are ultimately required, we may reverse a portion of such provisions in future periods based on the actual collection experience. Historically, the accounts receivable balances we have written off have generally been within our expectations.

### *Inventories*

We state inventories at the lower of cost or market using the first-in, first-out method. We value at lower of cost or market the slow moving and obsolete inventories based upon current and expected future product sales and the expected impact of product transitions or modifications. Historically, the inventory write-offs have generally been within our expectations.

### *Impairment of Long-Lived Assets*

Our long-lived assets consist of property, plant and equipment and intangible assets. We review our long-lived assets for impairment whenever events or business circumstances indicate that the carrying amount of an asset may not be recoverable. We measure the recoverability of assets to be held and used by a comparison of the carrying amount of an asset to future undiscounted net cash flows expected to be generated by the asset. We use judgment to forecast future cash flows including forecasting revenues and margins, and working capital needs. If we consider such assets impaired, we measure the impairment to be recognized by the amount by which the carrying amount of the assets exceeds the fair value of the assets.

### *Share-Based Compensation*

We account for share-based compensation costs under ASC 718, "Compensation – Stock Compensation." ASC 718 covers a wide range of share-based compensation arrangements including stock options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. We recognize the compensation cost relating to share-based payment transactions, including grants of employee stock options and restricted shares, in our financial statements. We measure that cost based on the fair value of the equity or liability instruments issued.

### *Long-Term Incentive Plan and Awards*

Awards under the Long-term Incentive Plan ("LTIP") are accounted for as liability awards as the awards are based on the performance of our common stock and are expected to be settled in cash. The fair value of the awards is calculated on a quarterly basis using a Monte Carlo valuation model and is recognized over the derived service period. Vesting of the awards is based on the probability of meeting the stock price criteria, the probability of which is considered in determining the estimated fair value.

### *Defined Benefit Pension Plans*

We have a liability attributed to defined benefit pension plans we offered to certain former and current employees of our subsidiaries in the UK and the Netherlands. The liability is dependent upon numerous factors, assumptions and estimates, and the continued benefit costs we incur may be significantly affected by changes in key actuarial assumptions such as the discount rate, mortality, compensation rates, or retirement dates used to determine the projected benefit obligation. Additionally, changes made to the provisions of the plans may impact current and future benefit costs. Changes in benefit obligations associated with these factors are recognized in future years over the expected average future service of the active employees or the average remaining life expectancies of inactive employees.

### *Income Taxes*

We recognize deferred tax assets and liabilities for future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases. We measure deferred tax assets and liabilities using enacted tax rates we expect to apply to taxable income in the years in which we expect to recover or settle those temporary differences. As of December 31, 2015, we have generated approximately \$122.1 million in U.S. net operating loss ("NOL") carry forwards that we cannot use to offset taxable income in foreign jurisdictions. We recognize a valuation allowance when we determine it is more likely than not that we will not realize a portion of the deferred tax asset. We have established a valuation allowance for U.S. and certain foreign deferred tax assets due to the uncertainty that we will generate enough income in those taxing jurisdictions to utilize the assets.

In addition, future utilization of NOL carry forwards is subject to certain limitations under Section 382 of the Internal Revenue Code of 1986, as amended. This section generally relates to a 50 percent change in ownership of a company over a three-year period. For Uroplasty, we believe that the issuance of historical Uroplasty common stock in the December of 2006 follow-on public offering resulted in an “ownership change” under Section 382. Additionally, we believe there were ownership changes of historical Uroplasty in December of 2012 and, as a result of the merger, in March of 2015. Accordingly, our ability to use pre-acquisition Uroplasty generated NOL tax attributes is limited as follows: approximately \$750,000 per year for periods prior to December 2006; approximately \$2,000,000 per year for periods after December 2006 and before December 2012; and approximately \$720,000 per year for periods after December 2012 and before March 2015. Also, we believe there was an ownership change of Cogentix in March of 2015 as a result of the merger causing a limitation in our ability to use pre-acquisition Cogentix generated NOL tax attributes for periods prior to March 2015 of approximately \$1,500,000 per year for the first five years and approximately \$430,000 thereafter.

At December 31, 2015, we had NOL carry forwards of approximately \$55.7 million for U.S. income tax purposes, which expire at various dates through 2036. The merger transaction caused an ownership change as of March 31, 2015. We have not performed a detailed analysis to determine whether an ownership change prior to March 31, 2015 had occurred. Such a change of ownership could limit our utilization of the net operating losses, and could be triggered by subsequent sales of securities by us or our stockholders.

We refer you to Note 9 to the “Notes to Consolidated Financial Statements” in Part II, Item 8 of this report for further discussion.

## **Results of Operations**

The reported operations for the nine-months ended December 31, 2014 and fiscal years ended March 31, 2015 and 2014, respectively include only the results of UPI. Results of VSCI will be included beginning on April 1, 2015, the day after the merger closed. As such, results for the nine-month transition period ended December 31, 2015 will be materially different than the reported numbers of the same period of the prior years.

### ***Nine-months ended December 31, 2015 compared to nine-months ended December 31, 2014***

**Net Sales.** Consolidated net sales of \$36.6 million in the current period represented a \$17.1 million, or an 87.7% increase, over net sales of \$19.5 million in the prior period. The increase in consolidated net sales is attributed to 20.8% sales growth of our Urgent PC System in addition to the merger with Vision-Sciences.

Net sales to customers in the U.S. of \$27.6 million in the current period represented an increase of \$13.1 million, or 90.0%, over net sales of \$14.5 million in the prior period.

Net sales in the U.S. of our Urgent PC System increased 26.3% to \$13.1 million in the current period, from \$10.4 million in the prior period. Net sales increased as a result of improved sales execution of our Urgent PC System within the U.S. resulting in an increase in the number of active customers, primarily due to new account conversions and improved customer retention rates.

Net sales in the U.S. of our Macroplastique product increased 1.6%, or \$67,000, to \$4.1 million in the current period. Macroplastique serves a small market, and the focus of our sales force has been on growing our Urgent PC and endoscopy technology business.

Net sales to customers outside the U.S. increased \$4.1 million to \$9.1 million, compared to \$5.0 million in the prior period.

Urgent PC System sales to customers outside of the U.S. of \$2.3 million in the current period decreased 3.6% from \$2.4 million in the prior period.

Macroplastique sales to customers outside of the U.S. decreased 24.8% to \$1.4 million in the current period, compared to \$1.9 million in the prior period. The sales decrease is attributed to a declining market as well to the shift in sales focus from Macroplastique to Urgent PC.

Consolidated net sales of our endoscopy technology was \$14.9 million. These sales are not included in our prior period reported net sales as this product line was acquired on March 31, 2015 from our merger with Vision-Sciences. Net sales in the U.S. for endoscopy technology were \$10.2 million and net sales outside the U.S for endoscopy technology were \$4.6 million.

Gross Profit: Gross profit was \$24.1 million (65.8% of net sales) in the current period. The 22.3% decrease in the gross profit percentage is attributed primarily to the merger with Vision-Sciences as we now have capital equipment sales which carry lower gross margins than the former Uroplasty products alone.

General and Administrative Expenses (G&A): G&A expenses of \$6.2 million in the current period increased \$1.0 million from \$5.1 million in the prior period. The increase in expenses is primarily due to one-time merger related costs of \$665,000, \$108,000 in legal fees to obtain our line of credit, additional legal fees pertaining to business development activities and increased personnel costs due to the merger with Vision-Sciences.

Research and Development Expenses ("R&D"): R&D expenses of \$3.2 million in the current period increased \$959,000 from \$2.2 million in the prior period. The increase is attributed primarily to \$696,000 of increased personnel costs attributed to our merger with Vision-Sciences and \$190,000 in legal fees pertaining to the evaluation and renewal of certain patents and trademarks.

Selling and Marketing Expenses ("S&M"): S&M expenses of \$18.8 million in the current period increased \$3.6 million from the prior period. The increase is attributed primarily to a \$3.0 million increase in personnel and travel costs due to the expansion and reorganization of our selling and marketing team, \$169,000 increase in the medical device tax due to the merger with Vision-Sciences, and \$122,000 in consulting costs related to product promotion and education, advertising, trade shows and conventions.

Amortization of Intangibles: Amortization of intangibles was \$1.9 million in the current period compared to \$24,000 in the prior period, primarily due to the acquisition of intangibles from the merger with Vision-Sciences.

Other Income (Expense): Other income (expense) includes interest income, interest expense, foreign currency exchange and other non-operating costs when incurred. Net other expense was \$1.1 million in the current period compared to net other income of \$3,000 in the prior period. Other expense increased primarily as the result the acquisition of related party debt and the amortization of the debt discount along with accrued interest associated with this debt as a result of the merger with Vision-Sciences.

We recognize exchange gains and losses primarily as a result of fluctuations in currency rates between the U.S. dollar (the functional reporting currency) and the Euro and British pound (currencies of our subsidiaries), as well as their effect on the dollar denominated short-term intercompany obligations between us and our foreign subsidiaries. We recorded foreign currency exchange gains of \$14,000 in the current period.

Income Tax Expense: We recorded income tax expense of \$40,000 in the current period. Income tax expense is attributed to our foreign subsidiaries and to the payment of minimum state taxes in the U.S. We cannot use our U.S. net operating loss carry forwards to offset taxable income in foreign jurisdictions. Our actual income tax expense differs from the statutory federal income tax benefit largely due to the recording of valuation allowances in all three periods presented.

***Twelve-months ended March 31, 2015 compared to Twelve-months ended March 31, 2014***

Net Sales. In fiscal 2015, consolidated net sales of \$26.5 million represented a \$1.9 million, or an 8% increase, over net sales of \$24.6 million in fiscal 2014. The increase in consolidated net sales is attributed to the sales growth of our Urgent PC System.

Net sales to customers in the U.S. of \$20.0 million in fiscal 2015, represented an increase of \$1.9 million, or 11%, over net sales of \$18.0 million in fiscal 2014.

[Table of Contents](#)

Net sales in the U.S. of our Urgent PC System increased 17% to \$14.4 million in fiscal 2015, from \$12.3 million last year. Net sales increased as a result of improved sales execution of our Urgent PC System within the U.S. resulting in an increase in the number of active customers, primarily due to new account conversions and improved customer retention rates.

Net sales in the U.S. of our Macroplastique product decreased 3%, or \$165,000, to \$5.4 million in fiscal 2015, compared to fiscal 2014. Macroplastique serves a small market and the focus of our sales force has been on Urgent PC.

Net sales to customers outside the U.S. in fiscal 2015 increased \$21,000 to \$6.6 million, compared to \$6.5 million in fiscal 2014.

Urgent PC System sales to customers outside of the U.S. of \$3.1 million in fiscal 2015 increased 14% from \$2.7 million in fiscal 2014. The increase in sales is attributed to the increase in adoption of the product by our customers, primarily in markets where we sell to hospitals directly.

Macroplastique sales to customers outside of the U.S. decreased 9% to \$2.5 million in fiscal 2015 over fiscal 2014. The sales decrease is attributed primarily to the shift in sales focus from Macroplastique to Urgent PC.

Gross Profit: Gross profit was \$23.4 million (88.2% of net sales) in fiscal 2015 and \$21.5 million (87.6% of net sales) in fiscal 2014.

The 0.6% increase in the gross profit percentage in fiscal 2015 is attributed primarily to a 0.4% impact of a favorable product mix, and a 0.2% impact from an increase in capacity absorption. The 1.0% increase in the gross profit percentage in fiscal 2014 is attributed primarily to a 0.2% impact of a favorable product mix, a 0.2% impact from an increase in capacity absorption, and a 0.3% impact from reduced royalty payments. Starting with fiscal 2014, we no longer pay royalties on sales of our bulking agent products in markets outside of the U.S.

General and Administrative Expenses (G&A): G&A expenses of \$8.0 million during fiscal 2015 increased \$1.4 million from \$6.5 million during fiscal 2014. The increase in expenses is due to primarily due to one-time merger related costs of \$2.4 million, partially offset by a decrease in legal and accounting costs of \$1.1 million which were incurred in the prior year for certain internal control issues.

Research and Development Expenses ("R&D"): R&D expenses of \$2.9 million during fiscal 2015, increased \$700,000 from \$2.2 million in fiscal 2014. The increase is attributed primarily to \$266,000 of costs attributed to clinical studies, \$250,000 related to personnel costs and \$147,000 in costs for consulting and sponsorships.

Selling and Marketing Expenses ("S&M"): S&M expenses of \$20.2 million in fiscal 2015 increased \$2.1 million from \$18.1 million in fiscal 2014. The increase is attributed primarily to a \$1.9 million increase in personnel and travel costs due to the expansion and reorganization of our selling and marketing team, and a \$333,000 increase in marketing costs related to product promotion and education, advertising, trade shows and conventions.

Amortization of Intangibles: Amortization of intangibles was \$31,000 in fiscal 2015 and \$30,000 in fiscal 2014.

Other Income (Expense): Other income (expense) includes interest income, interest expense, foreign currency exchange and other non-operating costs when incurred. Net other income was \$4,000 and \$17,000 for fiscal 2015 and 2014, respectively. Other income decreased primarily as the result of a decrease in interest income on lower cash and investment balances and interest rates.

We recognize exchange gains and losses primarily as a result of fluctuations in currency rates between the U.S. dollar (the functional reporting currency) and the Euro and British pound (currencies of our subsidiaries), as well as their effect on the dollar denominated short-term intercompany obligations between us and our foreign subsidiaries. In fiscal 2015 and fiscal 2014 we recorded foreign currency exchange (losses) gains of \$(4,000) and \$(5,000), respectively.

Income Tax Expense: In fiscal 2015 and fiscal 2014 we recorded income tax expense of \$66,000 and \$72,000, respectively. Income tax expense is attributed to our foreign subsidiaries and to the payment of minimum state taxes in the U.S. We cannot use our U.S. net operating loss carry forwards to offset taxable income in foreign jurisdictions. Our actual income tax expense differs from the statutory federal income tax benefit largely due to the recording of valuation allowances in all three periods presented.

### Non-GAAP Financial Measures

The following table reconciles our operating loss calculated in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures that exclude non-cash charges for share-based compensation, and depreciation and amortization from gross profit, operating expenses and operating loss. The non-GAAP financial measures used by management and disclosed by us are not a substitute for, or superior to, financial measures and consolidated financial results calculated in accordance with GAAP, and you should carefully evaluate our reconciliations to non-GAAP. We may calculate our non-GAAP financial measures differently from similarly titled measures used by other companies. Therefore, our non-GAAP financial measures may not be comparable to those used by other companies. We have described the reconciliations of each of our non-GAAP financial measures described above to the most directly comparable GAAP financial measures.

We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business. Analysts and investors frequently ask us for this information. We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.

	Expense Adjustments						Non-GAAP
	GAAP	Share-based Expense	Long-term Incentive Plan	Depreciation	Disposal of Assets	Amortization of Intangibles	
<b>Nine-months ended December 31, 2015</b>							
Gross Profit	\$ 24,103,000	\$ 25,000	\$ -	\$ 180,000	\$ -	\$ -	\$ 24,308,000
% of Net sales	65.8%						66.4%
Operating Expenses:							
General & administrative	5,531,000	(679,000)	78,000	(166,000)	-	-	4,764,000
Research and development	3,169,000	(55,000)	-	(10,000)	-	-	3,104,000
Selling and marketing	18,484,000	(220,000)	-	(311,000)	4,000	-	17,957,000
Amortization	1,903,000	-	-	-	-	(1,903,000)	-
Transaction costs	950,000	-	-	-	-	-	950,000
	<u>30,037,000</u>	<u>(954,000)</u>	<u>78,000</u>	<u>(487,000)</u>	<u>4,000</u>	<u>(1,903,000)</u>	<u>26,775,000</u>
Operating Loss	\$ (5,934,000)	\$ 979,000	\$ (78,000)	\$ 667,000	\$ (4,000)	\$ 1,903,000	\$ (2,467,000)

	Expense Adjustments						Non-GAAP
	GAAP	Share-based Expense	Long-term Incentive Plan	Depreciation	Disposal of Assets	Amortization of Intangibles	
<b>Nine-months ended December 31, 2014</b>							
Gross Profit	\$ 17,183,000	\$ 36,000	\$ -	\$ 13,000	\$ -	\$ -	\$ 17,232,000
% of Net sales	88.1%						88.3%
Operating Expenses:							
General & administrative	5,149,000	(755,000)	(132,000)	(111,000)	-	-	4,151,000
Research and development	2,226,000	(41,000)	-	(2,000)	-	-	2,183,000
Selling and marketing	15,107,000	(246,000)	-	(57,000)	-	-	14,804,000
Amortization	24,000	-	-	-	-	(24,000)	-
	<u>22,506,000</u>	<u>(1,042,000)</u>	<u>(132,000)</u>	<u>(170,000)</u>	<u>-</u>	<u>(24,000)</u>	<u>21,138,000</u>
Operating Loss	\$ (5,323,000)	\$ 1,078,000	\$ 132,000	\$ 183,000	\$ -	\$ 24,000	\$ (3,906,000)

**Expense Adjustments**

	Expense Adjustments						Non-GAAP
	GAAP	Share-based Expense	Long-term Incentive Plan	Depreciation	Disposal of Assets	Amortization of Intangibles	
<b>Year Ended March 31, 2015</b>							
Gross Profit	\$ 23,401,000	\$ 47,000	\$ -	\$ 17,000	\$ -	\$ -	\$ 23,465,000
% of Net sales							88.5%
Operating Expenses:							
General & administrative	7,956,000	(977,000)	(153,000)	(153,000)	(1,000)	-	6,672,000
Research and development	2,851,000	(52,000)	-	(2,000)	-	-	2,797,000
Selling and marketing	20,210,000	(313,000)	-	(76,000)	(38,000)	-	19,783,000
Amortization	31,000	-	-	-	-	(31,000)	-
	31,048,000	(1,342,000)	(153,000)	(231,000)	(39,000)	(31,000)	29,252,000
Operating Loss	\$ (7,647,000)	\$ 1,389,000	\$ 153,000	\$ 248,000	\$ 39,000	\$ 31,000	\$ (5,787,000)
Transaction costs							2,400,000
Operating Loss excluding transaction costs							(3,387,000)
<b>Year Ended March 31, 2014</b>							
Gross Profit	\$ 21,527,000	\$ 27,000	\$ -	\$ 33,000	\$ -	\$ -	\$ 21,587,000
% of Net sales							87.8%
Operating Expenses:							
General & administrative	6,522,000	(1,117,000)	-	(200,000)	-	-	5,205,000
Research and development	2,151,000	(51,000)	-	(4,000)	-	-	2,096,000
Selling and marketing	18,123,000	(241,000)	-	(86,000)	-	-	17,796,000
Amortization	30,000	-	-	-	-	(30,000)	-
	26,826,000	(1,409,000)	-	(290,000)	-	(30,000)	25,097,000
Operating Loss	\$ (5,299,000)	\$ 1,436,000	\$ -	\$ 323,000	\$ -	\$ 30,000	\$ (3,510,000)

On December 10, 2015, the Board of Directors of the Company determined that, in accordance with its bylaws and upon recommendation of the Audit Committee, the Company's fiscal year shall begin on January 1 and end on December 31 of each year starting on January 1, 2016. The required transition Period of April 1, 2015 to December 31, 2015 is included in this Form 10-K Transition Report. Amounts included in this report for the nine months ended December 31, 2014 are unaudited.

**Liquidity and Capital Resources**

*Cash Flows*

At December 31, 2015, our cash and cash equivalents and short-term investments balances totaled \$2.0 million. At December 31, 2015, we had working capital of approximately \$9.1 million.

Cash used in operating activities for the nine-month transition period ended December 31, 2015 and for the nine-months ended December 31, 2014, respectively was \$5.9 million and \$3.2 million, and in fiscal years ended March 31, 2015 and 2014, respectively was \$4.4 million and \$2.9 million. We used this cash primarily to fund the operating loss, net of non-cash charges for depreciation, amortization of intangibles and equity compensation, of \$2.5 million, \$3.9 million, \$3.4 million and \$3.5 million, in the nine-month transition period ended December 31, 2015 and 2014, respectively, and in fiscal 2015 and fiscal 2014, respectively. We have continued to show an operating loss because we have continued to invest, primarily in selling and marketing, to grow our U.S. business. The nine-month transition period ended December 31, 2015 net loss includes nonrecurring cash expenses of \$1.0 million attributed to integration costs primarily for legal, accounting and other fees associated with our merger.

In the nine-month period ended December 31, 2014 we generated \$3.5 million of net cash from the maturity of marketable securities. In fiscal 2015, we generated \$3.4 million of net cash from the sale of marketable securities and \$2 million in cash from the merger with Vision-Sciences, compared with \$7.9 million of net cash generated from the sale of marketable securities in fiscal 2014.

In the nine-month transition period ended December 31, 2015 and 2014, respectively, we used \$1.4 million and \$206,000 of net cash for the purchase of property, plant and equipment. In fiscal 2015, we used \$421,000 to purchase property, plant and equipment compared with approximately \$248,000 in fiscal 2014. The increase in fiscal 2015 compared to fiscal 2014 is related to the purchase of new computer equipment for our sales force and for the merger of our IT systems with VSCI.

In fiscal 2015, we generated proceeds from financing activities of \$68,000 from the exercise of stock options and \$360,000 in fiscal 2014. There were no stock options exercised in the nine-month transition period ended December 31, 2015.

#### *Sources of Liquidity*

We obtained an 18-month line of credit through Venture Bank in September 2015. We may obtain additional debt and/or equity financing during calendar year 2016. We have historically not generated cash from operations because we have yet to achieve profitability, and to achieve profitability, we must generate substantially more revenue than we have generated this year or in prior years.

Our ability to achieve significant revenue growth will depend, in large part, on our ability to achieve widespread market acceptance of our products and successfully expand our business in the U.S. We cannot guarantee that we will successfully achieve such revenue growth. If we fail to meet our projections of profitability and cash flow, or determine to use cash for matters we are not currently projecting, we may need to seek additional financing to meet our cash needs. We cannot assure you that such financing, if needed, will be available to us on acceptable terms, if at all.

The Company does not have any commitments for capital expenditures.

#### **Convertible Debt Arrangements – Related Party**

The following table is a summary of our convertible debt – related party at December 31, 2015:

	<b>Gross Principal Amount</b>	<b>Unamortized Debt Discount</b>	<b>Net Amount</b>
<b>Convertible Debt—Related Party</b>			
Note Payable A	\$ 20,000,000	\$ (3,639,000)	\$ 16,361,000
Note Payable B	3,500,000	(562,000)	2,938,000
Note Payable C	4,990,000	(952,000)	4,038,000
	<u>\$ 28,490,000</u>	<u>\$ (5,153,000)</u>	<u>\$ 23,337,000</u>

The Convertible Debt-Related Party is held by Mr. Lewis C. Pell, a member of Cogentix's board of directors, and consists of three convertible promissory notes:

- Note Payable A accrues annual interest at the rate of 0.84%. The outstanding principal amount of Note Payable A is convertible into shares of our common stock at a conversion price of \$6.00 per share.
- Note Payable B accrues annual interest at the rate of 1.66%. The outstanding principal amount of Note Payable B is convertible into shares of our common stock at a converted price of \$4.45.
- Note Payable C accrues annual interest at the rate of 1.91%. The outstanding principal amount of Note Payable C is convertible into shares of our common stock at a converted price of \$5.55.

At December 31, 2015, we had an aggregate amount of \$758,000 in accrued interest under the convertible notes payable, which is included in accrued expenses on our consolidated balance sheet.

The convertible promissory notes mature on March 31, 2020 or earlier upon a change of control (as defined). The convertible promissory notes generally cannot be converted prior to March 31, 2018. The convertible promissory notes may be converted earlier prior to a change in control or in connection with our prepayment of the convertible promissory notes. The convertible promissory notes may be prepaid, at our option and upon 15 days' notice to Mr. Pell, without other premium or penalty, with a combination of cash and common stock. Interest on the convertible promissory notes is payable on the maturity date or upon repayment or conversion of all or any portion of the principal under the note.

The convertible promissory notes were amended concurrently with the execution of the merger agreement to extend the maturity from the fifth anniversary their issuance dates to the fifth anniversary of the effective date of the merger and change the conversion date from anytime to generally not earlier than three years after the effective date of the merger.

Under purchase accounting for the merger, the convertible promissory notes were recorded at fair value, resulting in a discount from their face value of \$5,960,000. The discount is being amortized over the remaining term based on the effective interest rate method with an imputed interest rate of 4.72%. The amendments to the convertible notes payable were considered to be part of an arrangement entered into between Mr. Pell and Vision-Sciences during the merger negotiations that were separate from the business combination. Accordingly, the fair value of the notes was based on the terms that existed prior to the amendment. The fair value of the notes was determined using a lattice model with key assumptions of a risk free rate of 1.37%, market interest rate of 10.3%, and annualized volatility of 65%, less any increase in the fair value of the conversion feature resulting from the amendments. The increase in the fair value of the conversion feature was based on a comparative analysis of the conversion feature's value under both the original terms and modified terms using the same key assumptions.

Warrants to purchase shares of our common stock originally issued in connection with the issuance of the convertible promissory notes are described in Note 5 to the "Notes to Consolidated Financial Statements" in Part II, Item 8 of this report. We estimated the fair value of all of the warrants using a Black-Scholes valuation model that used the weighted average assumptions for the risk-free interest rate, expected life (in years), and expected volatility. We recorded the transaction as a deferred debt cost and amortized to expense over the term of the loan.

*Commitments and Contingencies*

Future payments under our contractual obligations as of December 31, 2015, consisting of royalties, purchase commitments, and operating leases, are summarized below:

	<u>Total</u>	<u>Payments Due by Period</u>			
		<u>Less Than 1 Year</u>	<u>1 – 3 Years</u>	<u>3 – 5 Years</u>	<u>More Than 5 Years</u>
Minimum purchase agreement (a)	\$ 1,329,000	\$ 1,329,000	\$ -	\$ -	\$ -
Operating lease commitments (b)	2,683,000	744,000	949,000	365,000	625,000
Total contractual obligations	<u>\$ 4,012,000</u>	<u>\$ 2,073,000</u>	<u>\$ 949,000</u>	<u>\$ 365,000</u>	<u>\$ 625,000</u>

- (a) In our normal course of business we have commitments, generally for periods of less than twelve months, to purchase from various vendors finished goods and manufacturing components under issued purchase orders.
- (b) Operating lease commitments include a long-term lease with Liberty Property Limited Partnership for an 18,258 square foot facility for our U.S. headquarters located at 5420 Felth Road, Minnetonka, Minnesota. The lease, which had an original expiration date in April 2014, was amended in January 2014. The amended lease began on May 1, 2014, has a term of 62 months and requires average annual minimum rent payments of approximately \$154,000. We lease a 20,500 square-foot office, warehouse and manufacturing facility in Orangeburg, New York pursuant to a lease agreement with GHP Office Realty, LLC that expires in August 2017. The lease requires average annual minimum rent payments of approximately \$349,000. On April 2, 2015, we leased approximately 24,400 square feet in Westborough, Massachusetts pursuant to a lease agreement with Glenborough Flanders Park, LLC expiring in December 2025. The lease requires average annual minimum rent payments of approximately \$134,000.

[Table of Contents](#)

Under a royalty agreement, we pay royalties of five percent of net sales of Macroplastique in countries where a patent is filed, subject to a monthly minimum of \$4,500. The royalties payable under this agreement ceased when certain patents referenced in the agreement expired in May 2015. Under a license agreement for Macroplastique, we pay a royalty of 10 Great Britain Pounds for each unit sold during the life of the patent. We recognized an aggregate of \$48,000, \$205,000, \$274,000, \$285,000 and \$353,000 of royalty expense, under these agreements for the nine-month transition period ended December 31, 2015, the nine-month period ended December 31, 2014, and in fiscal 2015, 2014 and 2013, respectively.

We have a defined benefit pension plan covering six current and twenty former employees in The Netherlands. We pay premiums to an insurance company to fund annuities for the current employees. We are responsible for funding additional annuities based on continued service and future salary increases. We closed this defined benefit plan for new employees in April 2005. As of that date, The Netherlands subsidiary established a defined contribution plan that now covers new employees. We also have a defined benefit pension plan for six former employees of our U.K. subsidiary. We closed this plan to further accrual for all employees effective December 31, 2004, and, effective March 2005, established a defined contribution plan that now covers new employees.

The following table presents the sensitivity of our funded status as of December 31, 2015, and expected 2016 pension expense to the following changes in key assumptions:

	<b>Increase/(Decrease) Funded Status at December 31, 2015</b>	<b>Increase/(Decrease) 2016 Pension Expense</b>
Assumption:		
Increase in discount rate by 1 percentage point	\$ 279,000	\$ (38,000)
Decrease in discount rate by 1 percentage point	(370,000)	64,000
Increase in estimated return on assets by 1 percentage point	n/a	(8,000)
Decrease of estimated return on assets by 1 percentage point	n/a	8,000
Increase in inflation rate by 1 percentage point	(311,000)	56,000
Decrease in inflation rate by 1 percentage point	263,000	(36,000)
Increase in compensation by 1 percentage point	(194,000)	29,000
Decrease in compensation by 1 percentage point	3,000	-

Regarding the Netherlands defined benefit plan, the market value of the assets is determined as the discounted stream of guaranteed benefit payments. Given the valuation method of the assets, the expected long-term rate of return on assets equals the discount rate. As such the Netherlands defined benefit plan is not included in the sensitivity analysis for the estimated return on assets, because the sensitivity on the estimated return on assets is implicitly already included in the sensitivity analysis for the discount rate.

**New Accounting Pronouncements**

See Note 1 to the “Notes to Consolidated Financial Statements” in Part II, Item 8 of this report.

## **Off-Balance Sheet Arrangements**

As of December 31, 2015, we had no off-balance sheet arrangements.

## **ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are a smaller reporting company and are not required to provide the information required by this Item.

## **ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA**

Our consolidated financial statements and notes of our consolidated financial statements are contained immediately after the signature page to this report beginning on page F-1, and are incorporated herein by references. Our financial statement schedule is contained in Part IV, Item 15 of this report, and is incorporated herein by reference.

## **ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE**

None.

## **ITEM 9A. CONTROLS AND PROCEDURES**

### **Disclosure Controls and Procedures**

Disclosure controls and procedures are defined by Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in applicable rules and forms and that such information is accumulated and communicated to management, including our CEO and CFO, in a manner that allows timely decisions regarding required disclosure.

As of December 31, 2015, we carried out an evaluation, under the supervision and with the participation of our management, including our President and CEO (principal executive officer) and our Senior Vice President and CFO (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act). Based upon that evaluation, each of our CEO (principal executive officer) and CFO (our principal financial officer) concluded that as of December 31, 2015, our disclosure controls and procedures were effective.

### **Management's Report on Internal Control over Financial Reporting**

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as that term is defined in Rule 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control system was designed to provide reasonable assurance to our management and Board of Directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in conformity with GAAP, and includes those policies and procedures that:

- pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP, and that receipts and expenditures are being made only in accordance with authorizations from our management and directors; and
- provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of our management, including principal executive officer, principal financial officer and principal accounting officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2015, based upon the framework in “2013 Internal Control — Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”). Based on this assessment and those criteria, management has determined that our internal control over financial reporting was effective as of December 31, 2015.

#### **Changes in Internal Control over Financial Reporting**

Based on the evaluation conducted by our management, with the participation of principal executive officer, principal financial officer and principal accounting officer, pursuant to Rules 13a-15(d) and 15d-15(d) promulgated under the Exchange Act, our management (including such officers) have concluded that there were the following changes to our internal control over financial reporting (as defined in Rules 13a-15(f) or 15d-15(f) under the Exchange Act) that occurred during the period covered by this annual report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting:

On March 31, 2015, we completed the merger with Uroplasty. As part of our ongoing activities after the merger and since September 31, 2015, we have completed our integration of our financial reporting functions and our controls and procedures between our legacy Uroplasty and Vision-Sciences businesses. We also augmented our company-wide controls to reflect the risks inherent in a business combination of the magnitude and complexity of the merger.

There were no other changes in our internal controls over financial reporting that occurred during the Transition Period ended December 31, 2015 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

#### **ITEM 9B. OTHER INFORMATION**

None.

### **PART III**

#### **ITEM 10. DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE**

The information contained under the headings “Proposal No. 1 - Election of Directors,” “Corporate Governance – Code of Ethics and Business Conduct,” “Corporate Governance – Director Nomination Process,” “Corporate Governance – Board Committees – Audit Committee” and “Share Ownership of Certain Beneficial Owners, Management and Directors -- Section 16 Beneficial Ownership Reporting Compliance” in the Proxy Statement is incorporated herein by reference.

The information concerning our executive officers required by this Item is provided under the caption “Executive Officers” in Part I, Item 1 of this report.

#### **ITEM 11. EXECUTIVE COMPENSATION**

The information contained under the heading “Executive Compensation” and “Director Compensation” in the Proxy Statement is incorporated herein by reference.

#### **ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS**

The information contained under the heading “Share Ownership of Certain Beneficial Owners, Management and Directors” in the Proxy Statement is incorporated herein by reference. Further, see the information contained in Part II, Item 5 under the heading “Securities Authorized for Issuance Under Equity Compensation Plans.”

#### **ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE**

The information contained under the headings “Related Person Relationships and Transactions” and “Corporate Governance – Director Independence” in the Proxy Statement is incorporated herein by reference.

**ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES**

This information contained under the headings “Proposal No. 2 – Ratification of Selection of Independent Registered Public Accounting Firm” “—Audit, Audit-Related, Tax and Other Fees,” and “—Pre-Approval Policies and Procedures” in the Proxy Statement is incorporated herein by reference.

**PART IV**

**ITEM 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES**

- (a) Documents filed as part of this Transition Report on Form 10-K:
1. Consolidated Financial Statements:

	<u>PAGE</u>
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations	F-5
Consolidated Statements of Comprehensive Loss	F-6
Consolidated Statements of Shareholders’ Equity	F-7
Consolidated Statements of Cash Flows	F-8
Notes to Consolidated Financial Statements	F-9

2. Financial Statement Schedule:

**Schedule I – Valuation and Qualifying Accounts**

	<u>Balance at beginning of fiscal year</u>	<u>Additions charged to expenses</u>	<u>Written off, less recoveries</u>	<u>Effects of foreign currency fluctuations</u>	<u>Balance at end of fiscal year</u>
<b>Allowance for doubtful accounts</b>					
Nine-month transition period ended December 31, 2015	\$ 18,000	\$ 66,000	\$ (57,000)	\$ -	\$ 27,000
Fiscal year ended March 31, 2015	25,000	8,000	(13,000)	(2,000)	18,000
Fiscal year ended March 31, 2014	21,000	8,000	(5,000)	1,000	25,000

	<u>Balance at beginning of fiscal year</u>	<u>Additions charged against revenues</u>	<u>Returns written off</u>	<u>Effects of foreign currency fluctuations</u>	<u>Balance at end of fiscal year</u>
<b>Allowance for sales returns</b>					
Nine-month transition period ended December 31, 2015	\$ 15,000	\$ 26,000	\$ -	\$ -	\$ 41,000
Fiscal year ended March 31, 2015	20,000	4,000	(9,000)	-	15,000
Fiscal year ended March 31, 2014	53,000	43,000	(76,000)	-	20,000

3. Exhibits

The exhibits to this report are listed on the Exhibit Index to this report and incorporated herein by reference. A copy of any of the exhibits listed will be furnished at a reasonable cost, upon receipt from any person of a written request for such exhibit. Such requests should be sent to Cogentix Medical, Inc., 5420 Feltl Road, Minnetonka, Minnesota 55343 Attn: Corporate Secretary. The Exhibit Index indicates each management contact or compensatory plan or arrangement referenced as an exhibit to this report.

**SIGNATURES**

In accordance with Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: March 29, 2016

COGENTIX MEDICAL, INC.

By /s/ Robert Kill  
Robert Kill  
President, Chief Executive Officer, Chairman of the Board of Directors  
and Corporate Secretary

In accordance with the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

<u>Name</u>	<u>Title / Capacity</u>	<u>Date</u>
<u>/s/ Robert Kill</u> Robert Kill	President, Chief Executive Officer, Chairman of the Board of Directors and Corporate Secretary (Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)	March 29, 2016
<u>/s/ Kenneth H. Paulus</u> Kenneth H. Paulus	Director	March 29, 2016
<u>/s/ Cheryl Pegus</u> Cheryl Pegus	Director	March 29, 2016
<u>/s/ Lewis C. Pell</u> Lewis C. Pell	Director	March 29, 2016
<u>/s/ Kevin H. Roche</u> Kevin H. Roche	Director	March 29, 2016
<u>/s/ James P. Stauner</u> James P. Stauner	Lead Director	March 29, 2016
<u>/s/ Howard I. Zauberman</u> Howard I. Zauberman	Director	March 29, 2016

---

COGENTIX MEDICAL, INC. AND SUBSIDIARIES

Index to Consolidated Financial Statements  
December 31, 2015

**TABLE OF CONTENTS**

	<b>Page(s)</b>
Report of Independent Registered Public Accounting Firm	F-2
Consolidated Financial Statements:	
Consolidated Balance Sheets	F-3
Consolidated Statements of Operations	F-5
Consolidated Statements of Comprehensive Loss	F-6
Consolidated Statements of Shareholders' Equity	F-7
Consolidated Statements of Cash Flows	F-8
Notes to Consolidated Financial Statements	F-9

**REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

Board of Directors and Shareholders

Cogentix Medical, Inc.

We have audited the accompanying consolidated balance sheets of Cogentix Medical, Inc. (a Delaware corporation) and subsidiaries (the “Company”) as of December 31, 2015 and March 31, 2015, and the related consolidated statements of operations, comprehensive loss, changes in shareholders’ equity, and cash flows for the nine months ended December 31, 2015 and for the years ended March 31, 2015 and 2014. Our audits of the basic consolidated financial statements included the financial statement schedules listed in the index appearing under Item 15(a)(2). These financial statements and financial statement schedules are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and financial statement schedules based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. We were not engaged to perform an audit of the Company’s internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Cogentix Medical, Inc. and subsidiaries as of December 31, 2015 and March 31, 2015, and the results of their operations and their cash flows for the nine months ended December 31, 2015 and for the years ended March 31, 2015 and 2014 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the related financial statement schedules, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly, in all material respects, the information set forth therein.

/s/ Grant Thornton LLP

Minneapolis, Minnesota  
March 29, 2016

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS

	<b>December 31, 2015</b>	<b>March 31, 2015</b>
Assets		
Current assets:		
Cash and cash equivalents	\$ 1,976,594	\$ 9,261,903
Accounts receivable, net	8,191,391	7,306,653
Inventories	4,584,844	4,825,984
Other	834,076	749,466
Total current assets	<u>15,586,905</u>	<u>22,144,006</u>
Property, plant, and equipment, net	2,554,822	1,813,343
Goodwill	18,749,888	18,749,888
Other intangibles, net	11,846,009	13,748,582
Deferred tax assets and other	269,121	296,860
Total assets	<u>\$ 49,006,745</u>	<u>\$ 56,752,679</u>

See accompanying Notes to Consolidated Financial Statements.

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
CONSOLIDATED BALANCE SHEETS

	<u>December 31,</u> <u>2015</u>	<u>March 31,</u> <u>2015</u>
Liabilities and Shareholders' Equity		
Current liabilities:		
Accounts payable	\$ 2,209,473	\$ 3,967,975
Income taxes payable	20,866	25,998
Accrued liabilities:		
Compensation	3,281,809	3,285,952
Other	949,497	2,450,058
Total current liabilities	6,461,645	9,729,983
Convertible debt – related party, net	23,336,854	22,529,497
Interest payable	757,615	523,743
Accrued pension liability	663,071	955,780
Deferred rent	671,088	-
Other	157,453	265,766
Total liabilities	32,047,726	34,004,769
Commitments and contingencies		
Shareholders' equity:		
Common stock \$.01 par value; 100,000,000 shares authorized, 26,057,327 and 25,676,212 shares issued and outstanding at December 31, 2015 and March 31, 2015, respectively.	260,574	256,763
Additional paid-in capital	76,485,650	75,530,641
Accumulated deficit	(58,910,707)	(51,883,229)
Accumulated other comprehensive loss	(876,498)	(1,156,265)
Total shareholders' equity	16,959,019	22,747,910
Total liabilities and shareholders' equity	\$ 49,006,745	\$ 56,752,679

See accompanying Notes to Consolidated Financial Statements.

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Nine Months Ended December 31,		Year Ended March 31,	
	2015	2014 (Unaudited)	2015	2014
Net sales	\$ 36,622,355	\$ 19,506,164	\$ 26,525,975	\$ 24,577,126
Cost of goods sold	<u>12,519,443</u>	<u>2,322,942</u>	<u>3,124,710</u>	<u>3,049,811</u>
Gross profit	<u>24,102,912</u>	<u>17,183,222</u>	<u>23,401,265</u>	<u>21,527,315</u>
Operating expenses				
General and administrative	5,530,909	5,148,998	5,751,053	6,522,389
Research and development	3,168,753	2,226,018	2,833,112	2,151,257
Selling and marketing	18,484,063	15,107,241	20,037,069	18,121,732
Merger related costs	950,469	-	2,395,979	-
Amortization of intangibles	<u>1,902,573</u>	<u>24,136</u>	<u>31,398</u>	<u>30,462</u>
	<u>30,036,767</u>	<u>22,506,393</u>	<u>31,048,611</u>	<u>26,825,840</u>
Operating loss	<u>(5,933,855)</u>	<u>(5,323,171)</u>	<u>(7,647,346)</u>	<u>(5,298,525)</u>
Other income (expense)				
Interest income	3,337	6,606	8,464	22,095
Interest expense	(1,071,441)	(250)	(489)	-
Foreign currency exchange gain (loss)	<u>14,313</u>	<u>(3,317)</u>	<u>(4,281)</u>	<u>(4,761)</u>
	<u>(1,053,791)</u>	<u>3,039</u>	<u>3,694</u>	<u>17,334</u>
Loss before income taxes	(6,987,646)	(5,320,132)	(7,643,652)	(5,281,191)
Income tax expense	<u>39,832</u>	<u>55,785</u>	<u>65,506</u>	<u>71,899</u>
Net loss	<u>\$ (7,027,478)</u>	<u>\$ (5,375,917)</u>	<u>\$ (7,709,158)</u>	<u>\$ (5,353,090)</u>
Basic and diluted net loss per common share	\$ (0.28)	\$ (0.34)	\$ (0.49)	\$ (0.35)
Weighted average common shares outstanding:				
Basic and diluted	25,377,955	15,755,950	15,753,157	15,344,949

See accompanying Notes to Consolidated Financial Statements.

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

	Nine Months Ended December 31,		Year Ended March 31,	
	<u>2015</u>	<u>2014</u> (Unaudited)	<u>2015</u>	<u>2014</u>
Net loss	\$ (7,027,478)	\$ (5,375,917)	\$ (7,709,158)	\$ (5,353,090)
Other comprehensive income (loss), net of tax:				
Foreign currency translation adjustments	(16,449)	(221,689)	(401,449)	133,810
Unrealized (loss) gain on available-for-sale investments	-	(775)	(775)	1,111
Pension adjustments	<u>296,216</u>	<u>40,591</u>	<u>(269,646)</u>	<u>(50,139)</u>
Total other comprehensive income (loss), net of tax	<u>279,767</u>	<u>(181,873)</u>	<u>(671,870)</u>	<u>84,782</u>
Comprehensive loss	<u>\$ (6,747,711)</u>	<u>\$ (5,557,790)</u>	<u>\$ (8,381,028)</u>	<u>\$ (5,268,308)</u>

See accompanying Notes to Consolidated Financial Statements.

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

	Common Stock Shares	Common Stock Amount	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total Shareholders' Equity
<b>Balance at March 31, 2013</b>	15,263,075	\$ 152,631	\$ 55,923,763	\$ (38,820,981)	\$ (569,177)	\$ 16,686,236
Share-based compensation expense	232,242	2,322	1,433,948	-	-	1,436,270
Proceeds from exercise of stock options	238,791	2,388	357,114	-	-	359,502
Comprehensive loss	-	-	-	(5,353,090)	84,782	(5,268,308)
<b>Balance at March 31, 2014</b>	15,734,108	157,342	57,714,824	(44,174,071)	(484,395)	13,213,700
Share-based compensation expense	293,528	2,935	1,386,234	-	-	1,389,169
Issuance of shares from merger	9,589,524	95,895	16,373,164	-	-	16,469,059
Proceeds from exercise of stock options, net of shares exchanged	59,052	591	56,419	-	-	57,010
Comprehensive loss	-	-	-	(7,709,158)	(671,870)	(8,381,028)
<b>Balance at March 31, 2015</b>	25,676,212	256,763	75,530,641	(51,883,229)	(1,156,265)	22,747,910
Share-based compensation expense	491,522	4,915	974,037	-	-	978,952
Shares exchanged in lieu of taxes	(110,407)	(1,104)	(19,028)	-	-	(20,132)
Comprehensive loss	-	-	-	(7,027,478)	279,767	(6,747,711)
<b>Balance at December 31, 2015</b>	26,057,327	\$ 260,574	\$ 76,485,650	\$ (58,910,707)	\$ (876,498)	\$ 16,959,019

See accompanying Notes to Consolidated Financial Statements.

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	Nine Months Ended December 31,		Year Ended March 31,	
	2015	2014 (Unaudited)	2015	2014
Cash flows from operating activities:				
Net loss	\$ (7,027,478)	\$ (5,375,917)	\$ (7,709,158)	\$ (5,353,090)
Adjustments to reconcile net loss to net cash used in operating activities:				
Depreciation and amortization	2,569,636	207,011	278,953	353,238
Loss (gain) on disposal of equipment	4,859	161	38,613	(2,872)
Amortization of premium on marketable securities	-	311	311	8,341
Share-based compensation expense	978,952	1,077,928	1,389,169	1,436,270
Amortization of discount on related party debt	807,356	-	-	-
Long term incentive plan	(78,188)	131,907	152,592	-
Tax expense (benefit)	65,799	5,129	(83,402)	6,498
Deferred rent	636,615	23,556	23,962	(37,055)
Restricted stock exchanged for taxes	(20,132)	-	-	-
Changes in operating assets and liabilities, net of merger:				
Accounts receivable	(1,663,510)	220,002	(337,842)	(257,794)
Inventories	246,273	73,626	140,610	207,046
Other current assets	696,742	48,142	121,688	76,092
Accounts payable	(1,759,500)	295,113	231,663	281,104
Interest payable	233,873	-	-	-
Accrued compensation	(4,579)	212,259	635,892	436,765
Accrued liabilities, other	(1,666,431)	(59,459)	674,283	(5,721)
Accrued pension liability, net	(29,940)	(56,226)	78,043	(51,000)
Deferred revenue	154,684	-	-	-
Net cash used in operating activities	<u>(5,854,969)</u>	<u>(3,196,457)</u>	<u>(4,364,623)</u>	<u>(2,902,178)</u>
Cash flows from investing activities:				
Proceeds from maturity of available-for-sale instruments	-	3,450,000	3,450,000	7,930,000
Cash acquired from merger with Vision-Sciences	-	-	2,019,610	-
Purchases of property, plant and equipment	(1,411,042)	(206,498)	(420,726)	(248,105)
Proceeds from sale of property, plant and equipment	-	3,104	4,103	6,773
Payments for intangible assets	-	-	-	(49,940)
Net cash (used in) provided by investing activities	<u>(1,411,042)</u>	<u>3,246,606</u>	<u>5,052,987</u>	<u>7,638,728</u>
Cash flows from financing activities:				
Proceeds from exercise of stock options	-	67,850	67,850	359,510
Net cash provided by financing activities	<u>-</u>	<u>67,850</u>	<u>67,850</u>	<u>359,510</u>
Effect of exchange rates on cash and cash equivalents	<u>(19,298)</u>	<u>(95,819)</u>	<u>(175,921)</u>	<u>51,686</u>
Net (decrease) increase in cash and cash equivalents	(7,285,309)	22,180	580,293	5,147,746
Cash and cash equivalents at beginning of period	<u>9,261,903</u>	<u>8,681,610</u>	<u>8,681,610</u>	<u>3,533,864</u>
Cash and cash equivalents at end of period	<u>\$ 1,976,594</u>	<u>\$ 8,703,790</u>	<u>\$ 9,261,903</u>	<u>\$ 8,681,610</u>
Supplemental disclosure of cash flow information:				
Cash paid during the period for income tax	\$ 39,832	\$ 56,144	\$ 65,504	\$ 71,899
Cash paid during the period for interest	\$ 30,213	\$ -	\$ -	\$ -

See accompanying Notes to Consolidated Financial Statements

COGENTIX MEDICAL, INC. AND SUBSIDIARIES  
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

For the nine-month transition periods ended December 31, 2015, the unaudited period ended December 31, 2014 and the years ended March 31, 2015 and 2014

**Note 1: Summary of Significant Accounting Policies**

**Nature of Business.**

Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with additional operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company. We design, develop, manufacture and market innovative proprietary technologies serving the urology, urogynecology/gyn, ENT (ear, nose and throat) and gastrointestinal markets. The Urgent® PC Neuromodulation System delivers percutaneous tibial nerve stimulation (PTNS) which has FDA clearance for the office-based treatment of overactive bladder (OAB) and has regulatory approvals for the treatment of OAB and fecal incontinence (FI) in various international markets. The FDA-cleared and CE marked PrimeSight Endoscopy Systems and EndoSheath Protective Barrier combine state-of-the-art endoscopic technology with a sterile, disposable microbial barrier, providing practitioners and healthcare facilities with a solution to meet the growing need for safe, efficient and cost-effective flexible endoscopy. The Company also offers Macroplastique®, a urethral bulking agent for the treatment of stress urinary incontinence. Outside the U.S., the Company markets additional bulking agents: PTQ® for the treatment of fecal incontinence and VOX® for vocal cord augmentation and vesicourethral reflux.

The Company is the result of the Merger effective as of March 31, 2015, of two medical device companies, Uroplasty, Inc. (“UPI”) and Vision-Sciences, Inc. (“VSCI”). On the effective date of the Merger, the two companies completed an all-stock merger, pursuant to which UPI merged with and into Merger Sub, a wholly owned subsidiary of VSCI. Merger Sub was the surviving company from the Merger, and changed its name to Uroplasty, LLC. VSCI continued to be the sole member of the surviving company. After the merger, VSCI and its consolidated subsidiaries, including the surviving company, operate under the name Cogentix Medical, Inc.

Upon closing of the Merger, the former UPI stockholders owned approximately 62.5% and the VSCI shareholders retained approximately 37.5% of the Company. Accordingly, while VSCI was the legal acquirer and issued its shares in the Merger, UPI is the acquiring company in the Merger for accounting purposes and the Merger has been accounted for as a reverse acquisition under the acquisition method of accounting for business combinations. As a result, the financial statements of the Company prior to the effective date of the Merger are the historical financial statements of UPI, whereas the financial statements of the Company after the effective date of the Merger reflect the results of the operations of UPI and VSCI on a combined basis. See additional disclosure provided in Note 2.

All share amounts and price per share amounts for all periods presented relate to VSCI shares with UPI shares and price per share converted to VSCI amounts based on the conversion ratio in the acquisition agreement and the one for five reverse stock split.

**Change in Fiscal Year.**

On December 10, 2015, the Board of Directors of the Company determined that, in accordance with its bylaws and upon recommendation of the Audit Committee, the Company’s fiscal year shall begin on January 1 and end on December 31 of each year starting on January 1, 2016. The required transition period of April 1, 2015 to December 31, 2015 is included in this Form 10-K Transition Report. Amounts included in this report for the nine months ended December 31, 2014 are unaudited.

**Liquidity and Capital Resources.**

We have incurred substantial operating losses since our inception. During the quarter ended December 31, 2015, the Company generated its first ever cash operating profit. This performance is the result of increased sales and reduced expenses. Management will continue to press for improvements in operating performance during calendar 2016 although there can be no assurance these efforts will continue to generate cash operating profits. As of December 31, 2015, we had cash and cash equivalents totaling approximately \$2.0 million. On September 18, 2015, we entered into a \$7.0 million line of credit with Venture Bank to provide non-dilutive resources to execute management’s growth strategies for the PrimeSight and Urgent PC product lines and for general corporate purposes. Note 6 contains further information regarding the line of credit. If operations do not generate sufficient cash in the future, and if we were to seek additional financing, there can be no assurance that any such additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.

**Basis of Presentation.**

The consolidated financial statements include the accounts of Cogentix Medical, Inc. and its wholly owned subsidiaries. We have eliminated all intercompany accounts and transactions in consolidation. We have reclassified certain prior-year amounts to conform to the current year's presentation.

**Revenue Recognition.**

We recognize revenue in accordance with the Financial Accounting Standards Board (the "FASB") Accounting Standards Codification ("ASC") 605 (Topic 605, *Revenue Recognition*). ASC 605 requires that four basic criteria must be met before revenue can be recognized:

1. persuasive evidence that an arrangement exists;
2. delivery has occurred or services were rendered;
3. the fee is fixed and determinable; and
4. collectability is reasonably assured

We recognize revenue when title passes to the customer, generally upon shipment of our products F.O.B. shipping point. Revenue for service repairs of equipment is recognized after service has been completed, and service contract revenue is recognized ratably over the term of the contract. We review our service contracts to determine if multiple element arrangements exist. If there are multiple elements, we allocate revenue to all elements based on the stand-alone selling prices by applying the relative stand-alone selling price methodology. Deferred revenue represents the selling price of any deliverables of the arrangement for which the customer has provided consideration, but the revenue recognition requirements have not been satisfied.

We include shipping and handling charges billed to customers in net sales, and include related costs incurred by us in cost of goods sold. Typically our agreements contain no customer acceptance provisions or clauses. We sell our products to end users and to distributors. Payment terms range from prepayment to 120 days. Sales to distributors are not contingent on the distributor selling the product to end users. Customers do not have the right to return products except for warranty claims. We offer customary product warranties. We present our sales in our statement of operations net of taxes, such as sales, use, value-added and certain excise taxes, collected from the customers and remitted to governmental authorities.

**Use of Estimates.**

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Our significant accounting policies and estimates include revenue recognition, accounts receivable, valuation of inventory, foreign currency translation/transactions, purchase price allocations on acquisition, the determination of recoverability of long-lived assets and liabilities and intangible assets, long-term incentive plans, share-based compensation, defined benefit pension plans, and income taxes.

### **Advertising Expenses.**

Advertising costs are expensed as incurred. Such costs incurred were approximately \$383,000 in the nine-month transition period ended December 31, 2015, \$325,000 in the nine-month period ended December 31, 2014 and \$437,000 and \$595,000 in the fiscal years ended March 31, 2015 and 2014, respectively.

### **Research and Development Expenses.**

Costs of research, new product development, and product redesign are charged to expense as incurred.

### **Share-Based Compensation.**

We account for share-based compensation costs under ASC 718, "Compensation – Stock Compensation". ASC 718 covers a wide range of share-based compensation arrangements including stock options, restricted share plans, performance-based awards, share appreciation rights, and employee share purchase plans. We recognize the compensation cost relating to share-based payment transactions, including grants of employee stock options and restricted shares, in our financial statements. We measure that cost based on the fair value of the equity or liability instruments issued.

### **Long-Term Incentive Plan and Awards.**

We have a long-term incentive plan ("LTIP"). Awards under the LTIP are accounted for as liability awards as the awards are based on the performance of our common stock and are expected to be settled in cash. The fair value of the awards is calculated on a quarterly basis using a Monte Carlo valuation model and is recognized over the derived service period. Vesting of the awards is based on meeting the stock price criteria, the probability of which is considered in determining the estimated fair value.

### **Defined Benefit Pension Plans.**

We have a liability attributed to defined benefit pension plans we offered to certain former and current employees of our subsidiaries in the UK and the Netherlands. The liability is dependent upon numerous factors, assumptions and estimates, and the continued benefit costs we incur may be significantly affected by changes in key actuarial assumptions such as the discount rate, mortality, compensation rates, or retirement dates used to determine the projected benefit obligation. Additionally, changes made to the provisions of the plans may impact current and future benefit costs. In accordance with the provisions of ASC 715, "Compensation – Retirement Benefits", changes in benefit obligations associated with these factors may not be immediately recognized as costs in the statement of operations, but are recognized in future years over the expected average future service of the active employees or the average remaining life expectancies of inactive employees.

### **Disclosures About Fair Value of Financial Instruments.**

Estimates of fair value for financial assets and liabilities are based on the framework established in the accounting guidance for fair value measurements. The framework defines fair value, provides guidance for measuring fair value and requires certain disclosures. The framework prioritizes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three broad levels of inputs may be used to measure fair value under the fair value hierarchy:

- Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.
- Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
- Level 3: Significant unobservable inputs that cannot be corroborated by observable market data and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.

If the inputs used to measure the financial assets and liabilities fall within more than one of the different levels described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.

During the reporting periods presented, the only asset or liability carried at fair value measured on a recurring basis was the long-term incentive plan accrual. The estimated fair value as of December 31, 2015 and March 31, 2015 was \$130,000 and \$730,000, respectively, which are considered level 3 measurements. The long-term incentive plan began on October 2, 2014 and is described in Note 5. The estimated fair value of the accrual is calculated on a quarterly basis using a Monte Carlo valuation model. Vesting is based on the probability of meeting the stock price criteria, the probability of which is considered in determining the estimated fair value.

Remeasurements to fair value on a nonrecurring basis relate primarily to our property, plant and equipment and intangible assets and occur when the derived fair value is below their carrying value on our Consolidated Balance Sheet. We had no remeasurements of such assets to fair value in any of the periods covered in this report.

The carrying amounts reported in the Consolidated Balance Sheets for cash and cash equivalents, accounts receivable, inventories, other current assets, accounts payable, accrued liabilities and convertible debt-related party approximate fair market value.

#### **Cash, Cash Equivalents and Marketable Securities.**

We consider all cash on-hand and highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. We classify marketable securities having original maturities of more than three months when purchased and remaining maturities of one year or less as short-term investments and marketable securities with remaining maturities of more than one year as long-term investments. We further classify marketable securities as either held-to-maturity or available-for-sale. We classify marketable securities as held-to-maturity when we believe we have the ability and intent to hold such securities to their scheduled maturity dates. All other marketable securities are classified as available-for-sale. We have not designated any of our marketable securities as trading securities.

We carry held-to-maturity marketable securities at their amortized cost and available-for-sale marketable securities at their fair value and report any unrealized appreciation or depreciation in the fair value of available-for-sale marketable securities in accumulated other comprehensive income (loss). We monitor our investment portfolio for any decline in fair value that is other-than-temporary and record any such impairment as an impairment loss. We recorded no impairment losses for other-than-temporary declines in the fair value of marketable securities in any of the periods covered in this report.

Cash and cash equivalents include highly liquid money market funds and debt securities with original maturities of three months or less totaling \$2.0 million and \$9.3 million at December 31 2015, and March 31, 2015, respectively. Money market funds present negligible risk of changes in value due to changes in interest rates, and their cost approximates their fair market value. We maintain cash in bank accounts, which, at times, may exceed federally insured limits. We have not experienced any losses in such accounts. Cash and cash equivalents held in foreign bank accounts totaled \$507,000 and \$896,000 at December 31, 2015 and March 31, 2015, respectively.

#### **Accounts Receivable.**

We grant credit to our customers in the normal course of business and, generally, do not require collateral or any other security to support amounts due. If necessary, we have an outside party assist us with performing credit and reference checks and establishing credit limits for the customer. Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. Historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.

Accounts outstanding longer than the contractual payment terms, are considered past due. We carry our accounts receivable at the original invoice amount less an estimated allowance for doubtful receivables based on a periodic review of all outstanding amounts. We determine the allowance for doubtful accounts based on the customer's financial health, and both historical and expected credit loss experience. We write off our accounts receivable when we deem them uncollectible. We record recoveries of accounts receivable previously written off when received. We are not always able to timely anticipate changes in the financial condition of our customers and if circumstances related to these customers deteriorate, our estimates of the recoverability of accounts receivable could be materially affected and we may be required to record additional allowances. Alternatively, if more allowances are provided than are ultimately required, we may reverse a portion of such provisions in future periods based on the actual collection experience. Historically, the accounts receivable balances we have written off have generally been within our expectations. The allowance for doubtful accounts was \$68,000 and \$33,000 at December 31, 2015, and March 31, 2015, respectively.

**Inventories.**

We state inventories at the lower of cost or market using the first-in, first-out method. We value at lower of cost or market the slow moving and obsolete inventories based upon current and expected future product sales and the expected impact of product transitions or modifications. Historically, the inventory write-offs have generally been within our expectations. Inventories consist of the following:

	<u>12/31/15</u>	<u>3/31/15</u>
Raw materials	\$ 2,385,000	\$ 3,156,000
Work-in-process	793,000	527,000
Finished goods	<u>1,407,000</u>	<u>1,143,000</u>
	<u>\$ 4,585,000</u>	<u>\$ 4,826,000</u>

Inventories acquired in a business combination are recorded at their estimated fair value less profit for sales efforts and expensed in cost of sales as that inventory is sold. As of March 31, 2015, the purchase accounting adjustment of \$240,000 related to VSCI inventory was recorded in cost of goods sold over approximately the first four months of the transition period ended December 31, 2015.

**Property, Plant and Equipment.**

We carry property, plant and equipment, including leasehold improvements, at cost, less accumulated depreciation or fair value if acquired in a business combination, which consists of the following balances:

	<u>12/31/15</u>	<u>3/31/15</u>
Land	\$ 133,000	\$ 133,000
Building	610,000	606,000
Leasehold improvements	1,222,000	807,000
Internal use software	782,000	749,000
Equipment	<u>3,042,000</u>	<u>6,888,000</u>
	<u>\$ 5,789,000</u>	<u>\$ 9,183,000</u>
Less accumulated depreciation and amortization	<u>(3,234,000)</u>	<u>(7,370,000)</u>
	<u>\$ 2,555,000</u>	<u>\$ 1,813,000</u>

We provide for depreciation using the straight-line method over useful lives of three to seven years for equipment and 40 years for the building. Certain products used as sales demonstration and service loaner equipment are transferred from inventory to machinery and equipment and are depreciated over 3 years. We charge maintenance and repairs to expense as incurred. We capitalize improvements and amortize them over the shorter of their estimated useful service lives or the remaining lease term. We recognized depreciation expense of approximately \$672,000 in the nine-month transition period ended December 31, 2015, \$183,000 in the nine-months ended December 31, 2014 and \$249,000 and \$323,000 in the fiscal years ended March 31, 2015 and 2014, respectively.

We capitalized internal use software and web site development costs of approximately \$34,000 in the nine-month transition period ended December 31, 2015, \$66,000 in the nine-month period ended December 31, 2014, and \$185,000 and \$25,000 in fiscal 2015 and 2014, respectively. These costs are amortized over a three-year period. The net book value of our capitalized software for internal use was approximately \$183,000 and \$183,000 at December 31, 2015 and March 31, 2015, respectively.

#### **Goodwill.**

Goodwill results from the Merger and represents the excess of the purchase price over the fair value of acquired tangible assets and liabilities and identifiable intangible assets. Annually on November 30 or if conditions indicate an additional review is necessary, the Company assesses qualitative factors to determine if it is more likely than not that the fair value of a reporting unit is less than its carrying amount and if it is necessary to perform the quantitative two-step goodwill impairment test. If the Company performs the quantitative test, it compares the carrying value of the reporting unit to an estimate of the reporting unit's fair value to identify potential impairment. The fair value of each reporting unit is estimated using a discounted cash flow model. Where available, and as appropriate, comparable market multiples are also used to corroborate the results of the discounted cash flow models. In determining the estimated future cash flow, the Company considers and applies certain estimates and judgments, including current and projected future levels of income based on management's plans, business trends, prospects and market and economic conditions and market-participant considerations. If the estimated fair value of the reporting unit is less than the carrying value, a second step is performed to determine the amount of the potential goodwill impairment. If impaired, goodwill is written down to its estimated implied fair value.

For the November 30, 2015 annual impairment test, the Company performed step one of the two-step goodwill impairment test. Based on the results of the step one analysis, the Company concluded that the fair value of its reporting unit was substantially in excess of the carrying value. There was no goodwill impairment loss for the nine-month transition period ended December 31, 2015.

#### **Impairment of Long-Lived Assets.**

Long-lived assets consist of property, plant and equipment and intangible assets. We review our long-lived assets for impairment whenever events or business circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability of assets held and used from a comparison of the carrying amount of an asset to future undiscounted net cash flows we expect to generate by the asset. If we consider such assets impaired, we measure the impairment recognized by the amount by which the carrying amount of the assets exceeds the fair value of the assets. We completed our impairment analysis and concluded there were no impairments in any of the periods covered in this report.

### Product Warranty.

We warrant our products to be free from defects in material and workmanship under normal use and service for a period of twelve months after the date of sale. Under the terms of these warranties, we repair or replace products we deem defective due to material or workmanship.

The following table summarizes changes in our warranty reserve:

	<u>12/31/15</u>	<u>3/31/15</u>
Warranty reserve at beginning of period	\$ 146,000	\$ 9,000
Warranties accrued during the period	50,000	1,000
Warranties settled during the period	(50,000)	-
Warranty reserve for VSCI	-	136,000
Warranty reserve at end of period	<u>\$ 146,000</u>	<u>\$ 146,000</u>

### Other Liabilities.

Other liabilities consist of the following:

	<u>12/31/15</u>	<u>3/31/15</u>
Investment banking fee payable	-	1,750,000
Sales tax and VAT payable	243,000	261,000
Accrued legal and accounting fees	69,000	189,000
Deferred rent	-	148,000
Deferred revenue	308,000	-
Other accrued expenses	329,000	102,000
	<u>\$ 949,000</u>	<u>\$ 2,450,000</u>

### Foreign Currency Translation.

We translate all assets and liabilities of our foreign subsidiaries using period-end exchange rates. We translate statements of operations items using average exchange rates for the period. We record the resulting translation adjustment within accumulated other comprehensive loss, a separate component of shareholders' equity. We recognize foreign currency transaction gains and losses in our consolidated statements of operations, including unrealized gains and losses on short-term intercompany obligations using period-end exchange rates.

We recognize foreign currency transaction gains and losses primarily as a result of fluctuations in currency rates between the U.S. dollar (the functional reporting currency) and the Euro and British pound (currencies of our subsidiaries), as well as their effect on the dollar denominated intercompany obligations between us and our foreign subsidiaries. All intercompany balances are revolving in nature and we do not deem any portion of them to be long-term. We recognized foreign currency transaction gains and losses of approximately \$(14,000) in the nine-month transition period ended December 31, 2015, \$(3,000) in the nine months ended December 31, 2014 and \$(4,000) and \$(5,000) in the fiscal years ended March 31, 2015 and 2014, respectively.

### Income Taxes.

We account for income taxes using the asset and liability method. The asset and liability method provides that deferred tax assets and liabilities be recorded based on the differences between the tax basis of assets and liabilities and their carrying amounts for financial reporting purposes. We reduce deferred tax assets by a valuation allowance, when we believe it is more likely than not that some portion or all of the deferred tax assets will not be realized.

ASC 740, "Accounting for Income Taxes", prescribes a recognition threshold and a measurement attribute for financial statement recognition of tax positions we take or expect to take in a tax return. It is management's responsibility to determine whether it is "more-likely-than-not" that a taxing authority will sustain a tax position upon examination, including resolution of any related appeals or litigation processes, based on the technical merits of the position.

Under our accounting policies we recognize interest and penalties accrued on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense.

**Basic and Diluted Net Loss per Share.**

We calculate basic net loss per common share amounts by dividing net loss by the weighted-average common shares outstanding, excluding outstanding shares contingently subject to forfeiture. For calculating diluted net loss per common share amounts, we add additional shares to the weighted-average common shares outstanding for the assumed exercise of stock options and vesting of restricted shares, if dilutive. Because we have had net losses, the following options and warrants outstanding and unvested restricted stock to purchase shares of our common stock were excluded from diluted net loss per common share because of their anti-dilutive effect, and therefore, basic net loss per common share equals dilutive net loss per common share:

Period ended:	<b>Number of options, warrants and unvested restricted stock</b>	<b>Range of exercise prices</b>
Nine-months December 31, 2015	3,637,000	\$1.64 - \$24.40
Nine-months December 31, 2014	2,285,000	\$2.84 - \$24.40
March 31, 2015	2,569,000	\$2.70 - \$24.40
March 31, 2014	2,476,000	\$1.06 - \$24.40
March 31, 2013	2,196,000	\$1.06 - \$24.40

***Recently Adopted Accounting Pronouncements***

In 2015, the Company adopted Accounting Standards Update (“ASU”) 2015-03, Interest – Imputation of Interest (Subtopic 835-30) – Simplifying the Presentation of Debt Issuance Costs. The amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of the debt liability. The Company adopted this standard in conjunction with obtaining its new loan facility. There was no impact of the retrospective adoption to prior periods.

***Recently Issued Accounting Pronouncements Not Yet Adopted.***

In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-2, Leases, under which lessees will recognize most leases on-balance sheet. This will generally increase reported assets and liabilities. For public entities, this ASU is effective for annual and interim periods in fiscal years beginning after December 15, 2018. ASU 2016-2 mandates a modified retrospective transition method for all entities. The Company will begin the process of determining the impact this ASU will have on the Company’s consolidated financial statements.

In November 2015, the FASB issued ASU 2015-17, *Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes*, which amends the guidance requiring companies to separate deferred income tax liabilities and assets into current and non-current amounts in a classified statement of financial position. This accounting guidance simplifies the presentation of deferred income taxes, such that deferred tax liabilities and assets be classified as non-current in a classified statement of financial position. This accounting guidance is effective for the Company beginning in the first quarter of 2017. We do not believe the adoption of this update will have a material impact on our consolidated financial statements.

In September 2015, the FASB issued ASU No. 2015-16, “Business Combinations (Topic 805).” The amendments in this update require that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. Under the new guidance, the acquirer should record, in the same period’s financial statements, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. On the face of the income statement or in the notes, the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods need to be reflected as if the adjustment to the provisional amounts had been recognized as of the acquisition date. The amendments in ASU No. 2016-16 are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We do not believe the adoption of this update will have a material impact on our consolidated financial statements.

In July 2015, the FASB issued ASU No. 2015-12, “Plan Accounting: Defined Benefit Pension Plans (Topic 815).” Under the new guidance, plans are no longer required to measure fully benefit-responsive investment contracts (FBRICs) at fair value, disaggregate investments by nature, risks and characteristics, disclose individual investments that represent five percent or more of net assets available for benefits, or disclose net appreciation or depreciation for investments by general price. The amendments in ASU No. 2015-12 are effective for fiscal years beginning after December 15, 2015 and earlier adoption is permitted. We are still evaluating whether or not this update is applicable to our business.

In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory (Topic 330).” Under the current guidance (i.e., ASC 330-10-352 before the ASU), an entity subsequently measures inventory at the lower of cost or market, with market defined as replacement cost, net realizable value (NRV), or NRV less a normal profit margin. An entity uses current replacement cost provided that it is not above NRV (i.e., the ceiling) or below NRV less an “approximately normal profit margin” (i.e., the floor). The new guidance requires entities to measure most inventory “at the lower of cost and net realizable value,” thereby simplifying the current guidance under which an entity must measure inventory at the lower of cost or market (market in this context is defined as one of three different measures). The ASU will not apply to inventories that are measured by using either the last-in, first-out (LIFO) method or the retail inventory method (RIM). The amendments in ASU No. 2015-11 are effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. We do not believe the adoption of this update will have a material impact on our consolidated financial statements.

In May 2014, the Financial Accounting Standards Board (“FASB”) issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606), as amended by ASU 2015-14, “Deferral of Effective Date, which requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 sets forth a new revenue recognition model that requires identifying the contract, identifying the performance obligations, determining the transaction price, allocating the transaction price to performance obligations and recognizing the revenue upon satisfaction of performance obligations. For public entities, this ASU is effective for annual reporting periods beginning after December 15, 2017 including interim reporting periods within that reporting period. The provisions can be adopted either retrospectively to each prior reporting period presented or as a cumulative-effect adjustment as of the date of adoption. The Company is currently in the process of determining the impact that this ASU will have on the consolidated financial statements and its method of adoption.

**Note 2. Business Combinations-Merger Between Uroplasty, Inc and Vision-Sciences, Inc**

The Merger has been accounted for as an acquisition of VSCI by UPI, in accordance with Accounting Standards Codification (ASC) Topic 805, “Business Combinations,” using the acquisition method of accounting with UPI as the accounting acquirer. Since the Company (formerly known as Vision-Sciences), as the parent company of UPI after the Merger, is the legal acquirer, the Merger has been accounted for as a reverse acquisition. Under these accounting standards, UPI’s total purchase price of \$16.5 million is calculated as if UPI had issued its shares to VSCI stockholders and converted options and warrants to purchase VSCI shares to options and warrants to purchase UPI’s common stock.

[Table of Contents](#)

Under the acquisition method of accounting, the total purchase price was allocated to the net tangible and intangible assets of VSCI acquired in the Merger, based on their fair values at the effective date of the Merger. The allocation was finalized without any change to the preliminary allocation and is as follows:

Cash and cash equivalents	\$ 2,020,000
Accounts receivable	4,249,000
Inventories	4,462,000
Other current assets	369,000
Property, plant and equipment	817,000
Goodwill	18,750,000
Other intangibles	13,660,000
Other non-current assets	97,000
<b>Total assets acquired</b>	<b>44,424,000</b>
Accounts payable and other liabilities	5,209,000
Deferred revenue	176,000
Convertible debt – related party	22,530,000
Other non-current liabilities	40,000
<b>Total liabilities assumed</b>	<b>27,955,000</b>
<b>Total purchase price</b>	<b>\$ 16,469,000</b>

The allocation of the purchase price to the net assets acquired and liabilities assumed resulted in the recognition of the following intangible assets:

	<u>Amount</u>	<u>Weighted Average Life-Years</u>
Developed technology	\$ 6,200,000	7
Customer relationships	7,270,000	5
Trade names	190,000	10
	<u>\$ 13,660,000</u>	

The supplemental unaudited pro forma net sales and net loss of the combined entity had the acquisition been completed on April 1, 2013:

(Unaudited)

	<u>December 31,</u> <u>2014</u>	<u>Year ended</u> <u>March 31,</u> <u>2015</u> <u>2014</u>	
<b>Supplemental pro forma combined results of operations:</b>			
Net sales	\$ 32,287,840	\$ 44,973,000	\$ 41,523,000
Net loss	(10,239,430)	(15,817,000)	(21,477,000)
Loss per share – basic and diluted	\$ (0.41)	\$ (0.62)	\$ (0.86)

Adjustments to the supplemental pro forma combined results of operations are as follows:

(Unaudited)	December 31, 2014	Year ended March 31,	
		2015	2014
Increase in amortization of intangibles	\$ 1,751,000	\$ 2,334,000	\$ 2,464,000
Adjust expenses related to merger (transaction costs, inventory step-up, deferred revenue adjustment)	(4,399,000)	(4,399,000)	4,801,000
Interest expense imputed on debt	899,000	1,198,000	1,144,000
Increase (decrease) in net loss	\$ (1,749,000)	\$ (867,000)	\$ 8,409,000

These unaudited pro forma condensed consolidated financial results have been prepared for illustrative purposes only and do not purport to be indicative of the results of operations that actually would have resulted had the acquisition occurred on the first day of the earliest period presented, or of future results of the consolidated entities. The unaudited pro forma condensed consolidated financial information does not reflect any operating efficiencies and cost savings that may be realized from the integration of the acquisition.

### **Note 3. Goodwill and Other Intangible Assets**

#### **Goodwill.**

As described in Note 2, on March 31, 2015, for accounting purposes, UPI was deemed to have acquired VSCI for a purchase price of \$16.5 million, and as a result, the Company recognized \$18.8 million in goodwill.

#### **Other Intangible Assets.**

Other intangible assets consisted of the following at reporting dates presented below:

	December 31, 2015		March 31, 2015	
	Gross Carrying Amount	Accumulated Amortization	Gross Carrying Amount	Accumulated Amortization
Developed technology	\$ 6,200,000	\$ 664,000	\$ 6,200,000	\$ -
Patents & trademarks	5,653,000	5,586,000	5,653,000	5,564,000
Trademarks and trade names	190,000	67,000	190,000	-
Customer relationships	7,270,000	1,150,000	7,270,000	-
	19,313,000	\$ 7,467,000	19,313,000	\$ 5,564,000
Accumulated amortization	7,467,000		5,564,000	
Net book value of amortizable intangible assets	\$ 11,846,000		\$ 13,749,000	

Amortization costs were approximately \$1,903,000, \$24,000, \$31,000 and \$30,000 in the nine-month transition period ended December 31, 2015, the nine-month period ended December 31, 2014, and the fiscal years ended March 31, 2015 and 2014, respectively. The weighted average remaining amortization period for intangible assets as of December 31, 2015 was approximately 5 years.

Estimated amortization expense for all intangible assets for the five years subsequent to December 31, 2015 is as follows:

Year ending December 31,	
2016	\$ 2,348,000
2017	2,348,000
2018	2,348,000
2019	2,348,000
2020	587,000

**Note 4 Convertible Debt – Related Party**

The following table is a summary of our convertible debt – related party:

	December 31, 2015			March 31, 2015		
	Gross Principal Amount	Unamortized Debt Discount	Net Amount	Gross Principal Amount	Unamortized Debt Discount	Net Amount
Note Payable A	\$ 20,000,000	\$ (3,639,000)	\$ 16,361,000	\$ 20,000,000	\$ (4,210,000)	\$ 15,790,000
Note Payable B	3,500,000	(562,000)	2,938,000	3,500,000	(650,000)	2,850,000
Note Payable C	4,990,000	(952,000)	4,038,000	4,990,000	(1,101,000)	3,889,000
	<u>\$ 28,490,000</u>	<u>\$ (5,153,000)</u>	<u>\$ 23,337,000</u>	<u>\$ 28,490,000</u>	<u>\$ (5,961,000)</u>	<u>\$ 22,529,000</u>

The Convertible Debt-Related Party is held by Mr. Lewis Pell, a member of Cogentix’s board of directors, and consists of three convertible promissory notes.

- Note Payable A accrues annual interest at the rate of 0.84%. The outstanding principal amount of Note Payable A is convertible into shares of our common stock at a conversion price of \$6.00 per share.
- Note Payable B accrues annual interest at the rate of 1.66%. The outstanding principal amount of Note Payable B is convertible into shares of our common stock at a conversion price of \$4.45 per share.
- Note Payable C accrues annual interest at the rate of 1.91%. The outstanding principal amount of Note Payable C is convertible into shares of our common stock at a conversion price of \$5.55 per share.

At December 31, 2015, we had an aggregate amount of \$758,000 in accrued interest under the convertible notes payable, which is included in interest payable on our consolidated balance sheet.

The convertible promissory notes mature on March 31, 2020 or earlier upon a change of control (as defined). The convertible promissory notes generally cannot be converted prior to March 31, 2018. The convertible promissory notes may be converted earlier prior to a change in control or in connection with our prepayment of the convertible promissory notes. The convertible promissory notes may be prepaid, at our option and upon 15 days’ notice to Mr. Pell, without other premium or penalty, with a combination of cash and common stock. Interest on the convertible promissory notes is payable on the maturity date or upon repayment or conversion of all or any portion of the principal under the note.

The convertible promissory notes were amended concurrently with the execution of the merger agreement to extend the maturity from the fifth anniversary from their issuance dates to the fifth anniversary of the effective date of the merger and to change the conversion date from anytime to generally not earlier than three years after the effective date of the merger.

Under purchase accounting for the merger, the convertible promissory notes were recorded at fair value, resulting in a discount from their face value of \$5,960,000. The discount is being amortized over the remaining term based on the effective interest rate method with an imputed interest rate of 4.72%. The amendments to the convertible notes payable were considered to be part of an arrangement entered into between Mr. Pell and the Company during the merger negotiations that were separate from the business combination. Accordingly, the fair value of the notes was based on the terms that existed prior to the amendment. The fair value of the notes was determined using a lattice model with key assumptions of a risk free rate of 1.37%, market interest rate of 10.3%, and annualized volatility of 65%, less any increase in the fair value of the conversion feature resulting from the amendments. The increase in the fair value of the conversion feature was based on a comparative analysis of the conversion feature’s value under both the original terms and modified terms using the same key assumptions.

Stock warrants originally issued in connection with the issuance of the convertible promissory notes are described in Note 5.

## **Note 5. Shareholder's Equity**

### **Reverse Acquisition.**

As discussed in Note 2, the merger is accounted for as reverse acquisition with VSCI as the legal acquirer and UPI as the accounting acquirer. Under reverse acquisition accounting, the dollar amount for common stock is based on the par value and number of shares issued by VSCI (reflecting the legal structure of VSCI as the legal acquirer) on the merger date plus subsequent shares issued by the Company. Additional paid-in capital represents that of UPI and includes the fair value of shares deemed for accounting purposes to have been issued by UPI on the merger date, as well as the fair value of the VSCI stock options and warrants included in the purchase price calculation. The UPI additional paid-in capital was also adjusted for the difference between the number of common shares outstanding and the historical number of shares of UPI common stock.

### **Share-based Compensation.**

At December 31, 2015, as a result of the merger, the Company had one active plan, the Cogentix Medical 2015 Omnibus Incentive Plan, for share-based compensation grants ("the 2015 Plan"). Under the 2015 Plan, if we have a change in control, all outstanding grants, including those subject to vesting or other performance targets, fully vest immediately. Under the 2015 Plan, we reserved 2,500,000 shares of our common stock for share-based grants and 1,276,186 shares remain available for grant at December 31, 2015.

On July 23, 2013, and in connection with the commencement of his employment, our CEO Robert Kill received a stock grant of 217,986 shares that did not have vesting restrictions.

We grant option awards with an exercise price equal to the closing market price of our stock at the date of the grant. We have options outstanding to purchase 2,573,640 shares of common stock granted under the 2015 Plan or UPI and VSCI plans. Options that were previously granted under the UPI plans generally expire over a period ranging from five to seven years from date of grant and vest at varying rates ranging up to three years. All outstanding VSCI options and restricted stock became fully vested due to the change of control upon closing of the merger.

We have fully vested options outstanding to purchase 217,986 shares of common stock, not granted under a plan, which expire in May 2016.

We grant options at the discretion of our directors. The options granted under the 2015 Plan generally provide for the exercise of options during a limited period following termination of employment, death or disability.

We recognize share-based compensation expense in the statement of operations based on the fair value at the time of grant of the share-based payment over the requisite service period. We incurred a total of approximately \$979,000, \$1,389,000 and \$1,436,000 in share-based compensation expense for the nine-month transition period ended December 31, 2015, and for the fiscal years ended 2015 and 2014, respectively.

We determine the fair value of the option awards using the Black-Scholes option pricing model. We used the following weighted-average assumptions to value the options granted during the nine-month transition period ended December 31, 2015 and the fiscal years ended 2015 and 2014:

	<b>December 31, 2015</b>	<b>March 31, 2015</b>	<b>March 31, 2014</b>
Expected life, in years	3.84	3.29	4.51
Risk-free interest rate	1.11%	.74%	1.36%
Expected volatility	63.9%	63.4%	89.1%
Expected dividend yield	0%	0%	0%

[Table of Contents](#)

The expected life for options granted represents the period of time we expect options to be outstanding based on historical data of option holder exercise and termination behavior for similar grants. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate over the expected life at the time of grant. Expected volatility is based upon historical volatility of our common stock. We estimate the forfeiture rate for stock awards to be approximately 10% for executive employees and directors and approximately 15% for non-executive employees for the nine-month transition period ended December 31, 2015 awards based on our historical experience.

The following table summarizes the activity related to our stock options for the nine-month transition period ended December 31, 2015 and fiscal 2015 and 2014:

	<u>Number of shares</u>	<u>Weighted average exercise price</u>	<u>Weighted average grant date fair value</u>	<u>Aggregate intrinsic value</u>	<u>Weighted average remaining life in years</u>
Balance at March 31, 2013	1,464,866	\$ 4.84		\$ 882,989	2.64
Options granted	682,296	3.54	\$ 2.36		
Options exercised	(251,410)	1.67		1,089,978	
Options surrendered	<u>(204,203)</u>	5.81			
Balance at March 31, 2014	1,691,549	4.67		2,451,075	3.85
Options granted	135,070	4.73	1.26		
Options exercised	(61,761)	1.10		170,944	
Options surrendered	<u>(469,466)</u>	6.91			
Balance at March 31, 2015	1,295,392	4.03		-	3.91
Options converted from VSCI	<u>955,473</u>	7.07	4.75		6.62
Balance at March 31, 2015	2,250,865	5.32		-	5.06
Options granted	617,914	1.64	0.79		
Options exercised	-				
Options surrendered	<u>(295,139)</u>	5.08			
Balance at December 31, 2015	<u><u>2,573,640</u></u>	4.46		-	5.24
Options exercisable at December 31, 2015	<u><u>1,699,792</u></u>	4.56		-	3.92

The total fair value of stock options vested during the nine-month transition period ended December 31, 2015 and fiscal 2015 and 2014, respectively was approximately \$519,000, \$723,000 and \$441,000, respectively.

We received net proceeds of \$68,000 in fiscal 2015 and \$360,000 in fiscal 2014 from the exercise of stock options. There were no options exercised for the nine-month transition period ended December 31, 2015.

[Table of Contents](#)

We grant restricted shares at the discretion of our directors with vesting terms ranging from six months to four years. The following table summarizes the activity related to our restricted stock for the nine-month transition period ended December 31, 2015 and fiscal 2015:

	<u>Number of Shares</u>	<u>Weighted average grant date fair value</u>	<u>Weighted average remaining life in years</u>	<u>Aggregate intrinsic value</u>
Balance at March 31, 2013	130,791	\$ 6.05	1.50	\$ 1,087,226
Shares granted	88,647	4.22		
Shares vested	(38,510)	5.69		304,148
Shares surrendered	<u>(74,652)</u>	6.03		
Balance at March 31, 2014	106,276	4.65	2.23	743,167
Shares granted	305,248	4.34		
Shares vested	(82,060)	4.41		185,957
Shares surrendered	<u>(11,723)</u>	5.56		
Balance at March 31, 2015	317,741	4.47	1.93	387,644
Shares granted	513,299	1.62		
Shares vested	(122,353)	4.42		157,835
Shares surrendered	<u>(21,777)</u>	2.73		
Balance at December 31, 2015	<u>686,910</u>	2.41	1.59	886,114

The aggregate intrinsic value shown above for the restricted shares represents the total pre-tax value based on the closing price of our common stock on the grant date.

At December 31, 2015, we had approximately \$1,104,000 of unrecognized share-based compensation cost, net of estimated forfeitures, related to stock options and restricted shares that we expect to recognize over a weighted-average requisite service period of approximately two years.

**Stock Warrants-Related Party.**

At December 31, 2015, the Company has warrants outstanding that were issued to Mr. Pell to purchase an aggregate of 376,123 shares of our common stock at a weighted average exercise price of \$9.31 per share. The duration in which the warrants may be exercised commences on the earlier of (i) March 31, 2018 or (ii) three days prior to the record date established for the declaration of any dividend or distribution of any rights in respect to our common stock in cash or other property other than our common stock, and terminates on the later of (x) the maturity date of the convertible promissory notes or (y) the date the convertible promissory notes are paid in full or converted into shares. In addition, the warrants may be exercised immediately prior to a change in control.

**Long-Term Incentive Plan and Awards.**

On October 1, 2014, the compensation committee of our board of directors and our board of directors approved and adopted a Performance Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan, as amended, and on October 2, 2014, grants of Performance Awards (the "Awards") were made to certain members of our senior management team.

Performance goals for the Awards are based on the achievement of specified stock price targets during the period beginning on the date of grant and ending on the fourth anniversary of the date of grant or, if earlier, the closing date of a change of control (as defined in the Plan) of the Company (the "Performance Period"). The stock price targets under the Awards are: \$7.57 price per share of common stock, \$10.32 price per share of common stock and \$13.76 price per share of common stock.

A stock price target is considered achieved on the date (a) the average closing price of the Cogentix common stock equals or exceeds a stock price target for at least 45 consecutive trading days or (b) of the consummation of a change of control of the Company, provided the closing price of Cogentix common stock on the last trading day immediately preceding the closing date of the change of control equals or exceeds a stock price target not previously achieved during the Performance Period.

The Awards are accounted for as liability awards under the share based compensation accounting guidance, as the awards are based on the performance of our common stock and are expected to be settled in cash. Expense for the Awards value is recognized over the derived service period of approximately 2.4 years. We recorded a liability of \$74,405 at December 31, 2015 and related income was \$78,000 for the nine-month transition period ended December 31, 2015 for the Awards.

**Note 6. Line of Credit**

On September 18, 2015, we entered into a loan agreement with Venture Bank, a Minnesota banking corporation, providing us with a committed \$7 million secured revolving credit facility ("Facility"), subject to eligible accounts receivable and inventory. The Facility will expire on March 18, 2017 and any loans outstanding on such date will mature and become payable. The Facility is secured by substantially all of our assets.

Under the Facility, we may borrow the lesser of: (a) the sum of (i) eighty percent (80%) of the value of eligible accounts receivable; and (ii) forty percent (40%) of the value of eligible inventory capped at the lesser of (1) \$2 million or (2) fifty percent (50%) of the Notes principal balance outstanding; or (b) \$7 million. As of December 31, 2015, based on eligible receivables and inventory, our total available borrowing base was \$5,653,000. We did not have any borrowings under the facility as of December 31, 2015.

Loans under the Facility bear interest at a rate per annum equal to the Wall Street Journal Prime Rate plus 2.25%, provided that in no case will the interest charged be less than 5.5%. In the event that there is an event of default under the Facility, the interest rate will be increased by 6.0% for the entire period that an event of default exists. In addition, the Borrowers will pay a non-usage fee of 0.25% based on the average unused and available portion of the Facility on a monthly basis.

**Note 7. Commitments and Contingencies**

**Royalties.**

We received an absolute assignment of a patent relating to the Macroplastique Implantation System, in return for a royalty of 10 British Pounds for each unit sold during the life of the patent, which expires in September 2017. Under the terms of an agreement with former officers and directors of our Company, we also pay royalties equal to five percent of the net sales of certain Macroplastique products, subject to a specified monthly minimum of \$4,500. We recognized an aggregate of \$48,000, \$274,000 and \$353,000 of royalty expense under these agreements for the nine-month transition period ended December 31, 2015 and in fiscal 2015 and 2014, respectively. The royalties payable under these agreements ended when certain patents referenced in the agreement expired in May 2015.

**Purchase Requirements.**

In our normal course of business we have commitments, generally for periods of less than one year, to purchase from various vendors finished goods and manufacturing components under issued purchase orders. As of the nine-month transition period ended December 31, 2015 payments of our contractual obligations for purchase commitments within the next twelve months are \$1,512,000.

**Operating Lease Commitments.**

We lease office, warehouse, and production space under operating lease agreements, which include escalating lease payments, and lease various automobiles for our European employees. These leases expire at various times through August 2025. At December 31, 2015, the approximate future minimum lease payments in subsequent calendar years under noncancelable operating leases with an initial term in excess of one year are as follows:

2016	\$	744,000
2017		610,000
2018		339,000
2019		228,000
Thereafter		762,000
	\$	<u>2,683,000</u>

Total operating lease expenses were approximately \$580,000 for the nine-month transition period ended December 31, 2015, \$77,000 for the nine-months ended December 31, 2014 and \$250,000 and \$294,000 in fiscal 2015 and 2014, respectively.

#### **Employment Agreements.**

We have entered into employment agreements with certain officers, the terms of which, among other things, specify a base salary subject to annual adjustments by mutual agreement of the parties, and a severance payment to the employee upon employment termination without cause. We provide for various severance amounts payable under the agreements after employment termination. Contemporaneously with the execution of their employment agreement, all of the officers executed an "Employee Confidentiality, Inventions, Non-Solicitation, and Non-Compete Agreement." This agreement prohibits the employee from disclosing confidential information, requires the employee to assign to us without charge all intellectual property relating to our business which is created or conceived during the term of employment, prohibits the employee from encouraging employees to leave our employment for any reason and prohibits competition with us during the term of employment and for a specified term thereafter.

#### **Product Liability.**

The manufacture and sale of medical devices exposes us to significant risk of product liability claims, some of which may have a negative impact on our business. Any defects or risks that we have not yet identified with our products may give rise to product liability claims. Our existing \$10 million of worldwide product liability insurance coverage may be inadequate to protect us from liabilities we may incur or we may not be able to maintain adequate product liability insurance at acceptable rates. If a product liability claim or series of claims is brought against us for uninsured liabilities or in excess of our insurance coverage and it is ultimately determined that we are liable, our business could suffer.

#### **Note 8: Savings and Retirement Plans**

We sponsor various plans for eligible employees in the United States, the United Kingdom ("U.K."), and The Netherlands. Our retirement savings plan in the United States conforms to Section 401(k) of the Internal Revenue Code of 1986, as amended, and participation is available to substantially all employees. We may also make discretionary contributions ratably to all eligible employees. We made discretionary contributions to the U.S. plan of approximately \$261,000 in the nine-month transition period ended December 31, 2015, \$206,000 in the nine-months ended December 31, 2014 and \$282,000 and \$224,000 for fiscal years ended March 31, 2015 and 2014, respectively.

Our international subsidiaries in the U.K. and The Netherlands have defined benefit retirement plans for eligible employees. These plans provide benefits based on the employee's years of service and compensation during the years immediately preceding retirement, termination, disability, or death, as defined in the plans. We froze the U.K. subsidiary's defined benefit plan on December 31, 2004. On March 10, 2005, we established a defined contribution plan for the U.K. subsidiary. As of April 1, 2005, we closed The Netherlands subsidiary's defined benefit retirement plan for new employees and established a defined contribution plan for them. The total contribution expense associated with the defined contribution plans in The Netherlands and the U.K. was approximately \$33,000 in the nine-month transition period ended December 31, 2015, \$19,000 in the nine-months ended December 31, 2014 and \$24,000 and \$22,000 for the fiscal years ended March 31, 2015, and 2014, respectively.

The amortization of actuarial gains or losses is included as a component of the annual expense for a period if, as of the beginning of the period, the cumulative net gain or loss exceeds 10% of the greater of the projected benefit obligation or plan assets. If amortization is required, the amortization is that excess divided by the expected average future service of the active employees participating in the plans or the average remaining life expectancies of inactive employees.

**The Netherlands defined benefit plan.**

The Netherlands defined benefit pension plan is funded through a guaranteed insurance contract with Zwitser Leven, an insurance company. Our contract with Zwitser Leven requires us to make annual premium payments which are sufficient to satisfy the vested benefit obligation (“VBO”). Zwitser Leven does not hold separate investment assets for our contract, but rather is obligated to provide the stream of future benefits for the annual premium payments we make. We calculate the market value of the pension plan assets, held in Zwitser Leven insured assets, as the stream, based on mortality, of the earned guaranteed benefit payments discounted at a market interest rate. The benefit obligation is calculated based on the same assumptions as well. Accordingly, the impact on pension plan assets of a change in assumption for discount rate and mortality would equally offset the change in VBO.

At December 31, 2015, we project the following benefit payments in subsequent years:

2016	\$ 21,000
2017	21,000
2018	21,000
2019	26,000
2020	26,000
2021 to 2025	156,000
	<u>\$ 271,000</u>

We contributed approximately \$73,000 in the nine-month transition period ended December 31, 2015, \$167,000 in the nine-months ended December 31, 2014, \$147,000 in fiscal 2015, \$216,000 in fiscal 2014, and expect to contribute approximately \$65,000 in 2016.

The following table summarizes the change in benefit obligations and the change in plan assets:

	<u>Nine months ended December 31, 2015</u>	<u>Fiscal year ended March 31, 2015</u>
Changes in benefit obligations:		
Projected benefit obligation, beginning of period	\$ 4,465,000	\$ 3,343,000
Service cost	109,000	133,000
Interest cost	51,000	102,000
Benefits paid	(16,000)	(7,000)
Plan amendment	-	(110,000)
Actuarial result	(977,000)	2,006,000
Foreign currency translation	33,000	(1,002,000)
Projected benefit obligation, end of period	<u>\$ 3,665,000</u>	<u>\$ 4,465,000</u>
Changes in plan assets:		
Plan assets, beginning of period	\$ 3,593,000	\$ 2,665,000
Contributions to plan	73,000	147,000
Management cost	(4,000)	(10,000)
Actual return on assets	(670,000)	1,603,000
Benefits paid	(16,000)	(7,000)
Foreign currency translation	26,000	(805,000)
Plan assets, end of period	<u>\$ 3,002,000</u>	<u>\$ 3,593,000</u>

The amount recognized in other comprehensive loss consists of:

	<b><u>Nine months ended December 31, 2015</u></b>	<b><u>Fiscal Year 2015</u></b>
Unrecognized net prior service benefit	\$ (313,000)	\$ (339,000)
Unrecognized net losses	656,000	941,000
	<u>\$ 343,000</u>	<u>\$ 602,000</u>

The projected benefit obligation, accumulated benefit obligations and the fair value plan were as follows:

	<b><u>December 31, 2015</u></b>	<b><u>March 31, 2015</u></b>
Projected benefit obligation	\$ 3,665,000	\$ 4,465,000
Accumulated benefit obligation	3,107,000	3,710,000
Fair value of plan assets	3,002,000	3,593,000

We have recorded the excess of the projected benefit obligation over the fair value of the plan assets on December 31, 2015 and March 31, 2015, of \$663,000 and \$872,000, respectively, as accrued pension liability.

The cost of our defined benefit retirement plan includes the following components:

	<b><u>Nine months ended December 31, 2015</u></b>	<b><u>Nine months ended December 31, 2014</u></b>	<b><u>Fiscal Year 2015</u></b>	<b><u>Fiscal Year 2014</u></b>
Gross service cost, net of employee contribution	\$ 98,000	\$ 92,000	\$ 118,000	\$ 113,000
Interest cost	51,000	81,000	102,000	108,000
Management cost	6,000	8,000	11,000	11,000
Expected return on assets	(42,000)	(58,000)	(72,000)	(72,000)
Amortization	1,000	(1,000)	(2,000)	-
	<u>\$ 114,000</u>	<u>122,000</u>	<u>\$ 157,000</u>	<u>\$ 160,000</u>

Major assumptions used in the above calculations include:

	<u>December 31, 2015</u>	<u>March 31, 2015</u>
Discount rate	2.40%	1.50%
Expected return on assets	2.40%	1.50%
Expected rate of increase in future compensation:		
General	2.5%	2.5%
Individual	0-3%	0-3%

The discount rate used is based upon the yields available on high quality corporate bonds with a term that matches the liabilities. The impact of the increase in discount rate used at December 31, 2015 as compared to March 31, 2015 was a decrease in the projected benefit obligation and actual return on assets. The market value of the assets is determined as the discounted stream of guaranteed benefit payments. Given the valuation method of the assets, the expected long-term rate of return on assets equals the discount rate.

**The U.K. defined benefit plan.**

As of December 31, 2015 and March 31, 2015, we held all the assets of the U.K. defined benefit pension plan in a Deposit Administration Contract with Phoenix Life Limited.

At December 31, 2015 we project the following benefit payments in subsequent years:

2016	\$ 83,000
2017	28,000
2018	160,000
2019	53,000
2020	-
2021 to 2025	783,000
	<u>\$ 1,107,000</u>

We contributed approximately \$33,000 in the nine-month transition period ended December 31, 2015, \$35,000 in the nine-months ended December 31, 2014, \$45,000 in fiscal 2015, \$43,000 in fiscal 2014, and expect to contribute approximately \$43,000 in 2016.

The following table summarizes the change in benefit obligations and the change in plan assets:

	<u>Nine months ended December 31, 2015</u>	<u>Fiscal Year March 31, 2015</u>
Changes in benefit obligations:		
Projected benefit obligation, beginning of period	\$ 814,000	\$ 755,000
Service cost	4,000	5,000
Interest cost	21,000	34,000
Other	(4,000)	(5,000)
Actuarial result	(91,000)	119,000
Foreign currency translation	-	(94,000)
Projected benefit obligation, end of period	<u>\$ 744,000</u>	<u>\$ 814,000</u>
Changes in plan assets:		
Plan assets, beginning of period	\$ 730,000	\$ 756,000
Contributions to plan	33,000	45,000
Management cost	(4,000)	(5,000)
Actual return on assets	19,000	21,000
Foreign currency translation	(3,000)	(87,000)
Plan assets, end of period	<u>\$ 775,000</u>	<u>\$ 730,000</u>

The amount recognized in other comprehensive loss consists of:

	<b>Nine months ended December 31, 2015</b>	<b>Fiscal year 2015</b>
Unrecognized net losses (gross of deferred taxes)	\$ 116,000	\$ 228,000

The projected benefit obligation, accumulated benefit obligation and the fair value plan assets were as follows:

	<b>December 31, 2015</b>	<b>March 31, 2015</b>
Projected benefit obligation	\$ 744,000	\$ 814,000
Accumulated benefit obligation	744,000	814,000
Fair value of plan assets	775,000	730,000

We have recorded the excess of the fair value of the plan assets over the projected benefit obligation of \$31,000, as of December 31, 2015, as prepaid pension asset. We have recorded the excess of the projected benefit obligation over the fair value of the plan assets on March 31, 2015 of \$84,000, as accrued pension liability.

The cost of our defined benefit retirement plan includes the following components for the years ended:

	<b>Nine months ended December 31, 2015</b>	<b>Nine months ended December 31, 2014</b>	<b>Fiscal Year 2015</b>	<b>Fiscal Year, 2014</b>
Gross service cost, net of employee contribution	\$ 4,000	\$ 4,000	\$ 5,000	\$ 5,000
Interest cost	21,000	25,000	34,000	33,000
Expected return on assets	(15,000)	(21,000)	(28,000)	(21,000)
Amortization	19,000	4,000	5,000	7,000
Net periodic retirement cost	\$ 29,000	12,000	\$ 16,000	\$ 24,000

Major assumptions used in the above calculations include:

	<u>December 31, 2015</u>	<u>March 31, 2015</u>
Discount rate	4.00%	3.40%
Expected return on assets	3.00%	2.60%

The discount rate used is based upon the yields available on high quality corporate bonds with a term that matches the liabilities. The expected return on assets assumption on the investment portfolio for the defined benefit plan is based on the long-term expected returns for the assets currently in the portfolio. Management uses historic return trends of the asset portfolio combined with recent market conditions to estimate the future rate of return.

**Plan Assets.**

The primary objective of the Netherlands pension plan is to meet retirement income commitments to plan participants at a reasonable cost. In The Netherlands, consistent with typical practice, the pension plan is funded through a guaranteed insurance contract with Zwitser Leven, an insurance company. Zwitser Leven is responsible for the investment strategy of the insurance premiums we make. We have characterized the assets of the pension plan as an “other contract.”

The primary objective of the U.K. pension plan is to meet retirement income commitments to plan participants at a reasonable cost. The objective is achieved through growth of capital and safety of funds invested. The pension plan assets are invested in a Deposit Administration Contract with Phoenix Life Limited, an insurance company, with underlying investments primarily in fixed interest U.K. government bonds.

The allocation of pension plan assets was as follows:

	<u>December 31, 2015</u>		<u>March 31, 2015</u>	
	<u>Target Allocation</u>	<u>Actual Allocation</u>	<u>Target Allocation</u>	<u>Actual Allocation</u>
Other Contract (Netherlands Plan)	100%	100%	100%	100%
Deposit Administration Contract (U.K. Plan)	100%	100%	100%	100%

We calculate the market value of the pension plan assets, held in Zwitser Leven insured assets, as the stream, based on mortality (an unobservable input), of the earned guaranteed benefit payments discounted at market interest rate. Accordingly, we have classified the Netherlands pension plan assets as Level 3 assets. The market value of the U.K. pension plan reflects the value of our contributions to the plan and the credited accrued interest at the rate specified in the Deposit Administration Contract. Accordingly, we have classified the U.K. plan assets as Level 2 assets.

The fair value of the pension plan assets by asset class is as follows:

Asset Class	Total	Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
<b>December 31, 2015</b>				
Other Contract (Netherlands Plan)	\$ 3,002,000	\$ (3,000)	\$ -	\$ 3,005,000
Deposit Administration Contract (U.K. Plan)	775,000	-	775,000	-
<b>March 31, 2015</b>				
Other Contract (Netherlands Plan)	\$ 3,593,000	\$ 15,000	\$ -	\$ 3,578,000
Deposit Administration Contract (U.K. Plan)	730,000	-	730,000	-

The reconciliation of beginning and ending balances for our Level 3 assets is as follows:

	Other Contract (Netherlands Pension Plan Assets)
Beginning balance as at April 1, 2015	\$ 3,578,000
Loss recognized in earnings	38,000
Actuarial Loss	(713,000)
Purchases	76,000
Sales	(16,000)
Transfers	16,000
Foreign currency translation	26,000
Ending balance as at December 31, 2015	<u>\$ 3,005,000</u>

The unrealized actuarial loss of \$713,000 for the nine months ended December 31, 2015, recognized in other comprehensive loss, is equally offset by an unrealized actuarial gain, recognized in other comprehensive income, in the vested benefit obligation.

**Note 9: Income Taxes**

The components of income tax expense consist of the following:

	<u>9 months 12/31/2015</u>	<u>9 months 12/31/2014</u>	<u>Fiscal year 3/31/2015</u>	<u>Fiscal year 3/31/2014</u>
Income tax provision:				
Current:				
Federal and state	14,000	10,000	8,000	13,000
Foreign	35,000	24,000	55,000	45,000
Deferred:				
Federal and state	-	-	-	-
Foreign	(9,000)	22,000	3,000	14,000
Total income tax expense	\$ 40,000	\$ 56,000	\$ 66,000	\$ 72,000

Actual income tax expense differs from statutory federal income tax benefit for the period presented is as follows:

	<b>9 months</b> <b>12/31/2015</b>	<b>9 months</b> <b>12/31/2014</b>	<b>Fiscal year</b> <b>3/31/2015</b>	<b>Fiscal year</b> <b>3/31/2014</b>
Statutory federal income tax benefit	\$ (2,376,000)	\$ (1,809,000)	\$ (2,600,000)	\$ (1,799,000)
State tax benefit, net of federal taxes	(212,000)	(163,000)	(210,000)	(125,000)
Foreign tax	(18,000)	(32,000)	(40,000)	(39,000)
Nondeductible expenses – other	92,000	91,000	126,000	122,000
Nondeductible exp – transaction costs	55,000	148,000	462,000	-
Subpart F Income	20,000	26,000	33,000	35,000
Valuation allowance increase	1,377,000	1,946,000	2,478,000	1,007,000
Stock compensation shortfall	128,000	-	-	-
Stock compensation true-up	83,000	132,000	132,000	267,000
NOL expiration and true-up	320,000	-	(53,000)	307,000
Foreign tax credits	-	-	-	-
Other	571,000	(283,000)	(262,000)	297,000
<b>Total income tax expense</b>	<b>\$ 40,000</b>	<b>\$ 56,000</b>	<b>\$ 66,000</b>	<b>\$ 72,000</b>

Deferred tax assets (liabilities) consist of the following:

	<b>12/31/2015</b>	<b>03/31/2015</b>
Fixed assets	\$ (50,000)	\$ 400,000
Intangible assets	(4,378,000)	(5,086,000)
Pension liability	135,000	199,000
Stock based compensation	1,661,000	1,624,000
Inventory	298,000	184,000
Debt discount	(1,929,000)	(1,881,000)
Other reserves and accruals	437,000	564,000
Deferred rent	250,000	12,000
Undistributed foreign earnings	(451,000)	(429,000)
Foreign tax credits	68,000	68,000
Net operating losses	20,812,000	19,885,000
	16,853,000	15,540,000
Less valuation allowance	(16,717,000)	(15,340,000)
	<b>\$ 136,000</b>	<b>\$ 200,000</b>

At December 31, 2015, we had U.S. net operating loss (NOL) carryforwards of approximately \$57.6 million for U.S. income tax purposes before any Section, which expire in 2018 through 2036. U.S. net operating loss carryforwards cannot be used to offset taxable income in foreign jurisdictions. In addition, future utilization of NOL carryforwards is subject to certain limitations under Section 382 of the Internal Revenue Code. This section generally relates to a 50 percent change in ownership of a company over a three-year period. For Uroplasty, we believe that the issuance of historical Uroplasty common stock in the December of 2006 follow-on public offering resulted in an “ownership change” under Section 382. Additionally, we believe there were ownership changes of historical Uroplasty in December of 2012 and, as a result of the merger, in March of 2015. Accordingly, our ability to use pre-acquisition Uroplasty generated NOL tax attributes is limited as follows: approximately \$750,000 per year for periods prior to December 2006; approximately \$2,000,000 per year for periods after December 2006 and before December 2012; and approximately \$720,000 per year for periods after December 2012 and before March 2015. Also, we believe there was an ownership change of Cogentix in March of 2015 as a result of the merger causing a limitation in our ability to use pre-acquisition Cogentix generated NOL tax attributes for periods prior to March 2015 of approximately \$1,500,000 per year for the first five years and approximately \$430,000 thereafter. We have not performed a detailed analysis to determine whether an ownership change prior to March 31, 2015 had occurred. Such a change of ownership could limit our utilization of the net operating losses, and could be triggered by subsequent sales of securities by us or our stockholders.

Certain stock option exercises resulted in tax deductions in excess of previously recorded tax benefits. The Company's NOL carry forwards of \$57.6 million referenced above include approximately \$1.9 million of income tax deductions in excess of previously recorded tax benefits. Although these additional tax deductions are reflected in NOL carry forwards referenced above, the related tax benefit will not be recognized until the deductions reduce taxes payable. Accordingly, since the tax benefit does not reduce the company's current taxes payable in the December 31, 2015 period, these tax benefits are not reflected in the Company's deferred tax assets presented above. The tax benefit of these excess deductions will be reflected as a credit to additional paid-in-capital when and if recognized.

¶ We provide for a valuation allowance when it is more likely than not that we will not realize a portion of the deferred tax assets. We have established a valuation allowance for U.S. and certain foreign deferred tax assets due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, we have not reflected any benefit of such deferred tax assets in the accompanying financial statements. The deferred tax asset increased by \$1,312,820 in the 9 months ending December 31, 2015, and by \$2,199,966 and \$1,010,227, respectively, in the fiscal years ending March 31, 2015 and 2014. The related valuation allowance increased by \$1,377,053 in the nine months ending December 31, 2015, and by \$2,477,900 and \$1,006,587, respectively, in the fiscal years ending March 31, 2015 and 2014.

We reviewed all income tax positions taken or that we expect to be taken for all open years and determined that our income tax positions are appropriately stated and supported for all open years.

Under our accounting policies, we recognize interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense. As of December 31, 2015 and March 31, 2015 and 2014, we recorded no accrued interest or penalties related to uncertain tax positions.

We have provided for U.S. deferred income taxes as of December 31, 2015 and March 31, 2015 and 2014 for the undistributed earnings from our non-U.S. subsidiaries.

The fiscal tax years 2011 through 2015 remain open to examination by the Internal Revenue Service and various state taxing jurisdictions to which we are subject. In addition, we are subject to examination by certain foreign taxing authorities for which the fiscal years 2011 through 2015 remain open for examination.

#### **Note 10: Business Segment Information**

ASC 280, "Segment Reporting," establishes disclosure standards for segments of a company based on management's approach to defining operating segments. Reportable segments are defined primarily by the nature of products and services, the nature of the production processes, and the type of customers for our products and services.

We operate in two markets, the medical market and the industrial market. Within the medical market, we have a number of product lines, endoscopy-based products, including our PrimeSight flexible fiber and video endoscopes used in the practices of urology, pulmonology, trans-nasal esophagoscopy and ENT (ear, nose and throat) and a proprietary sterile disposable microbial barrier, known as EndoSheath Protective Barrier, the Urgent PC® Neuromodulation System ("Urgent PC System") a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and associated symptoms; and Macroplastique® Implants ("Macroplastique"), an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence.

[Table of Contents](#)

None of the industrial market sales, net losses or assets are more than 10% of our total sales, losses or assets. Therefore, we aggregate our operating segments into one reportable segment in accordance with the objectives and principles of the applicable guidance.

Information regarding geographic area net sales to customers for the nine-month transition period ended December 31, 2015, the nine months ended December 31, 2014, and for the fiscal years ended March 31, 2015 and 2014, respectively, is as follows:

	<u>United States</u>	<u>United Kingdom</u>	<u>All Other Foreign Countries (1)</u>	<u>Consolidated</u>
<b>Nine-month transition period ended December 31, 2015</b>	\$ 27,236,000	\$ 3,213,000	\$ 6,173,000	\$ 36,622,000
<b>Nine months ended December 31, 2014</b>	\$ 14,512,000	\$ 1,923,000	\$ 3,071,000	\$ 19,506,000
<b>Fiscal year ended March 31, 2015</b>	\$ 19,970,000	\$ 2,506,000	\$ 4,050,000	\$ 26,526,000
<b>Fiscal year ended March 31, 2014</b>	\$ 18,042,000	\$ 2,485,000	\$ 4,050,000	\$ 24,577,000

(1) No other foreign country accounts for 10% or more of the consolidated net sales

Information regarding geographic area long-lived assets at December 31, 2015 and March 31, 2015 is as follows:

	<u>United States</u>	<u>United Kingdom</u>	<u>The Netherlands</u>	<u>Consolidated</u>
<b>December 31, 2015</b>	\$ 2,089,000	\$ 3,000	\$ 463,000	\$ 2,555,000
<b>March 31, 2015</b>	\$ 1,338,000	\$ 3,000	\$ 472,000	\$ 1,813,000

Accounting policies for the operations in the various geographic areas are the same as those described in Note 1. Sales attributed to each geographic area are net of intercompany sales and are attributed to countries based on location of customers. No single customer represents 10% or more of our consolidated net sales. Long-lived assets consist of property, plant and equipment.

**COGENTIX MEDICAL, INC.**  
**EXHIBIT INDEX TO TRANSITION REPORT ON FORM 10-K**

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
*2.1	Agreement and Plan of Merger dated as of December 21, 2014 by and among Vision-Sciences, Inc., Visor Merger Sub LLC, and Uroplasty, Inc.	Incorporated by reference to Exhibit 2.1 to Current Report on Form 8-K as filed with the SEC on December 22, 2014 (File No. 000-20970)
3.1	(a) Amended and Restated Certificate of Incorporation.	Incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended March 31, 2001 (File No. 000-20970)
	(b) Certificate of Amendment to Certificate of Incorporation.	Incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended March 31, 2001 (File No. 000-20970)
	(c) Certificate of Amendment to Certificate of Incorporation.	Incorporated by reference to Exhibit 99.2 to Current Report on Form 8-K as filed with the SEC on December 15, 2010 (File No. 000-20970)
	(d) Certificate of Amendment to Certificate of Incorporation.	Incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K as filed with the SEC on August 1, 2014 (File No. 000-20970)
	(e) Certificate of Amendment to Amended and Restated Certificate of Incorporation.	Incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K as filed with the SEC on March 31, 2015 (File No. 000-20970)
	(f) Certificate of Amendment to Amended and Restated Certificate of Incorporation.	Incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K as filed with the SEC on March 31, 2015 (File No. 000-20970)
3.2	Amended and Restated Bylaws.	Incorporated by reference to Exhibit 99.2 to Current Report on Form 8-K as filed with the SEC on July 15, 2009 (File No. 000-20970)
10.1	Common Stock Purchase Warrants of Vision-Sciences, Inc. issued to Lewis C. Pell dated November 9, 2009.	Incorporated by reference to Exhibit 10.46 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 filed with the SEC on November 12, 2009 (File No. 000-20970)
10.2	Common Stock Purchase Warrants of Vision-Sciences, Inc. issued to Lewis C. Pell dated September 30, 2011.	Incorporated by reference to Exhibit 99.2 to Current Report on Form 8-K filed on October 4, 2011 (File No. 000-20970)

[Table of Contents](#)

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
10.3	Letter Agreement dated December 21, 2014 by and between Vision-Sciences, Inc. and Lewis C. Pell regarding extension of warrants.	Incorporated by reference to Exhibit 4.4 to Current Report on Form 8-K as filed with the SEC on December 22, 2014 (File No. 000-20970)
10.4	Convertible Promissory Note issued by Vision-Sciences, Inc. issued to Lewis C. Pell dated as of September 19, 2012.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on September 20, 2012 (File No. 000-20970)
10.5	Additional Convertible Promissory Note issued by Vision-Sciences, Inc. to Lewis C. Pell dated September 25, 2013.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on September 30, 2013 (File No. 000-20970)
10.6	2014 Convertible Promissory Note issued by Vision-Sciences, Inc. to Lewis C. Pell dated June 16, 2014.	Incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K filed with the SEC of June 17, 2014 (File No. 000-20970)
10.7	Amendment to Convertible Promissory Note dated December 21, 2014 by and between Vision-Sciences, Inc. and Lewis C. Pell.	Incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K as filed with the SEC on December 22, 2014 (File No. 000-20970)
10.8	Amendment to Additional Convertible Promissory Note dated December 21, 2014 by and between Vision-Sciences, Inc. and Lewis C. Pell.	Incorporated by reference to Exhibit 4.2 to Current Report on Form 8-K as filed with the SEC on December 22, 2014 (File No. 000-20970)
10.9	Amendment to 2014 Convertible Promissory Note dated December 21, 2014 by and between Vision-Sciences, Inc. and Lewis C. Pell.	Incorporated by reference to Exhibit 4.3 to Current Report on Form 8-K as filed with the SEC on December 22, 2014 (File No. 000-20970)
10.10	Letter Agreement between Vision-Sciences, Inc. and Lewis C. Pell dated August 14, 2012.	Incorporated by reference to Exhibit 10.2 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 filed with the SEC on August 14, 2012 (File No. 000-20970)
10.11	Letter Agreement dated June 21, 2013 between the Company and Lewis C. Pell.	Incorporated by reference to Exhibit 10.30 to Annual Report on Form 10-K for the fiscal year ended March 31, 2013 filed with the SEC on June 25, 2013 (File No. 000-20970)
10.12	Letter Agreement dated May 29, 2014 between Vision-Sciences, Inc. and Lewis C. Pell.	Incorporated by reference to Exhibit 10.22 to Annual Report on Form 10-K for the fiscal year ended March 31, 2014 filed with the SEC on May 30, 2014 (File No. 000-20970)

[Table of Contents](#)

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
10.13	Letter Agreement dated October 24, 2014 between Vision-Sciences, Inc. and Lewis C. Pell.	Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 filed with the SEC on November 13, 2014 (File No. 000-20970)
10.14	Letter Agreement dated December 21, 2014 between Vision-Sciences, Inc. and Lewis C. Pell regarding termination of maintenance of liquidity obligation.	Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC of December 22, 2014 (File No. 000-20970)
10.15	Purchase Agreement between Vision-Sciences, Inc. and Lincoln Park Capital Fund, LLC dated April 27, 2012.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on April 27, 2012 (File No. 000-20970)
10.16	Modification Agreement between Vision-Sciences, Inc. and Lincoln Park Capital Fund, LLC dated July 26, 2012.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on July 26, 2012 (File No. 000-20970)
10.17	Form of Common Stock Purchase Agreement dated January 18, 2011.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on January 19, 2011 (File No. 000-20970)
**10.18	Employment Letter dated November 26, 2013 between Vision-Sciences, Inc. and Howard I. Zauberman.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed with the SEC on November 27, 2013 (File No. 000-20970)
**10.19	Employment Agreement dated June 26, 2014 between Vision-Sciences, Inc. and Gary Siegel.	Incorporated by reference to Exhibit 10.1 to Quarterly Report on Form 10-Q for the quarter ended June 30, 2014 filed with the SEC on August 14, 2014 (File No. 000-20970)
***10.20	Supply Agreement between Vision-Sciences, Inc. and Stryker Corporation dated September 22, 2010.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on September 28, 2010 (File No. 000-20970)
10.21	Lease Agreement between Vision-Sciences, Inc. and 30 Ramland Road LLC dated as of March 23, 2000.	Incorporated by reference to Exhibit 10.27 to Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the SEC on June 29, 2000 (File No. 333-72547)
10.22	First Amendment to Lease between Vision-Sciences, Inc. and 30 Ramland Road, LLC dated as of August 31, 2000.	Incorporated by reference to Exhibit 10.22 to Annual Report on Form 10-K for the fiscal year ended March 31, 2015 filed with the SEC on June 25, 2015 (File No. 000-20970)
10.23	Second Amendment to Lease between Vision-Sciences, Inc. and 30 Ramland Road, LLC dated as of January 7, 2005.	Incorporated by reference to Exhibit 10.23 to Annual Report on Form 10-K for the fiscal year ended March 31, 2015 filed with the SEC on June 25, 2015 (File No. 000-20970)

[Table of Contents](#)

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
10.24	Third Amendment to Lease between Vision-Sciences, Inc. and 30 Ramland Road, LLC dated as of December 26, 2006.	Incorporated by reference to Exhibit 10.38 to Annual Report on Form 10-K for the fiscal year ended March 31, 2008 filed with the SEC on July 3, 2008 (File No. 000-20970)
10.25	Fourth Amendment to Lease between Vision-Sciences, Inc. and 30 Ramland Road, LLC dated as of April 12, 2009.	Incorporated by reference to Exhibit 10.44 to Annual Report on Form 10-K for the fiscal year ended March 31, 2009 filed with the SEC on June 29, 2009 (File No. 000-20970)
10.26	Settlement Agreement and Release dated November 30, 1993 by and between Bioplasty, Inc., Bio-Manufacturing, Inc., Uroplasty, Inc., Arthur A. Beisang, Arthur A. Beisang III, MD and Robert A. Ersek, MD.	Incorporated by reference to Exhibit 6.1 to Uroplasty's Registration Statement on Form 10SB as filed with the SEC on July 10, 1996 (File No. 000-20989)
10.27	Agreement, dated October 14, 1998, by and between Uroplasty, Inc. and Samir M. Henalla (pertaining to Macroplastique Implantation System).	Incorporated by reference to Exhibit 10.15 to Uroplasty's Form 10-KSB/A for the year ended March 31, 2001 (File No. 000-20989)
10.28	Form of Purchase Agreement, dated as of March 15, 2007, by and between Uroplasty, Inc. and CystoMedix, Inc.	Incorporated by reference to Exhibit 10.36 to Uroplasty's Current Report on Form 8-K as filed with the SEC on March 20, 2007 (File No. 001-32632)
**10.29	Employment Agreement between Uroplasty, Inc. and Robert C. Kill dated July 22, 2013	Incorporated by reference to Exhibit 10.15 to Uroplasty's Annual Report on Form 10-K for the fiscal year ended March 31, 2013 (File No. 001-32632)
**10.30	First Amendment to the Employment Agreement between Uroplasty, Inc. and Robert C. Kill dated May 29, 2014	Incorporated by reference to Exhibit 10.1 to Uroplasty's Current Report on Form 8-K as filed with the SEC on June 3, 2014 (File No. 001-32632)
**10.31	Employment Agreement between Uroplasty, Inc. and Darin Hammers dated February 11, 2013	Incorporated by reference to Exhibit 10.14 to Uroplasty's Annual Report on Form 10-K for the fiscal year ended March 31, 2013 (File No. 001-32632)
**10.32	First Amendment to the Employment Agreement between Uroplasty, Inc. and Darin Hammers dated October 1, 2014	Incorporated by reference to Exhibit 10.1 to Uroplasty's Current Report on Form 8-K as filed with the SEC on October 3, 2014 (File No. 001-32632)
**10.33	Employment Agreement between Uroplasty, Inc. and Brett Reynolds dated July 25, 2013	Incorporated by reference to Exhibit 10.1 to Uroplasty's Current Report on Form 8-K as filed with the SEC on August 12, 2013 (File No. 001-32632)

[Table of Contents](#)

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
10.34	Confidential Separation and Release Agreement dated October 22, 2014, between Uroplasty, Inc. and Susan H. Holman	Incorporated by reference to Exhibit 10.1 to Uroplasty's Current Report on Form 8-K as filed with the SEC on October 24, 2014 (File No. 001-32632)
10.35	Lease Agreement between Uroplasty, Inc. and Liberty Property Limited Partnership dated January 20, 2006	Incorporated by reference to Exhibit 10.25 to Uroplasty's Current Report on Form 8-K as filed with the SEC on January 24, 2006 (File No. 001-32632)
10.36	First Amendment to Lease by and between Liberty Property Limited Partnership and Uroplasty, Inc. dated January 24, 2014	Incorporated by reference to Exhibit 10.21 to Uroplasty's Annual Report on Form 10-K for the fiscal year ended March 31, 2014 (File No. 001-32632)
10.37	Lease Agreement between Glenborough Flanders Park, LLC and Cogentix Medical, Inc. dated as of April 2, 2015.	Incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K as filed with the SEC on April 3, 2015 (File No. 000-20970)
**10.38	Cogentix Medical, Inc. 2015 Omnibus Incentive Plan	Incorporated by reference to Exhibit 4.10 to Registration Statement on Form S-8 as filed with the SEC on March 31, 2015 (File No. 333-203135)
**10.39	Uroplasty, Inc. 2002 Employee Stock Option Plan	Incorporated by reference to the copy filed as Appendix B to Uroplasty's Definitive Proxy Statement as filed with the SEC on August 1, 2002 (File No. 000-20989)
**10.40	Uroplasty, Inc. 2006 Amended Stock and Incentive Plan	Incorporated by reference to the copy attached as Appendix A to Uroplasty's Definitive Proxy Statement as filed with the SEC on July 25, 2008 (File No. 001-32632)
**10.41	Form of Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan	Incorporated by reference to Exhibit 10.1 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)
**10.42	Form of Non-employee Director Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan	Incorporated by reference to Exhibit 10.2 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)

[Table of Contents](#)

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
**10.43	Form of Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan	Incorporated by reference to Exhibit 10.3 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)
**10.44	Form of Non-employee Director Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan	Incorporated by reference to Exhibit 10.4 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)
**10.45	Uroplasty, Inc. Performance Award Grant Notice 2006 Equity and Incentive Plan	Incorporated by reference to Exhibit 10.2 to Uroplasty's Current Report on Form 8-K filed October 3, 2014 (File No. 001-32632)
**10.46	Vision-Sciences, Inc. 2000 Stock Incentive Plan	Incorporated by reference to Exhibit 10.26 to the Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the SEC on June 29, 2000 (File No. 333-72547)
**10.47	Vision-Sciences, Inc. 2003 Director Option Plan, as amended	Incorporated by reference to Exhibit 4 to the Registration Statement on Form S-8 filed with the SEC on October 10, 2008 (File No. 333-154150)
**10.48	Vision-Sciences, Inc. 2007 Stock Incentive Plan, as amended	Incorporated by reference to the Appendix A to the Definitive Proxy Statement filed with the SEC on July 27, 2007 on Schedule 14A (File No. 000-20970)
**10.49	Restricted Stock Agreement dated November 26, 2013 between Vision-Sciences, Inc. and Howard I. Zauberan	Incorporated by reference to Exhibit 10.2 to Current Report on Form 8-K filed with the SEC on November 27, 2013 (File No. 000-20970)
<a href="#">21.1</a>	Subsidiaries of Cogentix Medical, Inc.	Filed herewith
<a href="#">23.1</a>	Consent of Grant Thornton LLP, independent registered public accounting firm	Filed herewith
<a href="#">31.1</a>	Certification by the PEO and PFO pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
<a href="#">32.1</a>	Certification by the PEO and PFO pursuant to Section 18 USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed herewith

Table of Contents

<b>Exhibit No.</b>	<b>Exhibit</b>	<b>Method of Filing</b>
101.INS	XBRL Instance	Furnished herewith ****
101.SCH	XBRL Taxonomy Extension Schema	Furnished herewith ****
101.CAL	XBRL Taxonomy Extension Calculation	Furnished herewith ****
101.DEF	XBRL Taxonomy Extension Definition	Furnished herewith ****
101.LAB	XBRL Taxonomy Extension Labels	Furnished herewith ****
101.PRE	XBRL Taxonomy Extension Presentation	Furnished herewith ****

\* Certain schedules to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. We will furnish copies of any such omitted schedules to the SEC upon request.

\*\* Management contract or compensatory plan or arrangement filed as an exhibit to this report pursuant to Item 15(a) and 15(b) of Form 10-K.

\*\*\* Confidential treatment granted as to certain portions, which portions have been deleted and filed separately with the SEC.

\*\*\*\* XBRL information is furnished and not filed or a part of a registration statement or prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

**SUBSIDIARIES OF COGENTIX MEDICAL, INC.**  
December 31, 2015

<b><u>Subsidiary</u></b>	<b><u>State or Other Jurisdiction of Incorporation</u></b>
Machida Incorporated	Delaware
Uroplasty, LLC	Delaware
Uroplasty BV	The Netherlands
Uroplasty Ltd.	United Kingdom

Consent of Independent Registered Public Accounting Firm

We have issued our report dated March 29, 2016, with respect to the consolidated financial statements and schedule included in the Annual Report of Cogentix Medical, Inc. and subsidiaries on Form 10-K for the nine months ended December 31, 2015. We hereby consent to the incorporation by reference of said report in the Registration Statement of Cogentix Medical, Inc. on Form S-8 (File No. 333-203135).

/s/ Grant Thornton LLP

Minneapolis, Minnesota  
March 29, 2016

---

**CERTIFICATION PURSUANT TO  
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Robert Kill, certify that:

1. I have reviewed this report on Form 10-K for the nine-month transition period ended December 31, 2015 of Cogentix Medical, Inc. (the "Registrant");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

4. The Registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation; and

(d) disclosed in this report any change in the Registrant's internal control over financial reporting that occurred during the Registrant's most recent fiscal quarter (the Registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant's internal control over financial reporting; and

5. The Registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent function):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal control over financial reporting.

Date: March 29, 2016

By /s/ Robert Kill  
Robert Kill  
President, Chief Executive Officer, Chairman of the Board and Corporate Secretary

---

**CERTIFICATION PURSUANT TO  
18 U.S.C. SECTION 1350,  
AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Transition Report of Cogentix Medical, Inc. (the "Company") on Form 10-K for the nine-month transition period ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Robert Kill, the President, Chief Executive Officer, Chairman of the Board and Corporate Secretary of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and
- (2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: March 29, 2016

By /s/ Robert Kill  
Robert Kill  
President, Chief Executive Officer, Chairman of the Board and Corporate Secretary

---

